

Everolimus in Postmenopausal Hormone-Receptorâ€“E

New England Journal of Medicine

366, 520-529

DOI: [10.1056/nejmoa1109653](https://doi.org/10.1056/nejmoa1109653)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2013, 7, 307.	0.6	48
3	Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 109.	1.3	72
4	Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1579-1589.	1.1	21
5	Targeting Angiogenesis in Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, 1014-1026.	1.9	22
6	Abrogating endocrine resistance by targeting ER α and PI3K in breast cancer. <i>Frontiers in Oncology</i> , 2012, 2, 145.	1.3	46
7	Tunneling Nanotubes. <i>Communicative and Integrative Biology</i> , 2012, 5, 399-403.	0.6	103
9	Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition. <i>Current Opinion in Oncology</i> , 2012, 24, 623-634.	1.1	44
10	Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii11-vii19.	0.6	400
11	Reversing Hormone Resistance: Have We Found the Golden Key?. <i>Journal of Clinical Oncology</i> , 2012, 30, 2707-2709.	0.8	26
12	Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor α -Positive, Human Epidermal Growth Factor Receptor 2 α -Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2718-2724.	0.8	630
13	Polyendocrine Treatment in Estrogen Receptor α -Positive Breast Cancer: A α -FACT α -Yet to Be Proven. <i>Journal of Clinical Oncology</i> , 2012, 30, 1897-1900.	0.8	10
15	Emerging personalized oncology: sequencing and systems strategies. <i>Future Oncology</i> , 2012, 8, 637-641.	1.1	16
16	Targeting the Human Epidermal Growth Factor Receptor 2 Pathway in Breast Cancer. <i>Hospital Practice (1995)</i> , 2012, 40, 7-15.	0.5	10
17	Everolimus in HR-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 1738-1740.	13.9	3
18	Breast Cancer 2012 - New Aspects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 602-615.	0.8	19
20	Advances in Breast Cancer α - Looking Back over the Year. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 1117-1129.	0.8	17
21	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2143-2156.	0.9	6
22	Anastrozole and fulvestrant α -combination to unlock efficacy. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 556-557.	12.5	1

#	ARTICLE	IF	CITATIONS
23	Targeted therapy: overcoming drug resistance with clinical cancer genome. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 861-864.	1.1	4
24	Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer. <i>Future Oncology</i> , 2012, 8, 1383-1396.	1.1	12
25	mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. <i>Annals of Oncology</i> , 2012, 23, 2526-2535.	0.6	45
26	Hazard ratios in cancer clinical trials—a primer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 178-183.	12.5	36
27	Toward Individualized Breast Cancer Therapy: Translating Biological Concepts to the Bedside. <i>Oncologist</i> , 2012, 17, 577-584.	1.9	17
28	mTOR inhibition in management of advanced breast cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2012, 33, 89.	0.1	1
29	Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 223-229.	12.5	38
30	Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2012, 9, 143-163.	0.3	62
31	The role of S6K1 in ER-positive breast cancer. <i>Cell Cycle</i> , 2012, 11, 3159-3165.	1.3	58
32	Fuel, electricity, ER and HER2—a hybrid-car model of breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 426-426.	12.5	4
33	Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 2603-2612.	3.2	154
34	ABC1 Consensus Conference—a German Perspective. <i>Breast Care</i> , 2012, 7, 52-59.	0.8	5
35	Onychopathy Induced by Temsirolimus, a Mammalian Target of Rapamycin Inhibitor. <i>Dermatology</i> , 2012, 224, 204-208.	0.9	26
36	Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. <i>Liver Cancer</i> , 2012, 1, 247-256.	4.2	65
39	Endocrine resistance in advanced breast cancer: current evidence and future directions. <i>Breast Cancer Management</i> , 2012, 1, 305-314.	0.2	1
40	mTOR as a target in breast cancer: the emerging role of everolimus. <i>Breast Cancer Management</i> , 2012, 1, 47-56.	0.2	0
41	Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. <i>Critical Reviews in Oncogenesis</i> , 2012, 17, 69-95.	0.2	204
43	Using modern molecular markers to tailor breast cancer treatment: a new era for personalized medicine. <i>Breast Cancer Management</i> , 2012, 1, 105-108.	0.2	2

#	ARTICLE	IF	CITATIONS
44	Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. <i>Future Oncology</i> , 2012, 8, 273-292.	1.1	36
45	Targeted therapies in breast cancer. <i>Swiss Medical Weekly</i> , 2012, 142, w13550.	0.8	9
47	Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10958-10971.	2.9	27
48	Current approaches to the management of Her2-negative metastatic breast cancer. <i>Breast Cancer Research</i> , 2012, 14, 205.	2.2	16
49	BOLERO-2 - will this change practice in advanced breast cancer?. <i>Breast Cancer Research</i> , 2012, 14, 311.	2.2	9
50	Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. <i>Breast Cancer Research</i> , 2012, 14, 208.	2.2	58
51	Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. <i>Breast Cancer Research</i> , 2012, 14, R52.	2.2	20
52	Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R78.	2.2	38
53	Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. <i>Breast Cancer Research</i> , 2012, 14, R132.	2.2	31
55	Burden of de novo malignancy in the liver transplant recipient. <i>Liver Transplantation</i> , 2012, 18, 1277-1289.	1.3	104
57	Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 957-967.	1.1	94
58	Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1027-1039.	1.1	26
59	Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 39-48.	1.1	82
60	Metformin and breast cancer risk: a meta-analysis and critical literature review. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 639-646.	1.1	183
61	Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 205-216.	1.0	77
62	Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 251-261.	1.0	78
63	mTOR inhibitors in breast cancer: A systematic review. <i>Gynecologic Oncology</i> , 2012, 127, 662-672.	0.6	34
64	Epidemiology of melanoma in older patients. <i>Journal of Geriatric Oncology</i> , 2012, 3, S13.	0.5	0

#	ARTICLE	IF	CITATIONS
65	48th Annual Meeting of the American Society of Clinical Oncology: aspectos relevantes en cáncer de mama. Revista De Senología Y Patología Mamaria, 2012, 25, 147-151.	0.0	0
66	Overcoming endocrine resistance in breast cancer patients. Journal of Geriatric Oncology, 2012, 3, S12-S13.	0.5	0
67	Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1835-1843.	1.9	10
68	An overview of the mTOR pathway as a target in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 481-489.	1.5	33
69	Clinical Cancer Genome and Precision Medicine. Annals of Surgical Oncology, 2012, 19, 3646-3650.	0.7	21
70	Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning. Cancer Discovery, 2012, 2, 778-790.	7.7	443
71	Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway. Cancer Research, 2012, 72, 5048-5059.	0.4	183
72	Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Research and Treatment, 2012, 135, 415-432.	1.1	123
73	The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer. Clinical Cancer Research, 2012, 18, 5856-5864.	3.2	325
74	Management of Metastatic Castration-Resistant Prostate Cancer. Drugs, 2012, 72, 1011-1028.	4.9	31
75	Blocking both driver and escape pathways improves outcomes. Nature Reviews Clinical Oncology, 2012, 9, 133-134.	12.5	11
76	Potential practice-changing therapies in breast cancer: The year in review. Community Oncology, 2012, 9, S40-S43.	0.2	0
77	New Targeted Agents on the Therapeutic Horizon. Community Oncology, 2012, 9, S23-S25.	0.2	0
78	Targeting insulin-like growth factor in breast cancer therapeutics. Critical Reviews in Oncology/Hematology, 2012, 84, 8-17.	2.0	29
79	Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resistance Updates, 2012, 15, 268-275.	6.5	31
81	Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. Molecular Oncology, 2012, 6, 222-236.	2.1	63
82	Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nature Reviews Clinical Oncology, 2012, 9, 529-541.	12.5	63
83	Mechanisms of acquired resistance to targeted cancer therapies. Future Oncology, 2012, 8, 999-1014.	1.1	150

#	ARTICLE	IF	CITATIONS
84	Interactions of PI3K/Akt/mTOR and estrogen receptor signaling in breast cancer. <i>Breast Cancer Management</i> , 2012, 1, 235-249.	0.2	11
85	Novel targeted agents for the treatment of advanced breast cancer. <i>Future Medicinal Chemistry</i> , 2012, 4, 893-914.	1.1	10
87	The molecular profile of luminal B breast cancer. <i>Biologics: Targets and Therapy</i> , 2012, 6, 289.	3.0	149
88	PI3K/“AKT/“mTOR inhibitors for the systemic treatment of endometrial cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2012, 7, 421-430.	0.4	1
89	Potential role of enzastaurin in the treatment of patients with relapsed or refractory advanced cutaneous T-cell lymphomas: a review. <i>Orphan Drugs: Research and Reviews</i> , 2012, , 1.	0.6	0
90	The clinical trials of the Organisation for Oncology and Translational Research (OOTR). <i>International Journal of Biological Markers</i> , 2012, 27, 353-356.	0.7	0
91	Distinct perturbation of the transcriptome by the antidiabetic drug metformin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8977-8982.	3.3	169
92	Combinatorial drug therapy for cancer in the post-genomic era. <i>Nature Biotechnology</i> , 2012, 30, 679-692.	9.4	883
93	The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. <i>Future Oncology</i> , 2012, 8, 651-657.	1.1	104
94	Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer. <i>Pharmacotherapy</i> , 2012, 32, 383-396.	1.2	27
95	Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. <i>Nature Reviews Cancer</i> , 2012, 12, 487-493.	12.8	573
96	Evolving strategies to overcome endocrine resistance in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 105-109.	0.3	0
97	The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 157-166.	1.1	10
98	Tamoxifen resistance: From bench to bedside. <i>European Journal of Pharmacology</i> , 2013, 717, 47-57.	1.7	90
99	Targeting triple negative breast cancer: Is p53 the answer?. <i>Cancer Treatment Reviews</i> , 2013, 39, 541-550.	3.4	106
100	Molecular Mechanisms of Hormone Resistance of Breast Cancer. <i>Bulletin of Experimental Biology and Medicine</i> , 2013, 155, 384-395.	0.3	17
101	Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 991-1012.	2.5	30
102	Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors. <i>Onkologie</i> , 2013, 36, 295-302.	1.1	29

#	ARTICLE	IF	CITATIONS
103	Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. <i>BMC Cancer</i> , 2013, 13, 239.	1.1	16
104	Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases. <i>BMC Cancer</i> , 2013, 13, 32.	1.1	7
105	Luminal breast cancer: from biology to treatment. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 494-506.	12.5	183
106	Current Status of Anti-Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance. <i>Clinical Breast Cancer</i> , 2013, 13, 223-232.	1.1	64
107	Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. <i>Supportive Care in Cancer</i> , 2013, 21, 2341-2349.	1.0	44
108	The role of mTOR inhibitors in the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2013, 33, 1133-1134.	1.9	1
109	Everolimus: side effect profile and management of toxicities in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 453-462.	1.1	82
110	Hemodialysis no reason to withhold everolimus. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 273-274.	1.1	5
111	Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. <i>Drugs</i> , 2013, 73, 475-485.	4.9	34
113	Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 1196-1204.	1.3	9
114	Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 101-111.	2.0	46
115	Risk of de novo cancers after transplantation: Results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. <i>European Journal of Cancer</i> , 2013, 49, 336-344.	1.3	157
116	Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway. <i>Breast Care</i> , 2013, 8, 248-255.	0.8	40
117	Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3935-3943.	0.8	411
118	PET imaging of oestrogen receptors in patients with breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, e465-e475.	5.1	173
119	Advances in Molecular and Clinical Subtyping of Breast Cancer and Their Implications for Therapy. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 823-840.	0.6	30
120	Risk of hematologic toxicities in patients with solid tumors treated with everolimus: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 30-41.	2.0	10
121	mTOR kinase inhibitors as potential cancer therapeutic drugs. <i>Cancer Letters</i> , 2013, 340, 1-8.	3.2	128

#	ARTICLE	IF	CITATIONS
122	Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. <i>Breast Diseases</i> , 2013, 24, 79-81.	0.0	2
123	RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 880-884.	0.4	55
124	Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. <i>Lancet Oncology</i> , The, 2013, 14, 228-235.	5.1	147
125	Mutational analysis of breast cancer: Guiding personalized treatments. <i>Breast</i> , 2013, 22, S19-S21.	0.9	16
126	AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. <i>Breast Care</i> , 2013, 8, 181-185.	0.8	68
127	Dasatinib: a novel therapy for breast cancer?. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 795-801.	1.9	9
128	Optimal Sequencing of Anti-HER2 Therapy Throughout the Continuum of HER2-Positive Breast Cancer: Evidence and Clinical Considerations. <i>Drugs</i> , 2013, 73, 1665-1680.	4.9	6
129	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	0.6	2,805
130	Latest biopsy approach for suspected metastases in patients with breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 711-719.	12.5	22
131	Combination endocrine treatments unproven in breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, 917-918.	5.1	1
132	Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2013, 19, 3738-3744.	3.2	53
133	Everolimus in hormone receptor-positive advanced breast cancer: Targeting receptor-based mechanisms of resistance. <i>Breast</i> , 2013, 22, 405-410.	0.9	17
134	SEOM clinical guidelines for the management of metastatic breast cancer 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 1004-1010.	1.2	4
135	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. <i>Nature Genetics</i> , 2013, 45, 1439-1445.	9.4	960
136	Molecular Pathways: Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1644-1650.	3.2	46
137	Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways. <i>Journal of Clinical Oncology</i> , 2013, 31, 1592-1605.	0.8	249
138	A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 961-965.	1.1	15
139	The search for ESR1 mutations in breast cancer. <i>Nature Genetics</i> , 2013, 45, 1415-1416.	9.4	62

#	ARTICLE	IF	CITATIONS
140	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013, 13, 421-432.e8.	1.1	104
141	mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 α Inhibitors in PIK3CA-Mutant Breast Cancer. <i>Science Translational Medicine</i> , 2013, 5, 196ra99.	5.8	251
142	Biological therapies in breast cancer: Common toxicities and management strategies. <i>Breast</i> , 2013, 22, 1009-1018.	0.9	26
143	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 2047-2056.	1.2	28
144	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 437-446.	1.1	70
145	ASCO 2013: news in early-stage and advanced breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 227-232.	0.3	0
146	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. <i>Journal of the National Cancer Institute</i> , 2013, 105, 654-663.	3.0	88
147	PI3K Pathway Inhibitors: Better Not Left Alone. <i>Current Pharmaceutical Design</i> , 2013, 19, 895-906.	0.9	37
148	Endocrine therapy: is the first generation of targeted drugs the last?. <i>Journal of Internal Medicine</i> , 2013, 274, 144-152.	2.7	39
149	Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 116, e110-e116.	0.2	25
150	Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 412-419.	1.4	16
151	Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. <i>Investigational New Drugs</i> , 2013, 31, 1602-1608.	1.2	39
152	Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1089-1096.	1.1	24
153	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	2.2	320
154	A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 145-153.	1.1	48
157	Insulin and IGFs in Obesity-Related Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2013, 18, 277-289.	1.0	79
158	New Approaches for Hormone-Receptor Positive Metastatic Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013, 5, 309-320.	0.5	0
159	Biomarkers of Therapeutic Resistance in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013, 5, 275-283.	0.5	0

#	ARTICLE	IF	CITATIONS
160	Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. <i>Advances in Therapy</i> , 2013, 30, 870-884.	1.3	430
161	Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 81-88.	1.1	3
162	The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. <i>Breast Cancer Research</i> , 2013, 15, R96.	2.2	81
163	Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 703-714.	0.9	5
164	Endocrine Therapy for Advanced/Metastatic Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 715-736.	0.9	37
165	Genetically engineered mouse models of PI3K signaling in breast cancer. <i>Molecular Oncology</i> , 2013, 7, 146-164.	2.1	34
166	Tailoring mTOR-based therapy: molecular evidence and clinical challenges. <i>Pharmacogenomics</i> , 2013, 14, 1517-1526.	0.6	73
167	Evidence for Rapamycin Toxicity in Pancreatic Î²-Cells and a Review of the Underlying Molecular Mechanisms. <i>Diabetes</i> , 2013, 62, 2674-2682.	0.3	165
168	A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. <i>British Journal of Cancer</i> , 2013, 109, 1482-1487.	2.9	23
169	Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. <i>Breast</i> , 2013, 22, S12-S18.	0.9	77
170	Differentiating mTOR inhibitors in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2013, 39, 709-719.	3.4	85
171	Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. <i>Cancer</i> , 2013, 119, 1908-1915.	2.0	81
173	Endocytosis and Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a016949-a016949.	2.3	314
174	Targeting LKB1 signaling in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 194-210.	3.3	75
175	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 195-202.	0.8	252
176	New drugs, new knowledge, new targets. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 75-76.	12.5	9
177	The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap. <i>Cancer Discovery</i> , 2013, 3, 27-34.	7.7	200
178	Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 631-636.	1.1	26

#	ARTICLE	IF	CITATIONS
179	Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 397-406.	1.1	82
180	Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 143-147.	1.1	17
181	Development of PI3K inhibitors: lessons learned from early clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 143-153.	12.5	694
182	Advances in Targeted Therapy for the Prevention of Breast Cancer. <i>Breast Diseases</i> , 2013, 24, 309-314.	0.0	0
183	Targeted Therapy for Breast Cancer. <i>American Journal of Pathology</i> , 2013, 183, 1096-1112.	1.9	100
184	Bone metastases: Causes, consequences and therapeutic opportunities. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 254-256.	2.2	7
185	Paradigme de la prise en charge du cancer bronchique et de celle des autres cancers : homologies, analogies, dissemblances. <i>Revue Des Maladies Respiratoires Actualites</i> , 2013, 5, 562-571.	0.0	0
186	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. <i>European Journal of Cancer</i> , 2013, 49, 2621-2632.	1.3	53
187	Targeted cancer therapy – Are the days of systemic chemotherapy numbered?. <i>Maturitas</i> , 2013, 76, 308-314.	1.0	88
188	An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Advanced or Metastatic Breast Cancer. <i>Value in Health</i> , 2013, 16, A393-A394.	0.1	0
189	New Developments and Future Directions in Systemic Therapy. <i>Clinical Oncology</i> , 2013, 25, 117-126.	0.6	11
190	NICE guidance on everolimus in combination with exemestane for treatment of advanced HER2-negative, hormone-receptor-positive breast cancer after endocrine therapy. <i>Lancet Oncology, The</i> , 2013, 14, 1049-1050.	5.1	2
191	Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2013, 14, 989-998.	5.1	246
192	Tackling the Diversity of Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6380-6388.	3.2	141
193	A Phase II Trial of Tamsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 397-406.	0.9	52
194	A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 479-486.	0.4	54
195	Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. <i>Breast</i> , 2013, 22, 142-149.	0.9	10
196	Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2013, 35, 215-225.	1.1	18

#	ARTICLE	IF	CITATIONS
198	The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer. <i>Current Oncology Reports</i> , 2013, 15, 14-23.	1.8	20
199	Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 62-73.	1.9	60
200	New drugs for children and adolescents with cancer: the need for novel development pathways. <i>Lancet Oncology</i> , The, 2013, 14, e117-e124.	5.1	81
201	Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 829-842.	1.1	367
202	mTOR signaling for biological control and cancer. <i>Journal of Cellular Physiology</i> , 2013, 228, 1658-1664.	2.0	126
203	Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3090-3101.	2.9	28
204	Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: Old targets new hope. <i>Cancer Treatment Reviews</i> , 2013, 39, 403-412.	3.4	32
205	Emerging targeted agents in metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 191-210.	12.5	158
206	Appropriate Design of Prospective Studies. <i>Journal of Clinical Oncology</i> , 2013, 31, 510-511.	0.8	7
207	The evolution of the TOR pathway and its role in cancer. <i>Oncogene</i> , 2013, 32, 3923-3932.	2.6	136
208	Everolimus in colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 505-513.	0.9	22
209	Molecular characterization of anastrozole resistance in breast cancer: Pivotal role of the Akt/mTOR pathway in the emergence of <i>de novo</i> or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. <i>International Journal of Cancer</i> , 2013, 133, 1589-1602.	2.3	42
210	Using Multiple Targeted Therapies in Oncology: Considerations for Use, and Progress to Date in Breast Cancer. <i>Drugs</i> , 2013, 73, 505-515.	4.9	14
211	Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 39-49.	1.1	49
212	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA) Trial. <i>Lancet Oncology</i> , The, 2013, 14, 461-471.	5.1	849
213	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 935-946.	3.4	308
214	mTOR inhibitors in advanced breast cancer: Ready for prime time?. <i>Cancer Treatment Reviews</i> , 2013, 39, 742-752.	3.4	27
215	Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. <i>Statistics in Medicine</i> , 2013, 32, 2728-2746.	0.8	45

#	ARTICLE	IF	CITATIONS
216	Targeted therapies of metastatic breast cancer: Relationships with cancer stem cells. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 543-555.	2.5	11
217	New Microtubule Inhibitors in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2013, 5, 1-10.	0.5	5
218	Changing Concepts of Hormone Receptor-Positive Advanced Breast Cancer Therapy. <i>Clinical Breast Cancer</i> , 2013, 13, 159-166.	1.1	24
219	Prognostic Role of Human Epidermal Growth Factor Receptor 2 Status in Premenopausal Early Breast Cancer Treated With Adjuvant Tamoxifen. <i>Clinical Breast Cancer</i> , 2013, 13, 247-253.	1.1	10
220	Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer- Study BES 06. <i>Targeted Oncology</i> , 2013, 8, 137-143.	1.7	9
221	Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 715-722.	1.9	16
222	Estrogen-Mediated Mechanisms to Control the Growth and Apoptosis of Breast Cancer Cells. <i>Vitamins and Hormones</i> , 2013, 93, 1-49.	0.7	13
223	Sex Hormone Receptors in Breast Cancer. <i>Vitamins and Hormones</i> , 2013, 93, 99-133.	0.7	10
224	Tumor vasculature: the Achilles' heel of cancer?. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 7-20.	1.5	20
225	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - Results of the randomised GeparQuinto study (GBC 44). <i>European Journal of Cancer</i> , 2013, 49, 2284-2293.	1.3	75
226	Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer. <i>Future Medicinal Chemistry</i> , 2013, 5, 1023-1035.	1.1	38
227	The evolving landscape of protein kinases in breast cancer: Clinical implications. <i>Cancer Treatment Reviews</i> , 2013, 39, 68-76.	3.4	20
228	New strategies for targeting the hypoxic tumour microenvironment in breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 171-179.	3.4	167
229	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, R83-R99.	1.6	272
230	Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6360-6370.	3.2	82
232	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. <i>Future Oncology</i> , 2013, 9, 1653-1664.	1.1	10
233	Tumour heterogeneity in the clinic. <i>Nature</i> , 2013, 501, 355-364.	13.7	993
235	Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 167-172.	1.1	16

#	ARTICLE	IF	CITATIONS
236	Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3693-3702.	3.2	270
237	Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. <i>Breast Care</i> , 2013, 8, 256-262.	0.8	117
238	The development of endocrine therapy for women with breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 507-517.	3.4	63
239	Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 243-250.	0.7	5
241	Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion. <i>Breast Care</i> , 2013, 8, 293-299.	0.8	15
242	Mammalian Target of Rapamycin as a Rational Therapeutic Target for Breast Cancer Treatment. <i>Oncology</i> , 2013, 84, 43-56.	0.9	34
243	Relevance of Health Economics in the Medical Treatment of Breast Cancer: The View of the Professional Association of Practicing Gynecologic Oncologists e.V. (BNGO). <i>Breast Care</i> , 2013, 8, 29-33.	0.8	3
246	Everolimus-induced Severe Pulmonary Toxicity with Diffuse Alveolar Hemorrhage. <i>Annals of the American Thoracic Society</i> , 2013, 10, 727-729.	1.5	19
247	Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 679-685.	1.9	8
252	N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now) Tj ETQq1 1 0.7843146gBT /Overlock 10		
253	Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens. <i>Clinical Cancer Research</i> , 2013, 19, 3987-3995.	3.2	57
254	Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation. <i>Annals of Oncology</i> , 2013, 24, 1956-1957.	0.6	21
255	Targeted Therapy for Breast Cancer Prevention. <i>Frontiers in Oncology</i> , 2013, 3, 250.	1.3	118
256	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 1.	0.4	10
257	A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma. <i>Cancers</i> , 2013, 5, 418-429.	1.7	8
258	First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER. <i>Oncologist</i> , 2013, 18, 501-510.	1.9	63
259	Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive her2-Negative Advanced Breast Cancer after Progression or Recurrence on Nonsteroidal Aromatase Inhibitor Therapy: A Canadian Consensus Statement. <i>Current Oncology</i> , 2013, 20, 48-61.	0.9	23
261	Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma. <i>Melanoma Research</i> , 2013, 23, 468-473.	0.6	28

#	ARTICLE	IF	CITATIONS
263	Advances in the treatment of luminal breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2013, 25, 49-54.	0.9	16
264	Side-effects associated with targeted therapies in renal cell carcinoma. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 254-257.	0.5	7
265	Personalized medicine for metastatic breast cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 615-624.	1.1	6
266	Actionable mutations in muscle-invasive bladder cancer. <i>Current Opinion in Urology</i> , 2013, 23, 472-478.	0.9	15
268	Targeting receptor tyrosine kinases in HER2-negative breast cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 594-601.	1.1	9
269	Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 769-780.	0.7	11
270	Targeted therapies of solid cancers. <i>Current Opinion in Oncology</i> , 2013, 25, 296-304.	1.1	21
271	Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury,)</i> Tj ETQq1 1 0.784314 rgBT /Overl	1.0	106
272	Clinical Efficacy of Targeted Biologic Agents as Second-Line Therapy of Advanced Thyroid Cancer. <i>Oncologist</i> , 2013, 18, 1262-1269.	1.9	13
273	Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells. <i>Carcinogenesis</i> , 2013, 34, 703-712.	1.3	81
274	Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. <i>Clinical Cancer Research</i> , 2013, 19, 5474-5484.	3.2	72
275	Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor. <i>Journal of Clinical Oncology</i> , 2013, 31, 2128-2135.	0.8	359
276	Power of Rare Diseases: Found in Translation. <i>Science Translational Medicine</i> , 2013, 5, 201ps11.	5.8	24
277	Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. <i>Annals of Oncology</i> , 2013, 24, 2092-2097.	0.6	31
278	Where does radioimmunotherapy fit in the management of breast cancer?. <i>Immunotherapy</i> , 2013, 5, 895-904.	1.0	5
279	GDNF RET Signaling in ER-Positive Breast Cancers Is a Key Determinant of Response and Resistance to Aromatase Inhibitors. <i>Cancer Research</i> , 2013, 73, 3783-3795.	0.4	97
280	Hallmarks of Aromatase Inhibitor Drug Resistance Revealed by Epigenetic Profiling in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6632-6641.	0.4	79
281	Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 1269-1278.	1.5	40

#	ARTICLE	IF	CITATIONS
282	New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 587-593.	1.1	11
283	Circulating tumour cells: insights into tumour heterogeneity. <i>Journal of Internal Medicine</i> , 2013, 274, 137-143.	2.7	42
284	Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. <i>Breast Cancer: Basic and Clinical Research</i> , 2013, 7, BCBCR.S10071.	0.6	31
285	Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. <i>Endocrine-Related Cancer</i> , 2013, 20, R183-R201.	1.6	88
286	New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus. <i>Therapeutics and Clinical Risk Management</i> , 2013, 9, 27.	0.9	16
287	Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2013, 2013, 1-10.	0.4	20
288	Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes. <i>International Journal of Breast Cancer</i> , 2013, 2013, 1-15.	0.6	146
289	Treatment of Estrogen Receptor-Positive Breast Cancer. <i>Current Medicinal Chemistry</i> , 2013, 20, 596-604.	1.2	213
290	Genomic Profiling in Luminal Breast Cancer. <i>Breast Care</i> , 2013, 8, 414-422.	0.8	11
291	Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis. <i>Cancer Medicine</i> , 2013, 2, 862-871.	1.3	50
292	Challenges in the clinical development of PI3K inhibitors. <i>Annals of the New York Academy of Sciences</i> , 2013, 1280, 19-23.	1.8	38
293	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. <i>Pharmacological Reviews</i> , 2013, 65, 1351-1395.	7.1	33
294	Inhibiting the RAS/PI3K Pathway in Cancer Therapy. <i>The Enzymes</i> , 2013, 34 Pt. B, 107-136.	0.7	20
295	Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 14-32.	1.8	74
296	Immunosuppressants in cancer prevention and therapy. <i>Oncolmmunology</i> , 2013, 2, e26961.	2.1	42
297	Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 131-161.	0.8	40
298	Selective anti-cancer agents as anti-aging drugs. <i>Cancer Biology and Therapy</i> , 2013, 14, 1092-1097.	1.5	41
299	Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. <i>Oncogene</i> , 2013, 32, 5315-5330.	2.6	44

#	ARTICLE	IF	CITATIONS
300	Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. <i>British Journal of Cancer</i> , 2013, 108, 2478-2484.	2.9	31
301	Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. <i>Journal of Medical Economics</i> , 2013, 16, 278-288.	1.0	17
302	Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. <i>Oncogenesis</i> , 2013, 2, e83-e83.	2.1	69
303	Health-related quality of life and disease symptoms in postmenopausal women with HR ⁺ , HER2 ⁻ advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013, 29, 1463-1473.	0.9	24
304	Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6882-6890.	3.2	103
305	Endocrine resistance: mechanisms and therapeutic targets. <i>Clinical Investigation</i> , 2013, 3, 681-690.	0.0	2
306	HOXB13 Mediates Tamoxifen Resistance and Invasiveness in Human Breast Cancer by Suppressing ER α and Inducing IL-6 Expression. <i>Cancer Research</i> , 2013, 73, 5449-5458.	0.4	80
307	Improving Endocrine Therapy for Breast Cancer: It's Not That Simple. <i>Journal of Clinical Oncology</i> , 2013, 31, 171-173.	0.8	29
308	Angioedema in a Patient With Renal Cell Cancer Treated With Everolimus in Combination With an Angiotensin-Converting Enzyme Inhibitor. <i>Journal of Clinical Oncology</i> , 2013, 31, e57-e58.	0.8	9
309	Emerging treatments for metastatic breast cancer: update from 2012. <i>Breast Cancer Management</i> , 2013, 2, 33-45.	0.2	0
310	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R97.	2.2	17
311	Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 5-9.	2.3	25
312	The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 670-678.	2.3	96
313	Reply to A. Ocana et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 1253-1254.	0.8	0
314	Endocrine therapy for breast cancer. <i>Menopause</i> , 2013, 20, 714-716.	0.8	4
315	Conference Scene: Update from the 30th Miami Breast Cancer Conference. <i>Breast Cancer Management</i> , 2013, 2, 279-281.	0.2	0
317	Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 369-372.	0.5	37
318	Expression and activation of P38 MAP kinase in invasive ductal breast cancers: Correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins. <i>Oncology Reports</i> , 2013, 30, 1943-1948.	1.2	15

#	ARTICLE	IF	CITATIONS
319	Long-term efficacy and safety of exemestane in the treatment of breast cancer. <i>Patient Preference and Adherence</i> , 2013, 7, 245.	0.8	14
320	Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2013, 5, 27.	1.0	2
321	Granuloma-forming Interstitial Pneumonia Occurring One Year after the Start of Everolimus Therapy. <i>Internal Medicine</i> , 2013, 52, 263-267.	0.3	8
322	Major clinical research advances in gynecologic cancer in 2012. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 66.	1.0	36
323	Immunostimulatory activity of lifespan-extending agents. <i>Aging</i> , 2013, 5, 793-801.	1.4	27
324	Emerging targeted combinations in the management of breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2013, 5, 61.	1.0	4
325	Biologic Impact and Clinical Implication of mTOR Inhibition in Metastatic Breast Cancer. <i>International Journal of Biological Markers</i> , 2013, 28, 233-241.	0.7	3
326	Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e65166.	1.1	29
327	Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt. <i>PLoS ONE</i> , 2013, 8, e68973.	1.1	22
328	Arsenic Trioxide Overcomes Rapamycin-Induced Feedback Activation of AKT and ERK Signaling to Enhance the Anti-Tumor Effects in Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e85995.	1.1	25
329	Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2013, 13, 175-187.	0.8	36
330	Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches. <i>Frontiers in Pharmacology</i> , 2013, 4, 3.	1.6	20
331	Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling. <i>Current Cancer Drug Targets</i> , 2013, 13, 188-204.	0.8	72
332	Ten Years of Progress Against Breast Cancer: A Partnership of Basic and Clinical/Translational Science. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 132-136.	2.3	0
333	Treating Breast Cancer in the 21st Century: Emerging Biological Therapies. <i>Journal of Cancer</i> , 2013, 4, 117-132.	1.2	140
334	Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate. , 0, , .		1
336	Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers. <i>PLoS ONE</i> , 2014, 9, e88401.	1.1	30
337	Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e95219.	1.1	140

#	ARTICLE	IF	CITATIONS
338	Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines. PLoS ONE, 2014, 9, e105792.	1.1	23
339	Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature. Journal of Transplantation, 2014, 2014, 1-13.	0.3	41
340	Endocrine Resistance in Breast Cancer. New Journal of Science, 2014, 2014, 1-27.	1.0	55
341	Neoadjuvant Strategies for Triple Negative Breast Cancer: "State-of-the-art"™ and Future Perspectives. Anti-Cancer Agents in Medicinal Chemistry, 2014, 15, 15-25.	0.9	7
342	Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. Journal of Clinical Medicine, 2014, 3, 1-24.	1.0	51
343	Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. World Journal of Clinical Oncology, 2014, 5, 990.	0.9	87
344	Chemotherapy in Breast Cancer. The Ewha Medical Journal, 2014, 37, 75.	0.1	2
345	Insulin-Like Growth Factors, Insulin, and Growth Hormone Signaling in Breast Cancer: Implications for Targeted Therapy. Endocrine Practice, 2014, 20, 1214-1221.	1.1	20
346	Considerations for payers in managing hormone receptor-positive advanced breast cancer. ClinicoEconomics and Outcomes Research, 2014, 6, 331.	0.7	2
347	Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World Journal of Gastroenterology, 2014, 20, 6716.	1.4	39
348	PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 142-148.	0.6	18
349	mTOR and Regulation of Translation. , 2014, , 307-343.		3
350	New Therapies and Functional-Molecular Imaging. , 2014, , 77-96.		0
351	Targeting translation initiation in breast cancer. Translation, 2014, 2, e28968.	2.9	1
354	mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2817-26.	3.3	82
355	<i>PIK3CA</i> Activating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptor-Positive Breast Cancer?. Journal of Clinical Oncology, 2014, 32, 2932-2934.	0.8	32
356	Use of Proliferation Signal Inhibitors in Cardiac Transplantation. Current Transplantation Reports, 2014, 1, 273-281.	0.9	3
357	Genome-based approaches for the diagnosis of breast cancer: a review with perspective. Breast Cancer Management, 2014, 3, 173-193.	0.2	0

#	ARTICLE	IF	CITATIONS
358	Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. <i>Breast Cancer Research</i> , 2014, 16, 430.	2.2	61
359	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. <i>British Journal of Cancer</i> , 2014, 111, 1888-1898.	2.9	100
360	Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe. <i>Journal of Medical Economics</i> , 2014, 17, 837-845.	1.0	8
361	Successes and Limitations of Targeted Cancer Therapy in Breast Cancer. <i>Progress in Tumor Research</i> , 2014, 41, 15-35.	0.1	34
362	Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1529-1536.	1.1	13
363	Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. <i>Oncologist</i> , 2014, 19, 608-615.	1.9	205
364	p-mTOR expression is associated with better prognosis in luminal breast carcinoma. <i>Journal of Clinical Pathology</i> , 2014, 67, 961-967.	1.0	10
365	Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 847-858.	1.3	17
366	The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 955-964.	1.1	17
367	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 361-372.	1.0	30
368	Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. <i>Molecular and Cellular Oncology</i> , 2014, 1, e963447.	0.3	9
369	Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). <i>Biomedical Reports</i> , 2014, 2, 41-52.	0.9	85
370	Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis. <i>Bone Marrow Transplantation</i> , 2014, 49, 1412-1418.	1.3	21
371	Benefits of investment into modern medicines in Central and Eastern European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 71-79.	0.7	11
372	Everolimus Dramatically Improves Glycemic Control in Unresectable Metastatic Insulinoma: A Case Report. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 186-190.	0.6	14
373	Temsirolimus induces surfactant lipid accumulation and lung inflammation in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L1117-L1128.	1.3	15
375	Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. <i>Acta Oncologica</i> , 2014, 53, 174-185.	0.8	29
376	Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 649-665.	1.1	12

#	ARTICLE	IF	CITATIONS
377	mTOR in Viral Hepatitis and Hepatocellular Carcinoma: Function and Treatment. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	22
378	Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	40
379	Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	86
380	Progression-free or overall survivalâ€¦ revisited in BOLERO-2. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2014, 35, 1.	0.1	1
381	Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. <i>Clinical Cancer Research</i> , 2014, 20, 3507-3520.	3.2	100
382	Neoadjuvant endocrine therapy in breast cancer. <i>Breast Cancer Management</i> , 2014, 3, 195-203.	0.2	0
384	Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. <i>Breast Cancer Research</i> , 2014, 16, 434.	2.2	157
385	The mechanistic target of rapamycin pathway in sarcomas: from biology to therapy. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 653-664.	0.5	0
386	Molecular mechanisms regulating the hormone sensitivity of breast cancer. <i>Cancer Science</i> , 2014, 105, 1377-1383.	1.7	32
388	Letter to the Editor. <i>Journal of Medical Economics</i> , 2014, 17, 248-249.	1.0	0
389	Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer. <i>Clinical Investigation</i> , 2014, 4, 19-33.	0.0	9
391	Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer. <i>Immunotherapy</i> , 2014, 6, 811-819.	1.0	9
392	What is the potential of using PI3K inhibitors in the management of breast cancer in the clinic?. <i>Breast Cancer Management</i> , 2014, 3, 345-357.	0.2	0
393	Inhibition of RET Increases the Efficacy of Antiestrogen and Is a Novel Treatment Strategy for Luminal Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2115-2125.	3.2	39
394	Adverse Event Management of Oral Mucositis in Patients with Breast Cancer. <i>Breast Care</i> , 2014, 9, 232-237.	0.8	12
395	PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. <i>International Journal of Cancer</i> , 2014, 135, 1257-1263.	2.3	23
396	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. <i>Annals of Oncology</i> , 2014, 25, 1597-1603.	0.6	59
397	Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. <i>Annals of Oncology</i> , 2014, 25, 763-773.	0.6	67

#	ARTICLE	IF	CITATIONS
398	Reply to the letter to the editor â€“Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancerâ€” Tannock and Pond. <i>Annals of Oncology</i> , 2014, 25, 2096-2098.	0.6	0
399	Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer. <i>Annals of Oncology</i> , 2014, 25, 2096.	0.6	3
400	Clinical Outcome With Correlation to Disseminated Tumor Cell (DTC) Status After DTC-Guided Secondary Adjuvant Treatment With Docetaxel in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3848-3857.	0.8	71
401	Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. <i>Current Medical Research and Opinion</i> , 2014, 30, 1007-1016.	0.9	42
402	Mammalian target of rapamycin (<scp>mTOR</scp>) inhibitorâ€“associated nonâ€“infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. <i>BJU International</i> , 2014, 113, 376-382.	1.3	48
403	Loss of B â€“cell translocation gene 2 expression in estrogen receptorâ€“positive breast cancer predicts tamoxifen resistance. <i>Cancer Science</i> , 2014, 105, 675-682.	1.7	8
404	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. <i>Annals of Oncology</i> , 2014, 25, 808-815.	0.6	112
405	Managing Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway. <i>Breast Journal</i> , 2014, 20, 347-357.	0.4	3
406	Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial. <i>Breast Diseases</i> , 2014, 25, 349-351.	0.0	3
407	The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 154-166.	1.4	378
408	mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. <i>Future Oncology</i> , 2014, 10, 443-456.	1.1	11
409	Pharmacotherapy of bone metastases in breast cancer patients â€“ an update. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1109-1118.	0.9	8
410	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). <i>Annals of Oncology</i> , 2014, 25, 1871-1888.	0.6	402
411	Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. <i>Breast Cancer Research</i> , 2014, 16, R68.	2.2	26
412	Use of mTOR inhibitors in the treatment of malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 979-990.	0.9	5
413	Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1227-1234.	1.1	11
414	The efficacy of second-line hormone therapy for recurrence during adjuvant hormone therapy for breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 36-42.	1.4	1
415	Phase II study of everolimusâ€“erlotinib in previously treated patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 409-415.	0.6	43

#	ARTICLE	IF	CITATIONS
416	Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors. <i>Investigational New Drugs</i> , 2014, 32, 1308-1310.	1.2	10
417	Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer. <i>BMC Cancer</i> , 2014, 14, 794.	1.1	25
418	A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. <i>BMC Medicine</i> , 2014, 12, 93.	2.3	69
419	Everolimus in acute kidney injury in a patient with breast cancer: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 386.	0.4	6
420	Role of bone-anabolic agents in the treatment of breast cancer bone metastases. <i>Breast Cancer Research</i> , 2014, 16, 484.	2.2	35
421	Estrogen receptor mutations and their role in breast cancer progression. <i>Breast Cancer Research</i> , 2014, 16, 494.	2.2	83
422	The multitude of molecular analyses in cancer: the opening of Pandora's box. <i>Genome Biology</i> , 2014, 15, 447.	3.8	12
423	The renaissance of endocrine therapy in breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2014, 26, 41-47.	0.9	22
424	Rash to the mTOR Inhibitor Everolimus. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 266-271.	0.6	19
425	Nonsurgical oncological management of cancer pain. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 102-111.	0.5	19
426	Primary endocrine therapy as an approach for patients with localized breast cancer deemed not to be surgical candidates. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 53-58.	0.5	9
427	Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2014, 25, 1095-1101.	0.7	14
428	Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer—CALGB 40302 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 3959-3966.	0.8	77
429	Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. <i>European Respiratory Review</i> , 2014, 23, 30-35.	3.0	18
430	Treatment-Related Mortality With Everolimus in Cancer Patients. <i>Oncologist</i> , 2014, 19, 661-668.	1.9	12
431	Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer. <i>Science Translational Medicine</i> , 2014, 6, 229ra41.	5.8	72
432	Everolimus in Breast Cancer. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1194-1201.	0.9	8
433	Advances in mechanisms of resistance to aromatase inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 381-393.	1.1	9

#	ARTICLE	IF	CITATIONS
434	Everolimus. Recent Results in Cancer Research, 2014, 201, 373-392.	1.8	54
435	Unintended Consequences of Expensive Cancer Therapeuticsâ€”The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 1225.	1.2	263
436	Hormone Responsive Cancers. , 2014, , 651-698.e14.		0
437	Targeting PI3K/Akt/mTOR Signaling in Cancer. Frontiers in Oncology, 2014, 4, 64.	1.3	1,077
438	Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma. Case Reports in Medicine, 2014, 2014, 1-5.	0.3	7
439	Targeting PI3K/mTOR Signaling in Cancer. Frontiers in Oncology, 2014, 4, 84.	1.3	450
440	Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer: Targets and Therapy, 2014, 6, 123.	1.0	63
441	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 2014, 106, djt337-djt337.	3.0	218
442	ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism. European Journal of Endocrinology, 2014, 170, R43-R55.	1.9	73
443	Trop-2-targeting tetrakis-ranpirnase has potent antitumor activity against triple-negative breast cancer. Molecular Cancer, 2014, 13, 53.	7.9	22
444	PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Research, 2014, 16, 201.	2.2	94
445	Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Research, 2014, 16, R36.	2.2	63
446	Hyperglycemic-Inducing Neoadjuvant Agents Used in Treatment of Solid Tumors: A Review of the Literature. Oncology Nursing Forum, 2014, 41, E343-E354.	0.5	31
447	Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study. Journal of Clinical Oncology, 2014, 32, 2951-2958.	0.8	101
448	Clinical value of isoform-specific detection and targeting of AKT1, AKT2 and AKT3 in breast cancer. Breast Cancer Management, 2014, 3, 409-421.	0.2	3
449	Everolimus: a new hope for patients with breast cancer. Current Medical Research and Opinion, 2014, 30, 75-87.	0.9	21
450	mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Letters, 2014, 346, 309-317.	3.2	22
451	Boswellia ovalifoliolata abrogates ROS mediated NF- κ B activation, causes apoptosis and chemosensitization in Triple Negative Breast Cancer cells. Environmental Toxicology and Pharmacology, 2014, 38, 58-70.	2.0	26

#	ARTICLE	IF	CITATIONS
452	Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology. <i>European Journal of Cancer</i> , 2014, 50, 486-495.	1.3	66
453	Metabolic complications with the use of mTOR inhibitors for cancer therapy. <i>Cancer Treatment Reviews</i> , 2014, 40, 190-196.	3.4	67
454	Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. <i>Breast Cancer</i> , 2014, 21, 703-714.	1.3	57
455	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. <i>Targeted Oncology</i> , 2014, 9, 195-204.	1.7	20
456	Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. <i>Medical Oncology</i> , 2014, 31, 776.	1.2	26
457	A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 325-332.	1.1	52
458	Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 227-237.	1.1	19
459	Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 125-133.	1.1	33
460	Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 113-124.	1.1	42
461	The Fibroblast Growth Factor Receptor: A New Potential Target for the Treatment of Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 51-58.	0.5	2
463	Tumor Heterogeneity Confounds and Illuminates: A case for Darwinian tumor evolution. <i>Nature Medicine</i> , 2014, 20, 344-346.	15.2	57
464	Emergence of Constitutively Active Estrogen Receptor- β Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1757-1767.	3.2	529
465	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254.	3.3	25
466	Breast cancer. <i>Gynecologic Oncology</i> , 2014, 132, 264-267.	0.6	4
467	Targeting the nucleolus for cancer intervention. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 802-816.	1.8	198
468	mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 287-298.	1.1	42
469	Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook. <i>BioDrugs</i> , 2014, 28, 373-381.	2.2	14
470	Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study. <i>Tumor Biology</i> , 2014, 35, 1275-1286.	0.8	25

#	ARTICLE	IF	CITATIONS
471	Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. <i>Breast Cancer Research</i> , 2014, 16, R12.	2.2	56
472	PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. <i>Journal of Neuro-Oncology</i> , 2014, 117, 7-13.	1.4	15
473	Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. <i>Breast Cancer Research</i> , 2014, 16, R6.	2.2	46
474	Estrogen receptor (ER) \pm mutations in breast cancer: hidden in plain sight. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 11-19.	1.1	67
475	Best Targeted Sarcoma Treatment: Advances from the Musculoskeletal Tumor Society Annual Meeting. <i>Clinical Orthopaedics and Related Research</i> , 2014, 472, 820-821.	0.7	1
476	Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naïve, advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2014, 32, 123-134.	1.2	5
477	The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2014, 6, 59-70.	0.5	7
478	Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial. <i>Pharmacoeconomics</i> , 2014, 32, 101-108.	1.7	99
479	New Targeted Therapies for Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , 235-246.	0.1	0
480	Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 683-694.	1.6	45
481	Targeted therapies in gastroesophageal cancer. <i>European Journal of Cancer</i> , 2014, 50, 1247-1258.	1.3	45
482	Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 407-420.	0.9	87
483	Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. <i>Annals of Oncology</i> , 2014, 25, 831-836.	0.6	42
484	Current approaches to the treatment of metastatic brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 203-222.	12.5	233
485	Curcumin-induced Aurora-A suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 526-539.	1.9	31
486	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 580-591.	5.1	434
487	Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 862-871.	3.4	257
488	Neoadjuvant chemotherapy with sequential anthracycline docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). <i>Breast</i> , 2014, 23, 142-151.	0.9	5

#	ARTICLE	IF	CITATIONS
489	The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. <i>Clinical Transplantation</i> , 2014, 28, 635-648.	0.8	28
490	Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , 2014, 30, 67-74.	0.9	34
491	Inhibitors of Tumor Angiogenesis. , 2014, , 275-317.		1
492	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2014, , .	1.8	4
493	The management of breast cancer. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 753-757.	1.8	10
494	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 681-700.	0.9	41
495	Cardiotoxicity of systemic agents used in breast cancer. <i>Breast</i> , 2014, 23, 317-328.	0.9	49
496	Biomarkers of drugs targeting <sc>HER</sc>-family signalling in cancer. <i>Journal of Pathology</i> , 2014, 232, 219-229.	2.1	49
497	Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2014, 132, 585-592.	0.6	113
498	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, 142, 164-175.		648
499	Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. <i>Cancer Treatment Reviews</i> , 2014, 40, 205-214.	3.4	75
500	Breast cancer: Current and future endocrine therapies. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 695-723.	1.6	81
501	Time for more optimism in metastatic breast cancer?. <i>Cancer Treatment Reviews</i> , 2014, 40, 220-228.	3.4	59
502	Targeted therapy-induced diarrhea: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 165-179.	2.0	47
503	PI3K and cancer: lessons, challenges and opportunities. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 140-156.	21.5	1,398
504	Everolimus plus exemestane as first-line therapy in HR+, HER2 ⁺ advanced breast cancer in BOLERO-2. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 459-467.	1.1	74
505	Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. <i>Annals of Oncology</i> , 2014, 25, 415-422.	0.6	204
506	Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 11-28.	0.5	54

#	ARTICLE	IF	CITATIONS
507	Bone Metastases. Cancer Metastasis - Biology and Treatment, 2014, , .	0.1	5
508	Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast, 2014, 23, 2-9.	0.9	42
509	Targeting multiple pathways in breast cancer. Breast Cancer Management, 2014, 3, 87-101.	0.2	2
510	Aromatase Deficiency and Aromatase Excess. , 2014, , 165-190.		2
511	Adverse events with everolimus in BOLERO-2. Annals of Oncology, 2014, 25, 1861.	0.6	1
512	Three-year safety and efficacy of everolimus and low-dose cyclosporine in <i>de novo</i> pediatric kidney transplant patients. Pediatric Transplantation, 2014, 18, 350-356.	0.5	18
513	ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast, 2014, 23, 489-502.	0.9	269
514	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study. Pediatric Blood and Cancer, 2014, 61, 833-839.	0.8	87
515	Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. Breast, 2014, 23, 710-720.	0.9	37
516	Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 2515-2526.	1.9	17
517	The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor. Molecular Cancer Therapeutics, 2014, 13, 2547-2558.	1.9	106
518	Targeting protein kinase C in sarcoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 547-559.	3.3	6
519	Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity. Cancer Letters, 2014, 354, 336-347.	3.2	22
520	Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions?. Critical Reviews in Oncology/Hematology, 2014, 92, 235-257.	2.0	65
521	Strategies to Overcome Resistance to Hormonal Therapy. Breast Diseases, 2014, 25, 117-119.	0.0	2
522	Clinical development of mTOR inhibitors in breast cancer. Breast Cancer Research, 2014, 16, 203.	2.2	49
523	Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. SpringerPlus, 2014, 3, 535.	1.2	34
524	Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer. Future Oncology, 2014, 10, 2435-2448.	1.1	9

#	ARTICLE	IF	CITATIONS
525	Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. <i>Science</i> , 2014, 345, 216-220.	6.0	808
526	Aromatase inhibitors in the breast cancer clinic: focus on exemestane. <i>Endocrine-Related Cancer</i> , 2014, 21, R31-R49.	1.6	59
527	Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2014, 32, 2794-2803.	0.8	298
528	Signaling pathways in breast cancer: Therapeutic targeting of the microenvironment. <i>Cellular Signalling</i> , 2014, 26, 2843-2856.	1.7	79
529	Current Options for the Treatment of Facial Angiofibromas. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 558-568.	0.2	8
530	ADJUVANT CHEMOTHERAPY IN OLDER BREAST CANCER PATIENTS: HOW TO DECIDE. <i>Journal of Geriatric Oncology</i> , 2014, 5, S3.	0.5	1
531	Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308.	1.3	32
532	An update on the medical management of breast cancer. <i>BMJ, The</i> , 2014, 348, g3608-g3608.	3.0	54
533	Targeted Therapy in Older Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 2635-2646.	0.8	36
534	Prise en charge du cancer du sein. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 740-744.	0.0	1
535	Therapeutic Antibodies in Breast Cancer. <i>Seminars in Oncology</i> , 2014, 41, 576-588.	0.8	3
536	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. <i>Clinical Cancer Research</i> , 2014, 20, 3133-3145.	3.2	29
537	Prise en charge du cancer du sein, avancées et perspectives. <i>Medecine Nucleaire</i> , 2014, 38, 299-302.	0.2	0
539	Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. <i>Annals of Oncology</i> , 2014, 25, 605-610.	0.6	37
541	Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 433-441.	1.1	17
542	Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 669-673.	1.1	13
543	Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 211-219.	1.1	36
544	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 227-235.	1.1	19

#	ARTICLE	IF	CITATIONS
545	Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. <i>Annals of Oncology</i> , 2014, 25, 2357-2362.	0.6	446
546	Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 636-645.	1.0	25
547	Impact of patient ethnicity on the metabolic and immunologic effects of PI3K/mTOR pathway inhibition in patients with solid tumor malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 359-365.	1.1	8
548	Breast cancer and aging: results of the U13 conference breast cancer panel. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 1-6.	1.1	23
549	Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 153-162.	1.1	43
550	Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 245-258.	1.1	48
551	Emerging strategies to overcome resistance to endocrine therapy for breast cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 791-807.	2.7	23
552	PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. <i>Breast Cancer Research</i> , 2014, 16, R13.	2.2	54
553	Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R32.	2.2	64
554	Endocrine therapy: defining the path of least resistance. <i>Breast Cancer Research</i> , 2014, 16, 101.	2.2	2
555	Elevated Expression of Girdin in the Nucleus Indicates Worse Prognosis for Patients with Estrogen Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 648-656.	0.7	10
556	MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. <i>Science</i> , 2014, 345, 220-222.	6.0	278
557	Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2014, 26, 7-9.	7.7	8
558	Diagnostic challenges of respiratory adverse events during everolimus treatment. <i>Targeted Oncology</i> , 2014, 9, 287-291.	1.7	6
559	Advances in the approach to novel drug clinical development for breast cancer. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 647-668.	2.5	6
560	Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2014, 111, 858-865.	2.9	20
561	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1202-1209.	0.8	159
562	Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts. <i>Clinical Cancer Research</i> , 2014, 20, 4314-4325.	3.2	48

#	ARTICLE	IF	CITATIONS
563	mTor Inhibitors. , 2014, , 267-286.		3
564	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1192-1198.	3.4	51
565	Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 13-19.	1.1	37
566	Opciones terapéuticas actuales para los angiofibromas faciales. <i>Actas Dermo-sifilográficas</i> , 2014, 105, 558-568.	0.2	19
567	A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 241-250.	0.9	25
568	Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor-Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action. <i>Clinical Breast Cancer</i> , 2014, 14, 75-84.	1.1	25
569	Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 320-326.	3.4	21
570	The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. <i>Breast</i> , 2014, 23, 201-208.	0.9	57
571	When is downstream pathway inhibition important?. <i>Lancet Oncology</i> , The, 2014, 15, 541-542.	5.1	0
572	Mammalian Target of Rapamycin Inhibitors: The Beginning of the End or the End of the Beginning?. <i>European Urology</i> , 2014, 66, 282-283.	0.9	0
573	Personalized medicine for breast cancer: it is a new day!. <i>American Journal of Surgery</i> , 2014, 207, 321-325.	0.9	7
574	A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. <i>European Journal of Cancer</i> , 2014, 50, 2057-2064.	1.3	15
575	Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor-Positive Advanced Breast Cancer: Considerations for Oncologists. <i>Clinical Breast Cancer</i> , 2014, 14, 297-308.	1.1	24
576	Drug resistance to targeted therapies: D'jà vu all over again. <i>Molecular Oncology</i> , 2014, 8, 1067-1083.	2.1	187
577	Everolimus in Combination with Mycophenolate Mofetil as Pre- and Post-Transplantation Immunosuppression after Nonmyeloablative Hematopoietic Stem Cell Transplantation in Canine Littermates. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1301-1306.	2.0	11
578	Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. <i>Pharmacogenomics Journal</i> , 2014, 14, 28-34.	0.9	29
579	Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer. <i>Cancer Management and Research</i> , 2014, 6, 389.	0.9	15
580	Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 43.	1.0	26

#	ARTICLE	IF	CITATIONS
581	Treatment of Metastatic Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 759-761.	2.3	9
582	Update on Adjuvant Chemotherapy for Early Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2014, 8, BCBCR.S9454.	0.6	33
583	Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review). <i>International Journal of Oncology</i> , 2014, 45, 1793-1801.	1.4	142
584	Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer. <i>Oncology</i> , 2014, 87, 104-113.	0.9	28
585	Isoegomaketone induces apoptosis in SK-MEL-2 human melanoma cells through mitochondrial apoptotic pathway via activating the PI3K/Akt pathway. <i>International Journal of Oncology</i> , 2014, 45, 1969-1976.	1.4	11
587	Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective. <i>Breast Care</i> , 2014, 9, 52-59.	0.8	6
588	AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014. <i>Breast Care</i> , 2014, 9, 202-209.	0.8	13
589	Everolimus: finding its place in the treatment of hormone receptor-positive advanced breast cancer. <i>Clinical Practice (London, England)</i> , 2014, 11, 563-571.	0.1	0
590	L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway. <i>Oncology Reports</i> , 2014, 31, 2245-2251.	1.2	23
591	New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. <i>International Journal of Oncology</i> , 2015, 46, 1481-1490.	1.4	19
592	Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer. <i>Medicine (United States)</i> , 2015, 94, e1006.	0.4	10
593	AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015. <i>Breast Care</i> , 2015, 10, 199-205.	0.8	10
594	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 170-180.	1.4	105
595	S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts. <i>Endocrine-Related Cancer</i> , 2015, 22, 331-343.	1.6	24
596	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. <i>Journal of Internal Medicine</i> , 2015, 278, 545-570.	2.7	46
600	Cellular and molecular effects of the mTOR inhibitor everolimus. <i>Clinical Science</i> , 2015, 129, 895-914.	1.8	74
601	Optimizing Endocrine Therapy for Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, e56-e64.	2.3	21
602	Treating Triple-Negative Breast Cancer: Where Are We?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, e8-e18.	2.3	1

#	ARTICLE	IF	CITATIONS
603	Everolimus in the Treatment of Metastatic Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9, BCBCR.S29268.	0.6	42
604	Treating Elderly Patients with Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2015, 9, CMO.S26067.	0.6	14
605	Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2015, 9, CMO.S31586.	0.6	15
606	Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 468-474.	0.3	13
607	The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. <i>Chinese Journal of Cancer</i> , 2015, 34, 4-16.	4.9	162
608	Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line. <i>Oncology</i> , 2015, 89, 319-331.	0.9	3
610	Renal failure requiring hemodialysis in two patients with metastatic breast cancer treated with everolimus. <i>Breast Cancer Management</i> , 2015, 4, 129-134.	0.2	1
611	Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. <i>BMC Cancer</i> , 2015, 15, 692.	1.1	16
612	Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. <i>BMC Cancer</i> , 2015, 15, 727.	1.1	51
613	The BMC Medicine breast cancer collection: an illustration of contemporary research and clinical care. <i>BMC Medicine</i> , 2015, 13, 223.	2.3	1
614	PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells. <i>Cancer Cell International</i> , 2015, 15, 91.	1.8	21
615	Patients' preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments. <i>SpringerPlus</i> , 2015, 4, 674.	1.2	13
616	Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. <i>Experimental Hematology and Oncology</i> , 2015, 4, 31.	2.0	12
617	Overcoming Phosphatidylinositol 3-Kinase (PI3K) Activation in Breast Cancer: Emerging PI3K Inhibitors. <i>The Journal of Oncopathology</i> , 2015, 3, 27-39.	0.1	2
618	Everolimus treatment in advanced solid tumors: a personal view. <i>Future Science OA</i> , 2015, 1, FSO3.	0.9	1
619	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. <i>Biomarker Insights</i> , 2015, 10s3, BMI.S22430.	1.0	29
620	Current management of mTOR inhibitor-associated stomatitis. <i>Breast Cancer Management</i> , 2015, 4, 255-264.	0.2	0
621	Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?. <i>Clinical Transplantation</i> , 2015, 29, 654-663.	0.8	10

#	ARTICLE	IF	CITATIONS
622	mTOR inhibition in breast cancer. <i>Breast Cancer Management</i> , 2015, 4, 67-70.	0.2	0
623	Palliative systemic therapy for young women with metastatic breast cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2015, 9, 301-307.	0.5	6
624	Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 123-128.	1.8	39
625	Personalized Medicine: A Review with Regard to Biomarkers. <i>Journal of Bioequivalence & Bioavailability</i> , 2015, 07, .	0.1	12
626	The recent progress of neoadjuvant chemotherapy in triple negative breast cancer: A short review. <i>Journal of Solid Tumors</i> , 2015, 5, .	0.1	0
627	Clinical utility of exemestane in the treatment of breast cancer . <i>International Journal of Women's Health</i> , 2015, 7, 551.	1.1	13
628	Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. <i>OncoTargets and Therapy</i> , 2015, 8, 3323.	1.0	42
629	Mathematical Modelling of Metabolic Regulation in Aging. <i>Metabolites</i> , 2015, 5, 232-251.	1.3	22
630	Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers. <i>Frontiers in Oncology</i> , 2015, 5, 140.	1.3	27
631	Management of cancer of the breast. , 0, , 262-292.		1
632	Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review. <i>Journal of Cancer</i> , 2015, 6, 575-582.	1.2	5
633	Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives. <i>Current Cancer Drug Targets</i> , 2015, 15, 256-269.	0.8	26
634	Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor positive advanced breast cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 3629.	1.0	13
635	A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 19.	1.8	6
636	Correlation between Activation of PI3K/AKT/mTOR Pathway and Prognosis of Breast Cancer in Chinese Women. <i>PLoS ONE</i> , 2015, 10, e0120511.	1.1	37
637	17Å-Estradiol Regulates mTORC2 Sensitivity to Rapamycin in Adaptive Cardiac Remodeling. <i>PLoS ONE</i> , 2015, 10, e0123385.	1.1	9
638	Potential of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. <i>PLoS ONE</i> , 2015, 10, e0131400.	1.1	43
639	Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis. <i>PLoS ONE</i> , 2015, 10, e0145013.	1.1	25

#	ARTICLE	IF	CITATIONS
640	Management of patients with hormone receptor–positive breast cancer with visceral disease: challenges and treatment options. <i>Cancer Management and Research</i> , 2015, 7, 37.	0.9	19
641	Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2 ⁺ Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. <i>International Journal of Breast Cancer</i> , 2015, 2015, 1-9.	0.6	15
642	Targeting the PI3K/AKT/mTOR Pathway in Cancer Cells. , 0, , .		7
644	The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. <i>Aging</i> , 2015, 7, 1032-1049.	1.4	52
645	mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. <i>Oncotarget</i> , 2015, 6, 2088-2100.	0.8	30
646	Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4883-4887.	2.9	147
647	Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach. <i>Seminars in Oncology Nursing</i> , 2015, 31, 146-155.	0.7	41
648	Personalized Therapies for Cancer Treatment. , 2015, , 317-346.		0
649	Early diagnosis and treatment of breast cancer in Japanese kidney transplant recipients: a single center experience. <i>SpringerPlus</i> , 2015, 4, 196.	1.2	5
650	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 541-552.	12.5	121
651	Targeted Therapies for Prostate Cancer. <i>Cancer Investigation</i> , 2015, 33, 276-285.	0.6	7
652	Palbociclib in Hormone-Receptor ⁺ Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 209-219.	13.9	1,239
653	Genomic medicine and targeted therapy for solid tumors. <i>Journal of Surgical Oncology</i> , 2015, 111, 38-42.	0.8	13
654	Targeting the mammalian target of rapamycin pathway with everolimus: Implications for the management of metastatic breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 433-442.	0.5	7
655	Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015, 15, 395.	1.1	96
656	Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2 ⁺ metastatic breast cancer: a retrospective chart review in community oncology practices in the US. <i>Current Medical Research and Opinion</i> , 2015, 31, 1095-1103.	0.9	9
657	Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction. <i>Translational Research</i> , 2015, 166, 783-787.	2.2	7
658	Cancer-targeted therapies and radiopharmaceuticals. <i>BoneKEy Reports</i> , 2015, 4, 707.	2.7	2

#	ARTICLE	IF	CITATIONS
659	Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 477-486.	1.1	3
660	Recent insights into the pathophysiology of mTOR pathway dysregulation. <i>Research and Reports in Biology</i> , 2015, , 1.	0.2	0
661	AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2508-2518.	1.9	106
662	A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 5235-5244.	3.2	25
663	Current Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast Cancer. <i>Visceral Medicine</i> , 2015, 31, 424-432.	0.5	2
664	Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. <i>Breast Care</i> , 2015, 10, 168-172.	0.8	19
665	Systemic Treatment of Older Breast Cancer Patients: Choosing Wisely. <i>Breast Diseases</i> , 2015, 26, 287-290.	0.0	1
666	ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2831-2839.	1.9	23
667	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 206-219.	2.0	22
668	A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases. <i>Case Reports in Oncology</i> , 2015, 8, 101-105.	0.3	4
669	CDK4/6 inhibitors in luminal breast cancer. <i>Lancet Oncology</i> , The, 2015, 16, 2-3.	5.1	7
670	Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 60-65.	1.1	27
671	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2015, 16, 98-107.	5.1	270
672	Everolimus-Induced Hematologic Changes in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 48-53.	1.1	12
673	Outcomes and endpoints in trials of cancer treatment: the past, present, and future. <i>Lancet Oncology</i> , The, 2015, 16, e32-e42.	5.1	152
674	Case 1-2015. <i>New England Journal of Medicine</i> , 2015, 372, 162-170.	13.9	2
675	CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment. <i>Clinical Cancer Research</i> , 2015, 21, 995-1001.	3.2	293
676	The palladacycle, AJ-5, exhibits anti-tumour and anti-cancer stem cell activity in breast cancer cells. <i>Cancer Letters</i> , 2015, 357, 206-218.	3.2	26

#	ARTICLE	IF	CITATIONS
677	Heterogeneity of <i>PIK3CA</i> mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2015, 9, 749-757.	2.1	146
678	Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 547-561.	2.7	11
679	A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 1859-1868.	3.2	22
680	Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76.	3.4	83
681	Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 421-431.	1.9	29
682	Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells. <i>Molecular BioSystems</i> , 2015, 11, 1029-1040.	2.9	37
683	Management of locally advanced breast cancer—perspectives and future directions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 147-162.	12.5	113
684	Mechanisms of hormonal therapy resistance in breast cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 262-267.	1.0	14
685	Patient-derived xenograft models of breast cancer and their predictive power. <i>Breast Cancer Research</i> , 2015, 17, 17.	2.2	225
686	Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. <i>Gynecologic Oncology</i> , 2015, 136, 246-253.	0.6	104
687	A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2-advanced breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 94-104.	3.4	22
688	Immunotherapy for the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2015, 17, 5.	1.8	59
689	Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 291-301.	2.0	24
690	Ten things you should know about protein kinases: IUPHAR Review 14. <i>British Journal of Pharmacology</i> , 2015, 172, 2675-2700.	2.7	270
691	Current treatment strategies for inhibiting mTOR in cancer. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 124-135.	4.0	234
692	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. <i>Neuro-Oncology</i> , 2015, 17, 1261-1269.	0.6	126
693	Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). <i>Targeted Oncology</i> , 2015, 10, 365-373.	1.7	24
694	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2015, 26, 58-64.	0.6	111

#	ARTICLE	IF	CITATIONS
695	The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells. <i>Cancer Cell</i> , 2015, 27, 193-210.	7.7	308
696	The Molecular Biology of Breast Cancer. , 2015, , 523-530.e3.		0
697	A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2015, 33, 187-193.	1.2	35
698	PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 51-68.	1.1	41
699	Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1223-1229.	0.6	45
700	Targeting the translation machinery in cancer. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 261-278.	21.5	628
701	Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 325-331.	1.1	13
702	Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 268-272.	1.0	7
703	Adjuvant systemic therapy in breast cancer: quo vadis?. <i>Annals of Oncology</i> , 2015, 26, 1629-1634.	0.6	18
704	Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase. <i>British Journal of Cancer</i> , 2015, 112, 809-818.	2.9	67
705	Suppression of Early Hematogenous Dissemination of Human Breast Cancer Cells to Bone Marrow by Retinoic Acid-Induced 2. <i>Cancer Discovery</i> , 2015, 5, 506-519.	7.7	45
706	Renal effects of targeted anticancer therapies. <i>Nature Reviews Nephrology</i> , 2015, 11, 354-370.	4.1	95
707	Evolving paradigms in multifocal breast cancer. <i>Seminars in Cancer Biology</i> , 2015, 31, 111-118.	4.3	34
708	RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon γ -2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2015, 26, 1378-1384.	0.6	64
709	The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 66-88.	0.4	9
710	Treatment options in HR+/HER2- advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?. <i>Future Oncology</i> , 2015, 11, 975-981.	1.1	3
712	What to expect from high throughput genomics in metastatic breast cancers?. <i>Breast</i> , 2015, 24, S19-S22.	0.9	4
713	Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. <i>Gynecologic Oncology</i> , 2015, 138, 285-291.	0.6	47

#	ARTICLE	IF	CITATIONS
714	Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. <i>Future Oncology</i> , 2015, 11, 1809-1828.	1.1	19
715	Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1 α and Relation to Clinical Response. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 64-66.	0.9	6
716	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 816-829.	5.1	261
718	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 95-117.	1.1	27
719	Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2015, 16, 11055-11086.	1.8	104
720	PIK3CA: a Target or a Marker in Breast Cancers. <i>Current Breast Cancer Reports</i> , 2015, 7, 161-169.	0.5	6
722	Changing Treatment Paradigms in Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 528.	3.4	88
723	mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. <i>Cancer Letters</i> , 2015, 367, 76-87.	3.2	45
724	Precision medicine for metastatic breast cancer—limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 693-704.	12.5	272
725	Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2015, 51, 1865-1873.	1.3	60
726	Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3591-3596.	3.2	29
727	Living with Metastatic Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2015, 862, 243-254.	0.8	11
728	Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 930-936.	0.8	247
729	The 42nd David A. Karnofsky Memorial Award Lecture: Understanding. <i>Journal of Clinical Oncology</i> , 2015, 33, 510-517.	0.8	0
730	HOXB7 Is an ER α Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. <i>Cancer Discovery</i> , 2015, 5, 944-959.	7.7	72
731	The Strength of Association Between Surrogate End Points and Survival in Oncology. <i>JAMA Internal Medicine</i> , 2015, 175, 1389.	2.6	287
732	Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models. <i>Transplant Immunology</i> , 2015, 33, 45-50.	0.6	11
733	Clinical Translation of Nanomedicine. <i>Chemical Reviews</i> , 2015, 115, 11147-11190.	23.0	619

#	ARTICLE	IF	CITATIONS
734	Emerging physiological and pathological implications of tunneling nanotubes formation between cells. <i>European Journal of Cell Biology</i> , 2015, 94, 429-443.	1.6	84
735	Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2015, 31, 1573-1582.	0.9	4
736	Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 847-858.	1.1	15
737	Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?. <i>Oncologist</i> , 2015, 20, 719-724.	1.9	46
738	Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 642-649.	1.2	63
739	One step forward, two steps back: The story of everolimus in advanced breast cancer. <i>Breast</i> , 2015, 24, 529-531.	0.9	4
740	Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2 ⁺ Advanced Breast Cancer From a US Payer Perspective. <i>Clinical Breast Cancer</i> , 2015, 15, e263-e276.	1.1	21
741	ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 573-583.	12.5	458
742	Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2 ⁻) advanced breast cancer in Kazakhstan. <i>Journal of Medical Economics</i> , 2015, 18, 189-199.	1.0	5
743	Emerging drugs for the treatment of bone metastasis. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 637-651.	1.0	5
744	Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines. <i>Current Oncology</i> , 2015, 22, 29-42.	0.9	18
745	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>Investigational New Drugs</i> , 2015, 33, 700-709.	1.2	12
746	Influence of censoring on conclusions of trials for women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 721-724.	1.3	16
747	Targeted Therapy in Advanced Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 253-262.	0.8	14
748	Mechanisms of aromatase inhibitor resistance. <i>Nature Reviews Cancer</i> , 2015, 15, 261-275.	12.8	319
749	Câncer de mama metastásico. <i>EMC - Ginecologãa-Obstetricia</i> , 2015, 51, 1-14.	0.0	3
750	Therapies for triple negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 983-998.	0.9	85
751	In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 669-680.	1.1	46

#	ARTICLE	IF	CITATIONS
752	Treatment-related fatigue with everolimus and temsirolimus in patients with cancer—a meta-analysis of clinical trials. <i>Tumor Biology</i> , 2015, 36, 643-654.	0.8	8
754	Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. <i>Cancer Biology and Therapy</i> , 2015, 16, 567-579.	1.5	50
755	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. <i>BMC Medicine</i> , 2015, 13, 46.	2.3	27
756	Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing. <i>Human Genomics</i> , 2015, 9, 2.	1.4	36
757	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51.	5.8	276
758	Site-specific bioalkylation of rapamycin by the RapM 16-O-methyltransferase. <i>Chemical Science</i> , 2015, 6, 2885-2892.	3.7	47
759	Resistance to Aromatase Inhibitors in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, . .	0.1	4
760	Elucidating the genomic landscape of breast cancer: how will this affect treatment?. <i>Pharmacogenomics</i> , 2015, 16, 569-572.	0.6	2
761	Molecular characterization and targeted therapeutic approaches in breast cancer. <i>Breast Cancer Research</i> , 2015, 17, 60.	2.2	132
762	EPMA position paper in cancer: current overview and future perspectives. <i>EPMA Journal</i> , 2015, 6, 9.	3.3	86
763	Higher Risk of Infections with PI3K/AKT/mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. <i>Clinical Cancer Research</i> , 2015, 21, 1869-1876.	3.2	33
765	Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 231-242.	1.1	35
766	Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects. <i>Cancer Science</i> , 2015, 106, 337-343.	1.7	84
767	Molecular pathogenesis of ovarian clear cell carcinoma. <i>Future Oncology</i> , 2015, 11, 1389-1405.	1.1	26
768	The phosphoinositide 3-kinase pathway and therapy resistance in cancer. <i>F1000prime Reports</i> , 2015, 7, 13.	5.9	91
769	Reply to the letter to the editor “Measured and estimated glomerular filtration rate for carboplatin dose calculation” by Cathomas et al.. <i>Annals of Oncology</i> , 2015, 26, 249-250.	0.6	1
770	New targets in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 86-91.	0.3	0
771	Treatment patterns and duration in post-menopausal women with HR+/HER2 \sim metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010). <i>Current Medical Research and Opinion</i> , 2015, 31, 263-273.	0.9	27

#	ARTICLE	IF	CITATIONS
772	Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2. <i>Neoplasia</i> , 2015, 17, 279-288.	2.3	56
773	The biology behind PI3K inhibition in chronic lymphocytic leukaemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 25-36.	1.1	13
774	Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients. <i>Cancer Investigation</i> , 2015, 33, 70-77.	0.6	27
775	New approaches for improving outcomes in breast cancer in Europe. <i>Breast</i> , 2015, 24, 321-330.	0.9	42
776	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. <i>Clinical Cancer Research</i> , 2015, 21, 3412-3419.	3.2	101
777	Chemotherapy for Metastatic Breast Cancer – An Anachronism in the Era of Personalised and Targeted Oncological Therapy?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 574-583.	0.8	19
779	The changing role of ER in endocrine resistance. <i>Breast</i> , 2015, 24, S60-S66.	0.9	97
780	Targeted therapy in cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1113-1132.	1.1	139
781	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. <i>Clinical Cancer Research</i> , 2015, 21, 5092-5099.	3.2	3
782	Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study. <i>Breast</i> , 2015, 24, 718-722.	0.9	8
783	mTOR inhibitors and diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 101-108.	1.1	86
784	The role of steroid hormones in breast cancer stem cells. <i>Endocrine-Related Cancer</i> , 2015, 22, T177-T186.	1.6	35
785	Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 287-297.	1.1	26
786	Better Together: Targeted Combination Therapies in Breast Cancer. <i>Seminars in Oncology</i> , 2015, 42, 887-895.	0.8	45
787	Clinical and molecular complexity of breast cancer metastases. <i>Seminars in Cancer Biology</i> , 2015, 35, 85-95.	4.3	118
788	Optimal management of hormone receptor positive metastatic breast cancer in 2016. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 304-320.	1.4	104
789	Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. <i>BMC Health Services Research</i> , 2015, 15, 307.	0.9	10
790	Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. <i>BMC Cancer</i> , 2015, 15, 241.	1.1	16

#	ARTICLE	IF	CITATIONS
791	Targeted therapies for ER+/HER2- metastatic breast cancer. <i>BMC Medicine</i> , 2015, 13, 137.	2.3	59
792	mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells. <i>Journal of Immunology</i> , 2015, 195, 2038-2045.	0.4	23
793	The role of censoring on progression free survival: Oncologist discretion advised. <i>European Journal of Cancer</i> , 2015, 51, 2269-2271.	1.3	18
794	Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 2518-2523.	0.6	1
796	Breast Cancer Update 2014 – Focus on the Patient and the Tumour. <i>Geburtshilfe Und Frauenheilkunde</i> , 2015, 75, 170-182.	0.8	9
798	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
799	Multiple gene aberrations and breast cancer: lessons from super-responders. <i>BMC Cancer</i> , 2015, 15, 442.	1.1	11
800	Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 89-97.	1.1	22
801	Early Surrogate Markers of Treatment Activity: Where Are We Now?. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 24-28.	0.9	15
802	Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv212.	3.0	79
803	Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. <i>Neuro-Oncology</i> , 2015, 17, 1550-1559.	0.6	123
804	Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2101-2111.	0.9	2
805	Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR+/HER2- metastatic breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 315-326.	0.6	2
806	Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. <i>Future Oncology</i> , 2015, 11, 2251-2254.	1.1	1
807	Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2642-2652.	1.9	23
808	Palbociclib. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1252-1260.	0.9	28
809	Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. <i>Endocrine-Related Cancer</i> , 2015, 22, 831-840.	1.6	51
810	Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 98.	6.9	54

#	ARTICLE	IF	CITATIONS
811	The MAGE protein family and cancer. <i>Current Opinion in Cell Biology</i> , 2015, 37, 1-8.	2.6	184
812	Ligand-Independent Signalling Through Estrogen Receptor Pathways in Breast Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2015, , 115-144.	0.1	0
813	Microbe-associated immunomodulatory metabolites: Influence on T cell fate and function. <i>Molecular Immunology</i> , 2015, 68, 575-584.	1.0	23
814	Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?. <i>Current Oncology Reports</i> , 2015, 17, 46.	1.8	6
815	Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. <i>Cell Stem Cell</i> , 2015, 17, 260-271.	5.2	328
816	Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. <i>Future Oncology</i> , 2015, 11, 1687-1699.	1.1	46
817	Complications of hyperglycaemia with PI3KÄAKTÄmTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. <i>British Journal of Cancer</i> , 2015, 113, 1541-1547.	2.9	30
818	Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints. <i>Breast</i> , 2015, 24, S78-S83.	0.9	22
819	Metastasis to the Cervix Uteri 15 Years After Treatment of Lobular Carcinoma of the Breast. <i>Seminars in Oncology</i> , 2015, 42, e81-e94.	0.8	7
820	Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. <i>Future Oncology</i> , 2015, 11, 79-90.	1.1	15
821	Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies. <i>Scientific Reports</i> , 2015, 4, 6587.	1.6	39
822	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 25-35.	5.1	1,574
823	Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, e55-e62.	1.1	40
824	Loss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast Cancer. <i>Cancer Research</i> , 2015, 75, 436-445.	0.4	75
825	Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. <i>Annals of Oncology</i> , 2015, 26, 120-125.	0.6	75
826	<i>Breast Diseases</i> . , 2015, , .		7
827	Effectiveness of Targeted Therapy in Patients With Previously Untreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Breast Cancer</i> , 2015, 15, 90-100.e1.	1.1	40
828	The impact of tumor stroma on drug response in breast cancer. <i>Seminars in Cancer Biology</i> , 2015, 31, 3-15.	4.3	82

#	ARTICLE	IF	CITATIONS
829	Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?. <i>Cancer</i> , 2015, 121, 517-526.	2.0	19
830	Organic anion transporting polypeptide 2B1 expression correlates with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast cancer cells. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 133-141.	1.1	22
831	The Combination of Rapamycin and Resveratrol Blocks Autophagy and Induces Apoptosis in Breast Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 450-457.	1.2	90
832	Pharmacokinetic interaction involving fenofibrate and everolimus. <i>Annals of Oncology</i> , 2015, 26, 248-249.	0.6	14
833	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2015, 21, 49-59.	3.2	49
834	HIF1 α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells. <i>Molecular Cancer Research</i> , 2015, 13, 556-564.	1.5	77
835	Targeting PI3 kinase in cancer. , 2015, 146, 53-60.		129
836	Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials. <i>Acta Oncologica</i> , 2015, 54, 124-132.	0.8	9
837	Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. <i>Oncogene</i> , 2015, 34, 3617-3626.	2.6	211
838	Everolimus-associated stomatitis in a patient who had renal transplant. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217513.	0.2	6
839	Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. <i>Oncotarget</i> , 2016, 7, 57301-57309.	0.8	15
840	mTOR complex-2 stimulates acetyl-CoA and <i>de novo</i> lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer. <i>Oncotarget</i> , 2016, 7, 25224-25240.	0.8	39
841	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , 2016, 7, 10547-10556.	0.8	52
842	Management of mammalian target of rapamycin inhibitor-associated noninfectious pneumonitis in advanced breast cancer: A nursing perspective. <i>Journal of Nursing Education and Practice</i> , 2016, 7, .	0.1	0
843	Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Cancer Management and Research</i> , 2016, Volume 8, 85-94.	0.9	12
844	Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. <i>Oncotarget</i> , 2016, 7, 54120-54136.	0.8	23
845	Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 3997-4003.	1.0	7
846	Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. <i>Ecancermedicalscience</i> , 2016, 10, 609.	0.6	30

#	ARTICLE	IF	CITATIONS
847	Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 73.	1.0	17
848	Chasing Certainty: Issues of Evidence and Value in Cancer Care. <i>Journal of Oncology Practice</i> , 2016, 12, 1195.	2.5	1
849	Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e40-e54.	1.8	29
850	The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase. <i>Genes and Cancer</i> , 2016, 7, 73-85.	0.6	17
851	Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma. <i>Journal of Immunology Research</i> , 2016, 2016, 1-9.	0.9	10
852	Targeted Therapies for Brain Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1543.	1.8	67
853	PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. <i>OncoTargets and Therapy</i> , 2016, 9, 203.	1.0	196
854	The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1827.	1.8	27
855	Cell and Signal Components of the Microenvironment of Bone Metastasis Are Affected by Hypoxia. <i>International Journal of Molecular Sciences</i> , 2016, 17, 706.	1.8	19
856	Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1775.	1.8	58
857	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002201.	3.9	300
858	The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC). <i>PLoS ONE</i> , 2016, 11, e0149432.	1.1	3
859	Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0155844.	1.1	21
860	Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. <i>Frontiers in Pharmacology</i> , 2016, 7, 395.	1.6	131
861	Novel Treatments in Breast Cancer. <i>Clinical Medicine Insights Therapeutics</i> , 2016, 8, CMT.S18492.	0.4	1
862	The Role of Autophagy in Cancer and Chemotherapy. , 2016, , 253-265.		1
863	Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 879-882.	0.6	10
864	Reply to T. Reinert et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1960-1961.	0.8	0

#	ARTICLE	IF	CITATIONS
865	Media Reporting of Practiceâ€“Changing Clinical Trials in Oncology: A North American Perspective. <i>Oncologist</i> , 2016, 21, 269-278.	1.9	5
866	<scp>mTOR</scp> inhibitorâ€“induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. <i>International Journal of Cancer</i> , 2016, 138, 2312-2321.	2.3	76
867	Safety of everolimus plus exemestane in patients with hormone-receptorâ€“positive, HER2â€“negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). <i>Annals of Oncology</i> , 2016, 27, 1719-1725.	0.6	64
868	New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1158-1170.	1.1	75
869	Evolving Role of the Estrogen Receptor as a Predictive Biomarker: <i>ESR1</i> Mutational Status and Endocrine Resistance in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2950-2952.	0.8	13
870	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19â€“784 Diverse Solid Tumors. <i>JAMA Oncology</i> , 2016, 2, 1565.	3.4	195
871	Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000620.	0.5	5
872	A phase 2 clinical trial of everolimus plus bicalutamide for castrationâ€“resistant prostate cancer. <i>Cancer</i> , 2016, 122, 1897-1904.	2.0	47
873	Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: ¹⁸F-Fluoroestradiol PET Imaging Shows Return of ER Expression. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 144-147.	2.3	20
874	PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 515-524.	2.7	300
875	Neurological sequelae of cancer immunotherapies and targeted therapies. <i>Lancet Oncology</i> , The, 2016, 17, e529-e541.	5.1	71
876	Relevance of randomised controlled trials in oncology. <i>Lancet Oncology</i> , The, 2016, 17, e560-e567.	5.1	74
877	Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study. <i>Oncology and Therapy</i> , 2016, 4, 275-286.	1.0	1
878	Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance. <i>Progress in Molecular Biology and Translational Science</i> , 2016, 144, 539-562.	0.9	10
879	Recent developments and translational aspects in targeted therapy for metastatic breast cancer. <i>ESMO Open</i> , 2016, 1, e000036.	2.0	1
880	Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research. <i>Journal of Translational Medicine</i> , 2016, 14, 324.	1.8	21
881	Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 1-12.	2.0	18
882	Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 583-587.	2.5	19

#	ARTICLE	IF	CITATIONS
883	Assession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. <i>Clinical Chemistry</i> , 2016, 62, 1504-1515.	1.5	130
884	Interview for Breast Cancer Management with Dr David Montgomery: marketing authorization for Pfizer's metastatic breast cancer treatment, palbociclib (Ibrance®) in combination with endocrine therapy. <i>Breast Cancer Management</i> , 2016, 5, 145-150.	0.2	0
885	BET Bromodomain Proteins as Cancer Therapeutic Targets. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 123-129.	2.0	56
886	Chemosensitization role of fulvestrant in combination with chemotherapy in postmenopausal hormone receptor positive and human epidermal growth factor negative metastatic breast cancer. <i>Medical Hypotheses</i> , 2016, 97, 59-63.	0.8	0
887	Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. <i>Npj Breast Cancer</i> , 2016, 2, 16037.	2.3	26
888	A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1447-1456.	1.6	17
889	Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169.	1.0	102
890	Spatio-temporal Parameters of Endosomal Signaling in Cancer: Implications for New Treatment Options. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 836-843.	1.2	19
891	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 425-439.	5.1	1,344
892	Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 238-246.	1.1	8
893	Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells. <i>Clinical Immunology</i> , 2016, 168, 47-54.	1.4	21
894	mTOR inhibitors in urinary bladder cancer. <i>Tumor Biology</i> , 2016, 37, 11541-11551.	0.8	23
895	Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 3069-3103.	0.8	456
896	Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 335-343.	1.1	193
897	Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. <i>Nature Cell Biology</i> , 2016, 18, 632-644.	4.6	174
898	Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. <i>Journal of Medical Economics</i> , 2016, 19, 414-423.	1.0	2
899	The effect of immunosuppressive molecules on T-cell metabolic reprogramming. <i>Biochimie</i> , 2016, 127, 23-36.	1.3	53
900	Safety of mTOR inhibitors in breast cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1075-1085.	1.0	6

#	ARTICLE	IF	CITATIONS
901	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5755-5764.	3.2	20
902	Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials. <i>Future Oncology</i> , 2016, 12, 1529-1539.	1.1	7
903	Specialty pharmacy services for patients receiving oral medications for solid tumors. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 775-796.	0.5	14
904	Lymphangioliomyomatosis: Current understanding and potential treatments. , 2016, 158, 114-124.		39
905	Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 925-935.	1.0	67
906	Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1970-1972.	0.8	3
907	PI3K targeting in breast cancer: the end of the beginning?. <i>Lancet Oncology</i> , The, 2016, 17, 696-697.	5.1	1
909	Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). <i>Journal of Clinical Oncology</i> , 2016, 34, 2602-2609.	0.8	101
910	RAD001 (everolimus) attenuates experimental autoimmune neuritis by inhibiting the mTOR pathway, elevating Akt activity and polarizing M2 macrophages. <i>Experimental Neurology</i> , 2016, 280, 106-114.	2.0	25
911	ABC3 Consensus Commented from the Perspective of the German Guidelines. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 156-163.	0.8	6
912	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 811-821.	5.1	239
913	ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 253-265.	1.1	71
914	Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. <i>Acta Oncologica</i> , 2016, 55, 1196-1203.	0.8	18
915	Same Data; Different Interpretations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3729-3732.	0.8	6
916	Targeting the Mammalian Target of Rapamycin in Lung Cancer. <i>American Journal of the Medical Sciences</i> , 2016, 352, 507-516.	0.4	18
917	BEZ235: When Promising Science Meets Clinical Reality. <i>Oncologist</i> , 2016, 21, 1033-1034.	1.9	33
918	Critical parameters in targeted drug development: the pharmacological audit trail. <i>Seminars in Oncology</i> , 2016, 43, 436-445.	0.8	64
919	Current Status of Clinical Genomics in Patients with Metastatic Breast Cancer. <i>Breast Diseases</i> , 2016, 27, 182-186.	0.0	0

#	ARTICLE	IF	CITATIONS
920	Pushing estrogen receptor around in breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, T227-T241.	1.6	35
921	Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 91-99.	1.1	26
922	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. <i>Annals of Oncology</i> , 2016, 27, 1860-1866.	0.6	45
923	Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. <i>Cancer Treatment Reviews</i> , 2016, 50, 168-174.	3.4	12
924	Aromatase inhibitors: A comprehensive review in mechanisms of action, side effects and treatment in postmenopausal early breast cancer patients. <i>Hellenike Cheirurgike Acta Chirurgica Hellenica</i> , 2016, 88, 245-251.	0.1	7
925	Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. <i>Oncology Letters</i> , 2016, 12, 4107-4116.	0.8	17
926	ABC3 Consensus: Assessment by a German Group of Experts. <i>Breast Care</i> , 2016, 11, 61-70.	0.8	8
927	Renewed interest in the progesterone receptor in breast cancer. <i>British Journal of Cancer</i> , 2016, 115, 909-911.	2.9	28
928	Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. <i>Breast</i> , 2016, 29, 96-101.	0.9	16
929	Vinflunine for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1817-1823.	0.9	10
930	Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. <i>Endocrine-Related Cancer</i> , 2016, 23, R337-R352.	1.6	95
931	Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer. <i>Oncologist</i> , 2016, 21, 922-930.	1.9	10
932	Endocrine Therapy for Leptomeningeal Metastases from ER-Positive Breast Cancer: Case Report and a Review of the Literature. <i>Breast Journal</i> , 2016, 22, 218-223.	0.4	16
933	Smart Materials for Controlled Drug Release. , 2016, , 98-135.		0
934	Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 3-18.	0.7	8
935	Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 19-31.	0.7	2
936	Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. <i>Oncologist</i> , 2016, 21, 1035-1040.	1.9	18
937	Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 14-24.	2.0	10

#	ARTICLE	IF	CITATIONS
938	Prevalence of <i>ESR1</i> Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1310.	3.4	395
939	Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis. <i>BMC Cancer</i> , 2016, 16, 616.	1.1	12
940	<i>ESR1</i> Mutations in Cell-Free DNA of Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1315.	3.4	3
941	Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 1148-1156.	2.5	7
942	Metastatic breast cancer: focus on endocrine sensitivity. <i>Lancet</i> , The, 2016, 388, 2961-2962.	6.3	2
943	Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2525.	1.8	55
944	Endocrine treatment in breast cancer: Cure, resistance and beyond. <i>Cancer Treatment Reviews</i> , 2016, 50, 68-81.	3.4	114
945	New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2179-2189.	0.9	9
946	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 429-449.	1.4	31
947	Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer. <i>Current Problems in Cancer</i> , 2016, 40, 95-105.	1.0	18
948	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. <i>British Journal of Cancer</i> , 2016, 114, 889-896.	2.9	46
949	Is it time for everolimus-based combination in castration-resistant prostate cancer?. <i>Future Oncology</i> , 2016, 12, 1849-1852.	1.1	1
951	Metastatic breast cancer: The Odyssey of personalization. <i>Molecular Oncology</i> , 2016, 10, 1147-1159.	2.1	19
952	Targeted adjuvant therapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1263-1275.	1.1	11
953	Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. <i>ESMO Open</i> , 2016, 1, e000062.	2.0	43
954	Targeted therapy and elderly people: A review. <i>European Journal of Cancer</i> , 2016, 69, 199-215.	1.3	34
955	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	2.0	17
956	<i>Cancer Drug Discovery</i> . , 2016, , .		6

#	ARTICLE	IF	CITATIONS
957	Hepatitis B reactivation during everolimus treatment. <i>Acta Oncologica</i> , 2016, 55, 1505-1506.	0.8	4
958	Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. <i>Oncologist</i> , 2016, 21, 1250-1259.	1.9	85
959	Novel Strategies in Hormone Receptor-Positive Advanced Breast Cancer: Overcoming Endocrine Resistance. <i>Current Breast Cancer Reports</i> , 2016, 8, 193-205.	0.5	2
960	Novel investigational therapies for treating biliary tract carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1423-1436.	1.9	5
961	Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temozolomide in the Treatment of Cancer. <i>Cancer Investigation</i> , 2016, 34, 521-530.	0.6	24
962	Paradox CA 15 ³ increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series. <i>Biomarkers in Medicine</i> , 2016, 10, 1191-1195.	0.6	5
963	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , 2016, 8, 115.	3.6	64
964	Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR ⁺ Positive Breast Cancer. <i>Scientific Reports</i> , 2016, 6, 25615.	1.6	9
965	Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S12443.	0.6	8
966	Daunting but Worthy Goal. <i>Transplantation</i> , 2016, 100, 2569-2583.	0.5	16
967	mTOR pathway protein immunoreactivity as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis. <i>Journal of Oral Pathology and Medicine</i> , 2016, 45, 319-328.	1.4	29
968	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCT019041). <i>Investigational New Drugs</i> , 2016, 34, 104-111.	1.2	17
969	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. <i>Cancer Research</i> , 2016, 76, 4100-4112.	0.4	42
970	Comprehensive Gene Mutation Profiling of Breast Tumors: Is It Ready for Prime Time Use?. <i>Current Breast Cancer Reports</i> , 2016, 8, 53-59.	0.5	0
971	A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. <i>SpringerPlus</i> , 2016, 5, 45.	1.2	12
972	A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient. <i>Case Reports in Oncology</i> , 2016, 9, 112-118.	0.3	4
973	Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer. <i>British Journal of Cancer</i> , 2016, 115, 339-345.	2.9	11
974	CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1657-1667.	0.9	11

#	ARTICLE	IF	CITATIONS
975	Breast Cancer in Women Older Than 80 Years. <i>Journal of Oncology Practice</i> , 2016, 12, 123-132.	2.5	51
976	Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 63-71.	1.1	34
977	Amplified in Breast Cancer Regulates Transcription and Translation in Breast Cancer Cells. <i>Neoplasia</i> , 2016, 18, 100-110.	2.3	14
978	Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>Translational Oncology</i> , 2016, 9, 114-123.	1.7	27
979	Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management. <i>Oncologist</i> , 2016, 21, 855-860.	1.9	48
980	Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. <i>Advances in Therapy</i> , 2016, 33, 983-997.	1.3	9
981	Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1189-1196.	0.9	3
982	A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 101-109.	1.1	23
983	Les traitements adjuvants des cancers du sein : dernières avancées et perspectives pour des cancers très différents. <i>Oncologie</i> , 2016, 18, 120-127.	0.2	1
984	Biologics and Their Interactions with Radiation. , 2016, , 80-92.e4.		0
986	PI3K-AKT-mTOR Pathway Cooperates with the DNA Damage Repair Pathway: Carcinogenesis in Triple-Negative Breast Cancers and Beyond. <i>Cancer Drug Discovery and Development</i> , 2016, , 65-108.	0.2	0
987	The therapeutic potential of mTOR inhibitors in breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1189-1212.	1.1	93
988	Fulvestrant 500mg in postmenopausal patients with metastatic breast cancer: the initial clinical experience. <i>Breast Cancer</i> , 2016, 23, 617-623.	1.3	11
989	The Role of mTOR Inhibitors in Breast Cancer. , 2016, , 67-92.		0
990	Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?. <i>European Journal of Surgical Oncology</i> , 2016, 42, 333-342.	0.5	14
991	In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. <i>Annals of Oncology</i> , 2016, 27, 256-262.	0.6	69
992	Hormonal therapy for cancer. <i>Medicine</i> , 2016, 44, 30-33.	0.2	21
993	MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth. <i>Cancer Letters</i> , 2016, 372, 118-127.	3.2	36

#	ARTICLE	IF	CITATIONS
994	A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2650-2658.	3.2	63
995	miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. <i>Cancer Research</i> , 2016, 76, 1615-1626.	0.4	82
998	Is There a Future for AKT Inhibitors in the Treatment of Cancer?. <i>Clinical Cancer Research</i> , 2016, 22, 2599-2601.	3.2	38
999	Unravelling exemestane: From biology to clinical prospects. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 163, 1-11.	1.2	36
1000	Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 2913-8.	1.0	2
1001	A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. <i>Gynecologic Oncology</i> , 2016, 141, 108-112.	0.6	6
1002	Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites. <i>Clinical Therapeutics</i> , 2016, 38, 905-917.	1.1	2
1003	Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. <i>Clinical Oncology</i> , 2016, 28, 283-291.	0.6	3
1004	Metastatic disease of the breast and local recurrence. <i>Surgery</i> , 2016, 34, 47-51.	0.1	0
1005	Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells. <i>Oncogene</i> , 2016, 35, 4235-4243.	2.6	32
1006	Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. <i>Clinical Breast Cancer</i> , 2016, 16, 188-195.	1.1	11
1007	Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 74-87.	2.0	69
1008	Patterns in target-directed breast cancer research. <i>SpringerPlus</i> , 2016, 5, 109.	1.2	1
1009	Activating Mutations in <i>PIK3CB</i> Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110 β . <i>Cancer Research</i> , 2016, 76, 1193-1203.	0.4	52
1010	Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 18-22.	1.1	22
1011	Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 405-413.	1.1	17
1013	Resistance to Targeted Therapies in Breast Cancer. <i>Methods in Molecular Biology</i> , 2016, 1395, 105-136.	0.4	18
1014	Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1987-1994.	0.8	84

#	ARTICLE	IF	CITATIONS
1015	Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications. <i>Oncologist</i> , 2016, 21, 404-417.	1.9	83
1016	Using CTCs for pharmacogenomic analysis. <i>Pharmacological Research</i> , 2016, 106, 92-100.	3.1	4
1017	Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. <i>Current Medical Research and Opinion</i> , 2016, 32, 385-394.	0.9	6
1018	mTOR Inhibition Beyond Rapalogs. , 2016, , 251-275.		1
1019	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 57-68.	2.0	15
1020	Palbociclib: efficacious but predictive biomarkers still needed. <i>Lancet Oncology</i> , The, 2016, 17, 402-403.	5.1	2
1021	Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. <i>Annals of Oncology</i> , 2016, 27, 519-525.	0.6	68
1023	Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. <i>Drug Resistance Updates</i> , 2016, 24, 13-22.	6.5	31
1024	Targeting mTOR: A Little Bit of History and a Large Future. , 2016, , 1-17.		0
1025	Targeted Combinations for Hormone Receptorâ€“Positive Advanced Breast Cancer: Who Benefits?. <i>Journal of Clinical Oncology</i> , 2016, 34, 393-395.	0.8	3
1026	Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. <i>Oncologist</i> , 2016, 21, 28-32.	1.9	92
1027	A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). <i>European Journal of Cancer</i> , 2016, 53, 144-154.	1.3	29
1028	Cancer of the Breast: An Overview. , 2016, , 147-209.		0
1029	Palbociclib for the treatment of postmenopausal breast cancer â€“ an update. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 255-263.	0.9	15
1030	Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alphaâ€“Positive, <i>PIK3CA</i>-Mutant Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2250-2260.	3.2	29
1031	mTOR Inhibition for Cancer Therapy: Past, Present and Future. , 2016, , .		3
1032	Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 277-283.	3.2	19
1033	FOXO factors and breast cancer: outfoxing endocrine resistance. <i>Endocrine-Related Cancer</i> , 2016, 23, R113-R130.	1.6	39

#	ARTICLE	IF	CITATIONS
1034	Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , 2016, 16, 113-122.e1.	1.1	49
1035	Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 31-49.	1.9	35
1036	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1699-1712.	3.2	95
1037	Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. <i>Oncogene</i> , 2016, 35, 1877-1887.	2.6	116
1038	A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2016, 69, 450-456.	0.9	80
1039	mTORC1 directly phosphorylates and activates ER α upon estrogen stimulation. <i>Oncogene</i> , 2016, 35, 3535-3543.	2.6	70
1040	Devil's Wake: Early-stage bone colonization by breast cancer. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1026526.	0.3	2
1041	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	0.8	203
1042	The PI3K/AKT Pathway as a Target for Cancer Treatment. <i>Annual Review of Medicine</i> , 2016, 67, 11-28.	5.0	631
1043	Decreased LRRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. <i>Oncogene</i> , 2016, 35, 1143-1152.	2.6	12
1044	Immunosuppressive Medications. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 332-343.	2.2	184
1045	Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 228-235.	1.2	6
1046	Defining the optimal sequence for the systemic treatment of metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 149-161.	1.2	24
1047	Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 407-415.	3.2	88
1048	Breast cancer patient with everolimus-induced angioedema: A rare occurrence with potential for serious consequences. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 318-320.	0.5	5
1049	Combine and conquer: challenges for targeted therapy combinations in early phase trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 57-66.	12.5	239
1050	Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma. <i>Scientific Reports</i> , 2017, 7, 39597.	1.6	10
1051	Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. <i>Cancer Treatment Reviews</i> , 2017, 53, 111-119.	3.4	134

#	ARTICLE	IF	CITATIONS
1052	Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs. <i>Nature Communications</i> , 2017, 8, 14249.	5.8	52
1053	Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways. <i>Clinical Cancer Research</i> , 2017, 23, 3334-3342.	3.2	80
1054	Breast Cancer Metastasis. , 2017, , 13-31.		9
1055	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2017, 25, 1713-1739.	1.0	125
1056	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R123-R144.	1.6	64
1057	PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials. , 2017, 175, 91-106.		167
1058	The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. <i>Trends in Cancer</i> , 2017, 3, 39-55.	3.8	206
1059	Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles. <i>Cancer Research</i> , 2017, 77, 1927-1941.	0.4	112
1060	Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis. <i>Cancer Treatment Reviews</i> , 2017, 55, 10-15.	3.4	19
1061	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 297-310.	1.1	3
1062	<i>Stephania Tetrandra</i> and Ginseng-Containing Chinese Herbal Formulation NSENL Reverses Cisplatin Resistance in Lung Cancer Xenografts. <i>The American Journal of Chinese Medicine</i> , 2017, 45, 385-401.	1.5	20
1063	Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 319-326.	1.1	5
1064	CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. <i>Current Breast Cancer Reports</i> , 2017, 9, 26-33.	0.5	55
1065	Implementing Genome-Driven Oncology. <i>Cell</i> , 2017, 168, 584-599.	13.5	405
1066	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2213-2221.	0.4	168
1067	Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 614-624.	1.9	72
1068	Underlying Mechanisms for Distant Metastasis - Molecular Biology. <i>Visceral Medicine</i> , 2017, 33, 11-20.	0.5	100
1069	Identifying relations between imaging phenotypes and molecular subtypes of breast cancer: Model discovery and external validation. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1017-1027.	1.9	78

#	ARTICLE	IF	CITATIONS
1070	Design, synthesis, and biological evaluation of imidazo[1,2- b]pyridazine derivatives as mTOR inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 129, 135-150.	2.6	24
1071	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2 ⁺ advanced breast cancer: results from BOLERO-2. <i>British Journal of Cancer</i> , 2017, 116, 726-730.	2.9	112
1072	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2 ⁺ breast cancer that had progressed during or after prior endocrine therapy. <i>Breast Cancer Research</i> , 2017, 19, 18.	2.2	87
1073	Everolimus as an mTOR Inhibitor Suppresses Endometriotic Implants: an Experimental Rat Study. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 66-72.	0.8	15
1074	Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 439-450.	1.1	47
1076	Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 91-101.	2.0	15
1077	The prognostic significance of Cdc6 and Cdt1 in breast cancer. <i>Scientific Reports</i> , 2017, 7, 985.	1.6	69
1078	Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. <i>Oncologist</i> , 2017, 22, 648-654.	1.9	10
1079	Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. <i>Radiology</i> , 2017, 283, 314-340.	3.6	19
1080	Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. <i>Cancer Discovery</i> , 2017, 7, 561-574.	7.7	33
1081	Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 948-955.	1.9	81
1082	Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer. <i>Annals of Oncology</i> , 2017, 28, 1825-1831.	0.6	47
1083	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>BMC Cancer</i> , 2017, 17, 211.	1.1	24
1084	Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. <i>Pharmacological Research</i> , 2017, 121, 138-144.	3.1	25
1086	Recent progress towards clinically relevant ATP-competitive Akt inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2838-2848.	1.0	34
1087	Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. <i>Gynecologic Oncology</i> , 2017, 146, 64-68.	0.6	35
1088	Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer. <i>Future Oncology</i> , 2017, 13, 1371-1384.	1.1	5
1089	Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1389-1400.	1.9	44

#	ARTICLE	IF	CITATIONS
1090	Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials. <i>Oncology</i> , 2017, 92, 243-254.	0.9	4
1091	Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer. <i>Molecular Medicine Reports</i> , 2017, 15, 2957-2968.	1.1	9
1092	Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4919-4928.	3.2	74
1093	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , 2017, 23, 4680-4692.	3.2	8
1094	Diabetic Ketoacidosis and Acute Pancreatitis: Serious Adverse Effects of Everolimus. <i>Annals of Emergency Medicine</i> , 2017, 69, 666-667.	0.3	6
1095	New agents for endocrine resistance in breast cancer. <i>Breast</i> , 2017, 34, 1-11.	0.9	22
1096	A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 290-301.	0.3	11
1097	Do patient access schemes for high-cost cancer drugs deliver value to society? lessons from the NHS Cancer Drugs Fund. <i>Annals of Oncology</i> , 2017, 28, 1738-1750.	0.6	102
1098	Molecular Genetics of Endometrial Carcinoma. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	6
1099	Endometrial Carcinoma: Specific Targeted Pathways. <i>Advances in Experimental Medicine and Biology</i> , 2017, 943, 149-207.	0.8	53
1100	A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer. <i>Oncologist</i> , 2017, 22, 784-e74.	1.9	1
1101	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	4.9	39
1102	IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 343-353.	1.1	43
1103	Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 365-373.	1.1	12
1104	A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 54.	2.2	27
1105	Advances in systemic therapy for metastatic breast cancer: future perspectives. <i>Medical Oncology</i> , 2017, 34, 119.	1.2	34
1106	FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor. <i>Annals of Oncology</i> , 2017, 28, 2025-2027.	0.6	6
1107	Cancer and mTOR Inhibitors in Transplant Recipients. <i>Transplantation</i> , 2017, 101, 45-55.	0.5	104

#	ARTICLE	IF	CITATIONS
1108	Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole. <i>Anti-Cancer Drugs</i> , 2017, 28, 931-933.	0.7	1
1109	Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2017, 81, 9-16.	1.3	13
1110	A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2017, 14, 919-928.	1.5	24
1111	Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 335-346.	1.4	39
1112	Recomendaciones para el uso de everolimus en trasplante renal de novo: falsas creencias, mitos y realidades. <i>Nefrologia</i> , 2017, 37, 253-266.	0.2	12
1113	Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 525-536.	0.5	0
1114	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 904-916.	5.1	427
1116	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. <i>Medicine (United States)</i> , 2017, 96, e6931.	0.4	3
1117	Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. <i>Lancet Oncology</i> , The, 2017, 18, 887-894.	5.1	108
1118	Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2630-2639.	3.2	30
1119	Ketamine Causing Apnea?. <i>Annals of Emergency Medicine</i> , 2017, 69, 667-668.	0.3	0
1120	Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib. <i>Breast</i> , 2017, 35, 1-7.	0.9	23
1121	Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an <i>STK11</i> variant. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a000778.	0.5	20
1122	Phase I Trial of Everolimus and Capecitabine in Metastatic HER2 ⁺ Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 418-426.	1.1	5
1123	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 535-544.	1.1	16
1124	Targeted Treatment of Brain Metastases. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 37.	2.0	28
1125	Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials. <i>Breast Cancer</i> , 2017, 24, 345-352.	1.3	6
1126	SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis?. <i>Lancet Oncology</i> , The, 2017, 18, 564-565.	5.1	1

#	ARTICLE	IF	CITATIONS
1127	Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. <i>Breast Journal</i> , 2017, 23, 610-611.	0.4	7
1128	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. <i>Nature Communications</i> , 2017, 8, 14864.	5.8	112
1129	Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 587-594.	1.1	9
1130	A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. <i>Targeted Oncology</i> , 2017, 12, 323-332.	1.7	84
1131	Everolimus in the management of metastatic neuroendocrine tumours. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 132-141.	1.4	33
1133	AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. <i>Scientific Reports</i> , 2017, 7, 44244.	1.6	87
1134	Entinostat: a promising treatment option for patients with advanced breast cancer. <i>Future Oncology</i> , 2017, 13, 1137-1148.	1.1	94
1135	Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts. <i>Journal of Proteome Research</i> , 2017, 16, 1868-1879.	1.8	17
1136	Mutation matters in precision medicine: A future to believe in. <i>Cancer Treatment Reviews</i> , 2017, 55, 136-149.	3.4	36
1137	Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer. <i>Oncologist</i> , 2017, 22, 507-517.	1.9	27
1138	Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. <i>Lancet, The</i> , 2017, 389, 2403-2414.	6.3	168
1139	Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis. <i>Clinical Science</i> , 2017, 131, 27-36.	1.8	22
1140	Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer. <i>British Journal of Cancer</i> , 2017, 116, 10-20.	2.9	13
1141	Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 95-102.	1.4	11
1142	Patient database analysis of fulvestrant 500Âmg in the treatment of metastatic breast cancer: A European perspective. <i>Breast</i> , 2017, 32, 247-255.	0.9	12
1143	The role of sex hormones and steroid receptors on female reproductive cancers. <i>Steroids</i> , 2017, 118, 93-108.	0.8	113
1144	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. <i>Oncogene</i> , 2017, 36, 2737-2749.	2.6	34
1145	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2575-2583.	3.2	16

#	ARTICLE	IF	CITATIONS
1146	Bromelain-Functionalized Multiple-Wall Lipid-Core Nanocapsules: Formulation, Chemical Structure and Antiproliferative Effect Against Human Breast Cancer Cells (MCF-7). <i>Pharmaceutical Research</i> , 2017, 34, 438-452.	1.7	33
1147	Triple-negative breast cancer and the potential for targeted therapy. <i>Pharmacogenomics</i> , 2017, 18, 1595-1609.	0.6	165
1148	Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action. <i>Clinical Cancer Research</i> , 2017, 23, 7608-7620.	3.2	26
1149	High expression of endoglin in primary breast cancer may predict response to neoadjuvant chemotherapy. <i>Molecular Medicine Reports</i> , 2017, 16, 7185-7190.	1.1	3
1150	Community pharmacist-led telephone follow-up enabled close management of everolimus-induced adverse events in an outpatient with metastatic breast cancer. <i>Canadian Pharmacists Journal</i> , 2017, 150, 362-365.	0.4	4
1151	FDG PET and FES PET Predict PFS on Endocrine Therapy Response. <i>Clinical Cancer Research</i> , 2017, 23, 3475-3475.	3.2	0
1152	Colchicine is an active treatment for everolimus-induced oral ulcers. <i>European Journal of Cancer</i> , 2017, 87, 209-211.	1.3	4
1153	PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom. <i>Breast Care</i> , 2017, 12, 290-294.	0.8	21
1154	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. <i>Cancer Treatment Reviews</i> , 2017, 61, 53-60.	3.4	39
1155	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 870-878.	0.8	24
1156	Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 911-917.	1.1	14
1157	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	1.6	16
1158	Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells. <i>Oncology Letters</i> , 2017, 14, 3832-3838.	0.8	12
1159	Healthcare cost of HER2-positive and negative breast tumors in the United States (2012-2035). <i>Cancer Treatment Reviews</i> , 2017, 60, 12-17.	3.4	15
1160	Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. <i>Scientific Reports</i> , 2017, 7, 9842.	1.6	25
1161	Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. <i>Cancer Treatment Reviews</i> , 2017, 59, 93-101.	3.4	191
1162	Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 776-779.	0.7	2
1164	Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer. <i>Pharmacological Research</i> , 2017, 124, 20-33.	3.1	13

#	ARTICLE	IF	CITATIONS
1165	Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2 ⁻) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. <i>Breast</i> , 2017, 35, 115-121.	0.9	21
1166	Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities. <i>Nefrologia</i> , 2017, 37, 253-266.	0.2	7
1167	Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. <i>Cell</i> , 2017, 170, 577-592.e10.	13.5	506
1168	Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. <i>Pharmacogenomics</i> , 2017, 18, 1167-1178.	0.6	7
1169	Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib. <i>Annals of Oncology</i> , 2017, 28, 2021-2024.	0.6	5
1170	Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. <i>Cancer</i> , 2017, 123, 4631-4639.	2.0	43
1172	Four <i>PTEN</i> targeting co-expressed miRNAs and <i>ACTN4</i> targeting miR-548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue. <i>International Journal of Cancer</i> , 2017, 141, 2318-2328.	2.3	20
1173	Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report. <i>Oncology Letters</i> , 2017, 14, 1725-1730.	0.8	2
1174	The PI3K Pathway in Human Disease. <i>Cell</i> , 2017, 170, 605-635.	13.5	1,702
1175	Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. <i>Cancer Investigation</i> , 2017, 35, 552-561.	0.6	5
1176	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. <i>Future Oncology</i> , 2017, 13, 2137-2149.	1.1	7
1177	Are Cyclin-dependent Kinase 4/6 Inhibitors Needed for all Oestrogen Receptor-positive Metastatic Breast Cancers?. <i>Clinical Oncology</i> , 2017, 29, 703-706.	0.6	0
1178	Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death. <i>Brain</i> , 2017, 140, 2623-2638.	3.7	30
1181	Systemic Therapy in the Setting of Central Nervous System (CNS) Metastases in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 217-226.	0.5	0
1182	Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer. <i>Breast Care</i> , 2017, 12, 296-302.	0.8	8
1183	Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 693-709.	1.4	32
1184	Targeting the CDK4/6 Pathway in Breast Cancer. , 2017, , 807-817.		0
1185	Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate ² -hydroxylase expression. <i>Cancer Science</i> , 2017, 108, 2454-2461.	1.7	13

#	ARTICLE	IF	CITATIONS
1186	Endocrine Therapies in the Adjuvant and Advanced Disease Settings. , 2017, , 557-568.		0
1187	Targeting PI3K/AKT/mTOR Pathway. , 2017, , 787-793.		0
1188	Use of Everolimus in Liver Transplantation. Transplantation, 2017, 101, 239-251.	0.5	54
1189	Circumvent hesitancy between CDK4/6 and mTOR inhibitors in second-line treatment of HR+, erb2-metastatic breast cancer. Future Oncology, 2017, 13, 1451-1453.	1.1	1
1190	Breast cancer treatment-induced cardiotoxicity. Expert Opinion on Drug Safety, 2017, 16, 1021-1038.	1.0	58
1191	A pilot study of cabergoline for the treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 165, 585-592.	1.1	13
1192	Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treatment Reviews, 2017, 59, 22-32.	3.4	38
1193	Treatment for the endocrine resistant breast cancer: Current options and future perspectives. Journal of Steroid Biochemistry and Molecular Biology, 2017, 172, 166-175.	1.2	41
1194	Targeting the mTOR pathway in breast cancer. Tumor Biology, 2017, 39, 101042831771082.	0.8	20
1195	Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12). Metabolomics, 2017, 13, 98.	1.4	12
1196	Current challenges in the management of breast cancer brain metastases. Seminars in Oncology, 2017, 44, 85-100.	0.8	44
1197	Oncologist use and perception of large panel next-generation tumor sequencing. Annals of Oncology, 2017, 28, 2298-2304.	0.6	31
1198	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Research and Treatment, 2017, 165, 601-609.	1.1	25
1199	Breast cancer milestones 2007â€“2016. Memo - Magazine of European Medical Oncology, 2017, 10, 27-32.	0.3	0
1200	A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer. Current Medical Research and Opinion, 2017, 33, 1559-1569.	0.9	36
1201	Optimizing Quality of Life in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Treatment Options and Considerations. Oncology, 2017, 93, 143-156.	0.9	7
1202	Highlights of the San Antonio Breast Cancer Symposium 2016. Future Oncology, 2017, 13, 1291-1295.	1.1	0
1203	Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Investigational New Drugs, 2017, 35, 87-94.	1.2	9

#	ARTICLE	IF	CITATIONS
1204	A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2017, 19, 616-624.	1.2	3
1205	Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer. <i>Oncologist</i> , 2017, 22, 12-24.	1.9	14
1206	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. <i>Journal of Pathology</i> , 2017, 241, 173-182.	2.1	36
1207	Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 355-361.	0.4	19
1208	Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2017, 17, 11-17.	1.1	60
1209	Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 85-99.	12.5	163
1210	Pathology and Molecular Pathology of Breast Cancer. , 2017, , 173-231.		1
1211	An overview of rapamycin: from discovery to future perspectives. <i>Journal of Industrial Microbiology and Biotechnology</i> , 2017, 44, 537-553.	1.4	79
1212	Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 79-90.	1.1	23
1213	Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. <i>Annals of Oncology</i> , 2017, 28, 44-56.	0.6	43
1214	Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. <i>Clinical Cancer Research</i> , 2017, 23, 1710-1721.	3.2	164
1215	Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity Against Endocrine-Resistant Breast Cancer Cells. <i>Oncology Research</i> , 2017, 25, 1283-1295.	0.6	7
1216	Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming. <i>Genes and Development</i> , 2017, 31, 2235-2249.	2.7	41
1217	Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer. <i>Breast Care</i> , 2017, 12, 288-289.	0.8	1
1219	New agents for the management of resistant metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1815-1831.	0.9	5
1220	Emerging pathways in treating human epidermal growth factor receptor-2-negative breast cancer. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 2, 27.	0.5	0
1222	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. <i>Oncotarget</i> , 2017, 8, 44800-44810.	0.8	4
1223	Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities. <i>Korean Journal of Radiology</i> , 2017, 18, 28.	1.5	24

#	ARTICLE	IF	CITATIONS
1224	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. <i>International Journal of Oncology</i> , 2018, 52, 424-432.	1.4	9
1225	Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. <i>Genes</i> , 2017, 8, 217.	1.0	24
1226	Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1655.	1.8	23
1227	Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 26.	1.3	79
1228	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2017, 7, 230.	1.3	43
1229	Synergistic interactions with PI3K inhibition that induce apoptosis. <i>ELife</i> , 2017, 6, .	2.8	25
1230	Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-10.	1.9	65
1231	Ribosomal protein S3 regulates XIAP expression independently of the NF- κ B pathway in breast cancer cells. <i>Oncology Reports</i> , 2017, 38, 3205-3210.	1.2	20
1232	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. <i>Journal of Cancer</i> , 2017, 8, 2004-2009.	1.2	14
1233	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. <i>PLoS ONE</i> , 2017, 12, e0180192.	1.1	27
1234	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. <i>PLoS ONE</i> , 2017, 12, e0183639.	1.1	2
1235	A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO). <i>BMC Cancer</i> , 2017, 17, 499.	1.1	21
1236	Targeting protein quality control pathways in breast cancer. <i>BMC Biology</i> , 2017, 15, 109.	1.7	27
1237	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. <i>BMC Medicine</i> , 2017, 15, 134.	2.3	169
1238	Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 92.	2.2	21
1239	Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. <i>Trials</i> , 2017, 18, 497.	0.7	6
1242	Novel strategies to improve the endocrine therapy of breast cancer. <i>Oncology Reviews</i> , 2017, 11, 323.	0.8	25
1243	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, S34-S48.	0.5	15

#	ARTICLE	IF	CITATIONS
1244	Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy. <i>Cancers</i> , 2017, 9, 152.	1.7	41
1245	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2017, 8, 8910-8920.	0.8	108
1246	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259.	0.8	240
1247	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. <i>Oncotarget</i> , 2017, 8, 12417-12432.	0.8	24
1248	Novel Targeted Agents and Immunotherapy in Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 65-75.	1.8	8
1250	Novel systemic therapy against malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2017, 6, 295-314.	1.3	22
1251	Clinical implications of PTEN loss in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 222-234.	1.9	408
1252	Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 201-213.	1.1	13
1254	Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials. <i>Breast Cancer</i> , 2018, 25, 479-488.	1.3	40
1255	Targeting the PI3K pathway in cancer: are we making headway?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 273-291.	12.5	762
1256	EQUATOR-Oncology: reducing the latitude of cancer trial design and reporting. <i>British Journal of Cancer</i> , 2018, 118, 617-618.	2.9	2
1257	Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 745-754.	1.1	18
1258	ABC4 Consensus: Assessment by a German Group of Experts. <i>Breast Care</i> , 2018, 13, 48-58.	0.8	7
1259	Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells. <i>Cell Death and Disease</i> , 2018, 9, 376.	2.7	23
1260	Drug discovery targeting the mTOR pathway. <i>Clinical Science</i> , 2018, 132, 543-568.	1.8	65
1261	Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 908-920.	1.9	119
1262	Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer. <i>Oncologist</i> , 2018, 23, 660-669.	1.9	16
1263	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling) <i>Tj ETQq1 1 0.784314 rgB1 /Ove</i>		

#	ARTICLE	IF	CITATIONS
1264	Optimising endocrine therapy in postmenopausal women with advanced breast cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 705-721.	1.6	1
1265	Target Therapy for Esophageal Adenocarcinoma. <i>Methods in Molecular Biology</i> , 2018, 1756, 51-65.	0.4	2
1266	SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects. <i>Journal of Molecular Endocrinology</i> , 2018, 61, T233-T252.	1.1	55
1267	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. <i>European Journal of Cancer</i> , 2018, 96, 17-24.	1.3	211
1268	Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 23.	1.3	23
1269	Mechanisms of Resistance to PI3K and AKT Inhibitors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 117-146.	0.1	3
1270	Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 525-533.	1.1	12
1272	Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents. <i>Drugs and Aging</i> , 2018, 35, 93-115.	1.3	6
1273	Mechanisms of autophagy and relevant small-molecule compounds for targeted cancer therapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 1803-1826.	2.4	46
1274	Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer. <i>The Cochrane Library</i> , 2018, , .	1.5	2
1275	Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. <i>Clinical Cancer Research</i> , 2018, 24, 2452-2463.	3.2	32
1276	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. <i>Endocrinology</i> , 2018, , 765-785.	0.1	0
1277	Optimizing Breast Cancer Management. <i>Cancer Treatment and Research</i> , 2018, , .	0.2	2
1278	Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 397-406.	1.1	312
1280	The Return of the mTOR Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 71, 651-653.	1.2	9
1281	Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer. <i>Cancer Treatment and Research</i> , 2018, 173, 141-154.	0.2	13
1282	E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 1.	2.3	84
1283	A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. <i>Neuro-Oncology</i> , 2018, 20, 666-673.	0.6	108

#	ARTICLE	IF	CITATIONS
1284	Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 63, 144-155.	3.4	26
1285	Locally Advanced Breast Cancer. , 2018, , 819-831.e6.		3
1286	Endocrine Therapy for Breast Cancer. , 2018, , 907-923.e6.		2
1287	Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 639-647.	1.1	21
1288	PI3K inhibition to overcome endocrine resistance in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 1-15.	1.9	38
1289	Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 465-471.	0.8	20
1290	Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial. <i>Journal of Molecular Medicine</i> , 2018, 96, 111-117.	1.7	6
1291	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 249-256.	5.1	130
1292	PAQR4 has a tumorigenic effect in human breast cancers in association with reduced CDK4 degradation. <i>Carcinogenesis</i> , 2018, 39, 439-446.	1.3	24
1293	Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. <i>Annals of Oncology</i> , 2018, 29, 707-714.	0.6	46
1294	Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. <i>ESMO Open</i> , 2018, 3, e000291.	2.0	37
1295	Ultrasound assisted gene and photodynamic synergistic therapy with multifunctional FOXA1-siRNA loaded porphyrin microbubbles for enhancing therapeutic efficacy for breast cancer. <i>Biomaterials</i> , 2018, 173, 58-70.	5.7	46
1296	Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition. <i>Oncogene</i> , 2018, 37, 4046-4054.	2.6	12
1297	Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-“positive and Human Epidermal Growth Factor Receptor 2”-negative Metastatic Breast Cancer in Japan. <i>Pharmacoeconomics</i> , 2018, 36, 1113-1124.	1.7	4
1298	Efficacy of Palbociclib Combinations in Hormone Receptor-“Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment. <i>Clinical Breast Cancer</i> , 2018, 18, e1401-e1405.	1.1	24
1300	Acquired resistance to aromatase inhibitors: where we stand!. <i>Endocrine-Related Cancer</i> , 2018, 25, R283-R301.	1.6	74
1301	Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. <i>British Journal of Cancer</i> , 2018, 118, 966-971.	2.9	35
1302	Oral stomatitis and <sc>mTOR</sc> inhibitors: A review of current evidence in 20,915 patients. <i>Oral Diseases</i> , 2018, 24, 144-171.	1.5	18

#	ARTICLE	IF	CITATIONS
1303	Olaparib for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 519-530.	1.1	37
1304	Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature. <i>Digestion</i> , 2018, 97, 275-287.	1.2	17
1305	Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 977.	3.4	48
1306	Preclinical and clinical development of palbociclib and future perspectives. <i>Clinical and Translational Oncology</i> , 2018, 20, 1136-1144.	1.2	20
1307	Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer. <i>Medical Oncology</i> , 2018, 35, 48.	1.2	6
1308	Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 29-36.	2.0	35
1309	The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 119-122.	0.7	21
1310	The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 213-222.	1.2	70
1311	Patient Case Lessons: Endocrine Management of Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 192-204.	1.1	7
1312	Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study. <i>Clinical Breast Cancer</i> , 2018, 18, e41-e47.	1.1	9
1313	Emerging combination endocrine therapies for advanced breast cancer. <i>Breast Journal</i> , 2018, 24, 214-215.	0.4	0
1314	Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 114-116.	0.7	4
1315	Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. <i>Breast Cancer</i> , 2018, 25, 392-401.	1.3	134
1316	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	0.9	54
1317	Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature. <i>Clinical Lung Cancer</i> , 2018, 19, e151-e161.	1.1	50
1318	Drug-Induced Lung Injury. <i>Respiratory Disease Series</i> , 2018, , .	0.1	2
1319	Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 106-113.	1.4	23
1320	A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2050-2059.	3.2	96

#	ARTICLE	IF	CITATIONS
1321	Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin. <i>Toxicology in Vitro</i> , 2018, 46, 229-236.	1.1	13
1322	Changing Paradigms in the Management of Breast Cancer. , 2018, , .		1
1323	Nanomaterials as nanocarriers: a critical assessment why these are multi-chore vanquisher in breast cancer treatment. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 899-916.	1.9	19
1324	New Treatments for Metastatic Breast Cancer. , 2018, , 167-197.		0
1325	Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 589-611.	0.4	4
1326	Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2 ⁻ Advanced breast cancer: a review. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 607-614.	1.1	18
1327	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. <i>Endocrine-Related Cancer</i> , 2018, 25, R83-R113.	1.6	21
1328	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	0.9	56
1329	Emerging data on improving response to hormone therapy: the role of novel targeted agents. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 3-18.	1.1	2
1330	Genetic alterations in sporadic triple negative breast cancer. <i>Breast</i> , 2018, 38, 30-38.	0.9	21
1331	Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain. <i>Clinical and Translational Oncology</i> , 2018, 20, 753-760.	1.2	5
1332	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 87-100.	5.1	307
1333	Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. <i>Targeted Oncology</i> , 2018, 13, 21-38.	1.7	78
1334	Bone-Targeted Therapies in Cancer-Induced Bone Disease. <i>Calcified Tissue International</i> , 2018, 102, 227-250.	1.5	80
1335	Dosing time dependent <i>in vitro</i> pharmacodynamics of Everolimus despite a defective circadian clock. <i>Cell Cycle</i> , 2018, 17, 33-42.	1.3	21
1336	Targeting FGFR pathway in breast cancer. <i>Breast</i> , 2018, 37, 126-133.	0.9	89
1337	Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 57-67.	1.1	15
1338	Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 17-27.	1.1	12

#	ARTICLE	IF	CITATIONS
1339	Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. <i>Clinical Pharmacokinetics</i> , 2018, 57, 637-644.	1.6	21
1340	Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-8.	1.5	8
1341	Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. <i>Oncotarget</i> , 2018, 9, 8810-8822.	0.8	15
1342	National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3259-3268.	0.8	19
1343	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. <i>Journal of Clinical Oncology</i> , 2018, 36, 1556-1563.	0.8	134
1344	Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 78-86.	1.8	36
1345	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 342-349.	0.8	120
1346	Management of Hormone Receptor-Positive Metastatic Breast Cancer. , 0, , .		0
1347	Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells. <i>Oncotarget</i> , 2018, 9, 23451-23461.	0.8	7
1348	Evaluation of the Efficacy of Cancer Drugs by Using the Second Largest Eigenvalue of Metabolic Cancer Pathways. <i>Journal of Computer Science and Systems Biology</i> , 2018, 11, .	0.0	4
1349	Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1. <i>Journal of Cancer</i> , 2018, 9, 3802-3811.	1.2	18
1350	The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. <i>Cancer Cell</i> , 2018, 34, 823-839.e7.	7.7	93
1351	Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway. <i>Cancer Biology and Medicine</i> , 2018, 15, 314.	1.4	6
1352	Weighing In on mTOR Complex 2 Signaling: The Expanding Role in Cell Metabolism. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-15.	1.9	44
1353	Targeting the Hippo Pathway for Breast Cancer Therapy. <i>Cancers</i> , 2018, 10, 422.	1.7	80
1354	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. <i>Targeted Oncology</i> , 2018, 13, 641-648.	1.7	10
1355	Progress in Breast Cancer-Can We Do Better?. <i>Current Oncology</i> , 2018, 25, 7-8.	0.9	0
1356	Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880733.	1.4	27

#	ARTICLE	IF	CITATIONS
1357	Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 35-53.	0.8	16
1358	Celastrol induces ubiquitin-dependent degradation of mTOR in breast cancer cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8977-8985.	1.0	36
1360	Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 900.	1.1	15
1361	Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 1226-1237.	1.3	10
1362	Update Breast Cancer 2018 (Part 4) " Genomics, Individualized Medicine and Immune Therapies " in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1119-1128.	0.8	3
1363	Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. <i>Genome Medicine</i> , 2018, 10, 86.	3.6	14
1364	Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer. <i>Oncotarget</i> , 2018, 9, 21468-21477.	0.8	12
1365	Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. <i>Oncology and Therapy</i> , 2018, 6, 141-156.	1.0	30
1366	Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1319-1327.	0.9	17
1367	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. <i>PLoS Genetics</i> , 2018, 14, e1007679.	1.5	14
1368	The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials. <i>PLoS ONE</i> , 2018, 13, e0204202.	1.1	2
1369	Translational control of the undifferentiated phenotype in ER+ positive breast tumor cells: Cytoplasmic localization of ER+ and impact of IRES inhibition. <i>Oncology Reports</i> , 2018, 39, 2482-2498.	1.2	2
1370	C1+ceramide and sphingosine+1+phosphate/S1PR2 have opposite effects on cell growth through mTOR signaling pathway regulation. <i>Oncology Reports</i> , 2018, 40, 2977-2987.	1.2	9
1371	Value Assessment in Oncology Drugs: Funding of Drugs for Metastatic Breast Cancer in Canada. <i>Current Oncology</i> , 2018, 25, 161-170.	0.9	9
1372	Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour. <i>BMJ Open</i> , 2018, 8, e017240.	0.8	20
1373	Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor+ positive/human epidermal growth factor receptor 2+ negative metastatic breast cancer in PALOMA-3. <i>European Journal of Cancer</i> , 2018, 104, 21-31.	1.3	53
1374	Synthesis and anticancer activity of novel rapamycin C+28 containing triazole moiety compounds. <i>Archiv Der Pharmazie</i> , 2018, 351, e1800123.	2.1	5
1375	Precision medicine based on tumorigenic signaling pathways for triple+ negative breast cancer (Review). <i>Oncology Letters</i> , 2018, 16, 4984-4996.	0.8	27

#	ARTICLE	IF	CITATIONS
1376	WINDOW consortium: A path towards increased therapy efficacy against glioblastoma. Drug Resistance Updates, 2018, 40, 17-24.	6.5	15
1377	Profile of abemaciclib and its potential in the treatment of breast cancer. OncoTargets and Therapy, 2018, Volume 11, 5253-5259.	1.0	28
1378	Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital. Case Reports in Oncology, 2018, 11, 511-520.	0.3	3
1379	Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern) Tj ETQq1 1 0.78431412 BT /Over	0.7	12
1380	Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer. Journal of Cancer, 2018, 9, 358-366.	1.2	6
1381	Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy. International Journal of Cancer, 2018, 143, 3008-3018.	2.3	16
1382	Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial). Open Access Journal of Clinical Trials, 0, Volume 10, 13-18.	1.5	0
1383	Trends in breast cancer mortality by stage at diagnosis among young women in the <sc>U</sc>nited <sc>S</sc>tates. Cancer, 2018, 124, 3500-3509.	2.0	106
1384	Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α -positive breast cancer cells. International Journal of Cancer, 2018, 143, 2871-2883.	2.3	32
1385	A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 2018, 37, 599-614.	2.7	63
1386	C-3- and C-4-Substituted Bicyclic Coumarin Sulfamates as Potent Steroid Sulfatase Inhibitors. ACS Omega, 2018, 3, 10748-10772.	1.6	21
1387	A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Research, 2018, 20, 109.	2.2	48
1388	Advances in the use of PARP inhibitor therapy for breast cancer. Drugs in Context, 2018, 7, 1-30.	1.0	101
1389	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. ESMO Open, 2018, 3, e000368.	2.0	35
1390	Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. BioMed Research International, 2018, 2018, 1-8.	0.9	9
1391	Leukocytoclastic Vasculitis Associated with Exemestane/Everolimus Therapy in a Previously Irradiated Skin: Case Report. British Journal of Research, 2018, 05, .	0.1	0
1392	Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report. Annals of Thoracic and Cardiovascular Surgery, 2018, 24, 151-153.	0.3	5
1393	Phase II Study of Tselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 4380-4387.	3.2	49

#	ARTICLE	IF	CITATIONS
1394	Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 183, 51-61.	1.2	29
1395	<i>Molecular Biology of Breast Cancer.</i> , 2018, , 569-588.		6
1396	Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 909-928.	0.9	53
1397	Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway. <i>Anticancer Research</i> , 2018, 38, 3427-3434.	0.5	13
1398	Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1367.	3.4	67
1399	Updates in the Evaluation and Management of Breast Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 794-807.	1.4	39
1400	Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. <i>Oncologist</i> , 2018, 23, 974-981.	1.9	19
1401	Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 14.	2.3	10
1403	Clinical Potential of Estrogen and Progesterone Receptor Imaging. <i>PET Clinics</i> , 2018, 13, 415-422.	1.5	30
1404	Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer. <i>BioMed Research International</i> , 2018, 2018, 1-12.	0.9	12
1405	Clinical and molecular aspects of breast cancer: Targets and therapies. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 14-34.	2.5	49
1406	mTOR and Tumor Cachexia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2225.	1.8	24
1407	Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. <i>Current Oncology</i> , 2018, 25, 18-27.	0.9	96
1408	Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2~ advanced or metastatic breast cancer. <i>Current Medical Research and Opinion</i> , 2018, 34, 2143-2150.	0.9	7
1409	Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 113-121.	1.1	17
1410	mTOR Cross-Talk in Cancer and Potential for Combination Therapy. <i>Cancers</i> , 2018, 10, 23.	1.7	108
1411	Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer. <i>Journal of Cancer</i> , 2018, 9, 1145-1151.	1.2	19
1412	Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 44.	2.2	17

#	ARTICLE	IF	CITATIONS
1413	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 23-29.	1.0	15
1414	Integrative omics analyses broaden treatment targets in human cancer. <i>Genome Medicine</i> , 2018, 10, 60.	3.6	17
1415	Personalizing aromatase inhibitor therapy in patients with breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 70, 47-55.	3.4	27
1416	Everolimus-based combination therapies for HR+, HER2 ⁺ metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 69, 204-214.	3.4	48
1417	Everolimus. <i>Recent Results in Cancer Research</i> , 2018, 211, 101-123.	1.8	68
1418	Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. <i>Journal of Hematology and Oncology</i> , 2018, 11, 80.	6.9	36
1419	Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2018, 8, 89.	1.3	64
1420	Recent Advances in the Treatment of Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 227.	1.3	263
1421	MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. <i>Targeted Oncology</i> , 2018, 13, 423-436.	1.7	5
1422	The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 747.	1.8	42
1423	Targeting mTOR as a Therapeutic Approach in Medulloblastoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1838.	1.8	13
1424	Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-11.	0.6	19
1425	Pharmacogenomics: Setting Newer Paradigms of Genetics in Therapy and Medicine. , 2018, , 37-58.		0
1426	Estrogen-regulated feedback loop limits the efficacy of estrogen receptor ⁺ -targeted breast cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 7869-7878.	3.3	55
1427	Cardiovascular sequelae of breast cancer treatments: A review. <i>Current Problems in Cancer</i> , 2018, 42, 409-421.	1.0	4
1428	Hormone Receptor ⁺ Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. <i>Current Oncology</i> , 2018, 25, 131-141.	0.9	31
1429	The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer. <i>Hormones and Cancer</i> , 2018, 9, 215-228.	4.9	36
1430	Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. <i>BMC Cancer</i> , 2018, 18, 194.	1.1	18

#	ARTICLE	IF	CITATIONS
1431	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 67, 63-70.	3.4	79
1432	Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 111-120.	1.1	38
1433	Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. <i>Oncotarget</i> , 2018, 9, 16389-16399.	0.8	37
1434	The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality. <i>Current Cancer Drug Targets</i> , 2018, 18, 480-498.	0.8	5
1435	Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878685.	1.4	5
1436	Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?. <i>Cancer Management and Research</i> , 2018, Volume 10, 1015-1025.	0.9	5
1437	New Drug Candidate Targeting the 4A1 Orphan Nuclear Receptor for Medullary Thyroid Cancer Therapy. <i>Molecules</i> , 2018, 23, 565.	1.7	18
1438	The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 185-197.	3.3	40
1439	Endocrine Therapy for Breast Cancer in the Primary Care Setting. <i>Current Oncology</i> , 2018, 25, 285-291.	0.9	40
1440	Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 308.	1.3	62
1441	Expert opinion on the metabolic complications of mTOR inhibitors. <i>Annales D'Endocrinologie</i> , 2018, 79, 583-590.	0.6	8
1442	Computational Design of Multi-Target Drugs Against Breast Cancer. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 443-458.	0.1	2
1443	Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. <i>Annals of Translational Medicine</i> , 2018, 6, 163-163.	0.7	86
1444	Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review. <i>Hellenic Journal of Cardiology</i> , 2018, 59, 196-200.	0.4	11
1445	The role of abemaciclib in treatment of advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	14
1446	4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 469-480.	0.8	3
1447	Breast Cancer in Men. <i>New England Journal of Medicine</i> , 2018, 378, 2311-2320.	13.9	208
1448	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. <i>Oncology</i> , 2018, 95, 138-146.	0.9	7

#	ARTICLE	IF	CITATIONS
1449	Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials. <i>PLoS ONE</i> , 2018, 13, e0192464.	1.1	51
1450	Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. <i>Precision Clinical Medicine</i> , 2018, 1, 29-48.	1.3	79
1451	Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. <i>Oncogene</i> , 2019, 38, 47-59.	2.6	20
1452	Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. <i>Investigational New Drugs</i> , 2019, 37, 271-281.	1.2	7
1453	Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer. <i>Annals of Pharmacotherapy</i> , 2019, 53, 195-203.	0.9	5
1454	Bone-Modifying Agents and Anticancer Agents with Bone Effects. , 2019, , 13-25.		1
1455	Hormone-Responsive Cancers. , 2019, , 717-741.e8.		2
1456	Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma. <i>International Review of Cell and Molecular Biology</i> , 2019, 343, 219-297.	1.6	16
1457	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 419-430.	3.0	55
1458	Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase III 4EVER trial. <i>International Journal of Cancer</i> , 2019, 144, 877-885.	2.3	31
1459	Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines. <i>Pharmaceutics</i> , 2019, 11, 384.	2.0	18
1460	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1226-1238.	5.1	76
1462	mTOR: Role in cancer, metastasis and drug resistance. <i>Seminars in Cancer Biology</i> , 2019, 59, 92-111.	4.3	299
1463	Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. <i>Journal of Clinical Oncology</i> , 2019, 37, 2490-2500.	0.8	20
1464	Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models. <i>Scientific Reports</i> , 2019, 9, 10898.	1.6	5
1466	Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 686.	1.3	41
1467	Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced Î²-TrCP degradation. <i>Oncogene</i> , 2019, 38, 6270-6282.	2.6	53
1468	MONALEESA clinical program: a review of ribociclib use in different clinical settings. <i>Future Oncology</i> , 2019, 15, 2673-2686.	1.1	21

#	ARTICLE	IF	CITATIONS
1469	<i>ESR1</i> mutations in breast cancer. <i>Cancer</i> , 2019, 125, 3714-3728.	2.0	154
1470	A Review of Local and Systemic Therapy in Breast Cancer. , 2019, , 637-690.		0
1471	Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. <i>Targeted Oncology</i> , 2019, 14, 441-451.	1.7	11
1472	Assessment of the efficacy of successive endocrine therapies in hormone receptor- and HER2-negative metastatic breast cancer: a real-life multicentre national study. <i>European Journal of Cancer</i> , 2019, 118, 131-141.	1.3	11
1473	Pharmacogenetics of therapeutics. , 2019, , 41-74.		0
1475	Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy. , 2019, , 449-462.		0
1476	Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. <i>Case Reports in Oncology</i> , 2019, 12, 494-499.	0.3	5
1477	The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy. <i>Cancers</i> , 2019, 11, 1021.	1.7	52
1478	Random Allocated Study of Wrapping Oblate for Prevention of Everolimus-associated Stomatitis in Patients With Metastatic Renal Cell Carcinoma. <i>Anticancer Research</i> , 2019, 39, 3937-3944.	0.5	0
1479	Management of toxicity to isoform α -specific PI3K inhibitors. <i>Annals of Oncology</i> , 2019, 30, x21-x26.	0.6	70
1480	Spirolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. <i>Cancers</i> , 2019, 11, 1550.	1.7	13
1481	Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer. <i>In Vivo</i> , 2019, 33, 2037-2044.	0.6	2
1482	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 119.	2.2	21
1483	Homeopathic supportive care protocol for oral inhibitors of cyclin dependent kinases 4 and 6 (CDK) Tj ETQq1 1 0.784314 rgBT /Overl 10, e69-e73.	0.1	1
1484	Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3K inhibitors. <i>Science</i> , 2019, 366, 714-723.	6.0	185
1485	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6598-6605.	3.2	17
1486	A Newly Established Murine Cell Line as a Model for Hepatocellular Cancer in Non-Alcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5658.	1.8	5
1487	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16

#	ARTICLE	IF	CITATIONS
1488	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	11
1489	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1556.	3.4	62
1490	Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?. <i>JAMA Oncology</i> , 2019, 5, 1564.	3.4	19
1491	Systemic treatment of metastatic breast cancer: SABCS 2018. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 253-256.	0.3	1
1492	Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer. <i>Cells</i> , 2019, 8, 1010.	1.8	25
1493	Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer. <i>Future Oncology</i> , 2019, 15, 3309-3326.	1.1	6
1494	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	5.1	131
1495	Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed cells. <i>Scientific Reports</i> , 2019, 9, 13405.	1.6	6
1496	The Growth-Arrest-Specific (GAS)-5 Long Non-Coding RNA: A Fascinating lncRNA Widely Expressed in Cancers. <i>Non-coding RNA</i> , 2019, 5, 46.	1.3	54
1497	Stem Cells and Cellular Origins of Breast Cancer: Updates in the Rationale, Controversies, and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 820.	1.3	54
1498	Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 188-196.	1.1	2
1499	Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. <i>BMC Cancer</i> , 2019, 19, 84.	1.1	8
1500	Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer. <i>BMC Cancer</i> , 2019, 19, 41.	1.1	16
1501	pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation. <i>Npj Breast Cancer</i> , 2019, 5, 7.	2.3	18
1502	Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan. <i>Breast Cancer: Basic and Clinical Research</i> , 2019, 13, 117822341882513.	0.6	1
1503	Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer. <i>Breast Cancer</i> , 2019, 26, 748-757.	1.3	1
1504	Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2773.	1.8	13
1505	Update on Precision Medicine in Breast Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 45-80.	0.2	27

#	ARTICLE	IF	CITATIONS
1506	Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984679.	1.4	16
1507	Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. <i>Cells</i> , 2019, 8, 605.	1.8	12
1508	Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. <i>BMC Cancer</i> , 2019, 19, 611.	1.1	5
1509	Revisiting mTOR inhibitors as anticancer agents. <i>Drug Discovery Today</i> , 2019, 24, 2086-2095.	3.2	18
1511	AKT and ERK dual inhibitors: The way forward?. <i>Cancer Letters</i> , 2019, 459, 30-40.	3.2	144
1512	Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 256-267.	0.8	17
1513	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18
1515	Therapeutic innovations in breast cancer. <i>Presse Medicale</i> , 2019, 48, 1131-1137.	0.8	5
1516	A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1320-1327.	1.0	1
1517	Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 92.	1.0	17
1518	Endocrine Resistance in Hormone Receptor Positive Breast Cancer – From Mechanism to Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 245.	1.5	150
1519	Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1607-1618.	2.5	18
1520	Finding the Magic in Magic Mouthwash – Reply. <i>JAMA Internal Medicine</i> , 2019, 179, 724.	2.6	1
1521	Health-related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan. <i>European Journal of Cancer Care</i> , 2019, 28, e13069.	0.7	11
1522	Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 268-280.	0.8	21
1523	VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 637-647.	1.1	11
1524	mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro. <i>Cells</i> , 2019, 8, 431.	1.8	19
1525	Deciphering the universe of genetic context-dependencies using mouse models of cancer. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 97-104.	1.5	3

#	ARTICLE	IF	CITATIONS
1526	Targeting the PI3-kinase pathway in triple-negative breast cancer. <i>Annals of Oncology</i> , 2019, 30, 1051-1060.	0.6	180
1527	Tissue mimetic 3D scaffold for breast tumor-derived organoid culture toward personalized chemotherapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 180, 334-343.	2.5	46
1528	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1012-1019.	1.3	2
1529	Tucidinosat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 806-815.	5.1	154
1530	Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. <i>Lancet Oncology</i> , The, 2019, 20, 746-748.	5.1	5
1531	Everolimus-Induced Severe Hypertriglyceridemia and Acute Pancreatitis in a Patient With Tuberous Sclerosis. <i>American Journal of Therapeutics</i> , 2019, 26, e558-e559.	0.5	3
1532	Targeting stem cells in the realm of drug-resistant breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 115-135.	1.0	33
1533	Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer. <i>Translational Oncology</i> , 2019, 12, 764-774.	1.7	11
1534	Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. <i>Ecancelmedicalscience</i> , 2019, 13, 904.	0.6	12
1535	Metastatic disease of the breast and local recurrence. <i>Surgery</i> , 2019, 37, 181-185.	0.1	1
1536	Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2019, 5, 6.	0.4	6
1537	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , 2019, 37, 336-349.	0.8	101
1538	Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan. <i>Breast Cancer</i> , 2019, 26, 652-662.	1.3	9
1539	Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1001-1011.	1.9	34
1540	Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. <i>Journal of Clinical Oncology</i> , 2019, 37, 1148-1150.	0.8	17
1541	Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of everolimus use with diabetes. <i>Endocrine Journal</i> , 2019, 66, 571-574.	0.7	10
1542	Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer. <i>Oncologist</i> , 2019, 24, 305-312.	1.9	11
1543	Translational highlights in breast cancer research and treatment: recent developments with clinical impact. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 67-75.	0.9	16

#	ARTICLE	IF	CITATIONS
1544	CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. <i>Current Oncology Reports</i> , 2019, 21, 25.	1.8	122
1545	Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells. <i>Clinical Cancer Research</i> , 2019, 25, 2900-2914.	3.2	24
1546	Pharmacotherapeutic options for patients with refractory breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 851-861.	0.9	3
1547	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 755.	1.8	406
1548	Current Treatment Options for Breast Cancer Brain Metastases. <i>Current Treatment Options in Oncology</i> , 2019, 20, 19.	1.3	10
1549	Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. <i>Acta Oncologica</i> , 2019, 58, 385-387.	0.8	2
1550	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. <i>Oncologist</i> , 2019, 24, 893-900.	1.9	25
1551	Downregulation of BAG1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway. <i>Oncology Reports</i> , 2019, 41, 1901-1910.	1.2	5
1554	Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study. <i>Oncologist</i> , 2019, 24, 1153-1158.	1.9	9
1555	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019, 24, 603-611.	1.9	43
1556	Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials. <i>Oncology Reviews</i> , 2019, 13, 455.	0.8	12
1557	Overview of the relevance of PI3K pathway in HR-positive breast cancer. <i>Annals of Oncology</i> , 2019, 30, x3-x11.	0.6	92
1558	Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 9669-9683.	1.0	7
1559	mTOR Inhibitors. , 2019, , 261-282.		0
1560	Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 135.	2.2	12
1561	The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. <i>Cancers</i> , 2019, 11, 1894.	1.7	53
1562	Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 568-574.	1.0	13
1564	Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. <i>Annals of Oncology</i> , 2019, 30, x27-x42.	0.6	63

#	ARTICLE	IF	CITATIONS
1565	Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1309-1319.	0.8	11
1566	Pharmacodynamic Monitoring of mTOR Inhibitors. Therapeutic Drug Monitoring, 2019, 41, 160-167.	1.0	10
1567	CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer. Medicine (United States), 2019, 98, e13909.	0.4	4
1568	Targeting mTOR and Metabolism in Cancer: Lessons and Innovations. Cells, 2019, 8, 1584.	1.8	149
1569	Plant defensin <i>PvD1</i> modulates the membrane composition of breast tumour-derived exosomes. Nanoscale, 2019, 11, 23366-23381.	2.8	8
1570	Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1328-1335.	0.8	3
1571	Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers. JCO Precision Oncology, 2019, 3, 1-13.	1.5	0
1572	Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER + breast cancer. FASEB Journal, 2019, 33, 1644-1657.	0.2	13
1573	Progress in adjuvant systemic therapy for breast cancer. Nature Reviews Clinical Oncology, 2019, 16, 27-44.	12.5	175
1574	Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 141-153.	1.7	8
1575	Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer. Current Medical Research and Opinion, 2019, 35, 73-80.	0.9	20
1576	PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study. Journal of the Formosan Medical Association, 2019, 118, 1333-1338.	0.8	24
1577	A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. Cancer Discovery, 2019, 9, 354-369.	7.7	104
1578	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 2019, 134, 39-45.	2.0	200
1579	Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society. Breast Cancer Research and Treatment, 2019, 173, 679-691.	1.1	5
1580	Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. Investigational New Drugs, 2019, 37, 331-337.	1.2	18
1581	Overcoming Endocrine Resistance in Breast Cancer. , 2019, , 393-422.		2
1582	Recent advances in breast cancer research impacting clinical diagnostic practice. Journal of Pathology, 2019, 247, 552-562.	2.1	24

#	ARTICLE	IF	CITATIONS
1583	Estrogen Receptor and Breast Cancer. <i>Cancer Drug Discovery and Development</i> , 2019, , .	0.2	4
1584	Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. <i>Clinical Cancer Research</i> , 2019, 25, 2737-2744.	3.2	34
1585	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019, 37, 345-351.	1.2	28
1586	Hypertriglyceridemia-Associated Drug-Induced Acute Pancreatitis. <i>Pancreas</i> , 2019, 48, 22-35.	0.5	22
1587	Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study. <i>In Vivo</i> , 2019, 33, 281-287.	0.6	9
1588	SEOM clinical guidelines in advanced and recurrent breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 31-45.	1.2	14
1589	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 697-706.	0.8	3
1590	A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry.. <i>Breast</i> , 2019, 44, 46-51.	0.9	2
1591	Optimal regimen for treatment-naïve hormone receptor-positive HER-2 negative metastatic breast cancer. <i>Future Oncology</i> , 2019, 15, 105-107.	1.1	0
1592	Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China. <i>Breast</i> , 2019, 43, 1-6.	0.9	12
1593	Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 407-415.	1.1	12
1594	Molecular Mechanisms of Endocrine Resistance. <i>Cancer Drug Discovery and Development</i> , 2019, , 265-307.	0.2	5
1595	Treatment of advanced HR+/HER2~ breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib. <i>Acta OncolÁgica</i> , 2019, 58, 147-153.	0.8	7
1596	Steroid Hormone and Nuclear Receptor Signaling Pathways. , 2019, , 183-197.		0
1597	Systemic Treatment of HER2-Negative Metastatic Breast Cancer. , 2019, , 483-508.		0
1598	Hierarchical Testing of a Primary and a Secondary Endpoint in a Group Sequential Design With Different Information Times. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 398-406.	0.6	14
1599	The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. <i>Journal of Bone Oncology</i> , 2019, 14, 100199.	1.0	3
1600	Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1104, 234-239.	1.2	33

#	ARTICLE	IF	CITATIONS
1601	Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results. <i>Pathology and Oncology Research</i> , 2019, 25, 149-156.	0.9	4
1602	Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388.	0.5	9
1603	Intracellular Signaling. , 2020, , 24-46.e12.		0
1604	Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1731-1741.	0.8	60
1605	Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. <i>Oncologist</i> , 2020, 25, e223-e230.	1.9	10
1606	Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 155-176.	2.1	34
1608	A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 89-97.	1.1	6
1609	Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2~ Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 1-11.	1.1	20
1610	Old wine in new bottles: Drug repurposing in oncology. <i>European Journal of Pharmacology</i> , 2020, 866, 172784.	1.7	61
1611	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. <i>Annals of Palliative Medicine</i> , 2020, 9, 4430-4445.	0.5	0
1612	Understanding the benefits and challenges of first-line cyclin-dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women. <i>Breast Journal</i> , 2020, 26, 630-642.	0.4	3
1613	Tumor angiogenesis: causes, consequences, challenges and opportunities. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 1745-1770.	2.4	927
1614	Brain malignancies: Glioblastoma and brain metastases. <i>Seminars in Cancer Biology</i> , 2020, 60, 262-273.	4.3	208
1615	The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165661.	1.8	10
1616	Bone Metastasis: Current State of Play. <i>Translational Oncology</i> , 2020, 13, 308-320.	1.7	30
1617	Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study. <i>Translational Oncology</i> , 2020, 13, 321-328.	1.7	16
1618	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	1.1	5
1619	Precision Medicine and Targeted Therapies in Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 51-62.	0.6	32

#	ARTICLE	IF	CITATIONS
1620	High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2 ⁺ postmenopausal breast cancer patients treated with everolimus and exemestane. <i>Molecular Oncology</i> , 2020, 14, 490-503.	2.1	14
1621	Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 687-697.	1.1	13
1622	Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells. <i>Breast Cancer</i> , 2020, 27, 415-425.	1.3	15
1623	Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. <i>Applied Microbiology and Biotechnology</i> , 2020, 104, 575-587.	1.7	323
1624	Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis. <i>Biometrical Journal</i> , 2020, 62, 658-669.	0.6	3
1625	Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. <i>Breast</i> , 2020, 49, 55-62.	0.9	49
1626	Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations. <i>Journal of Oncology</i> , 2020, 2020, 1-13.	0.6	6
1627	Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer. <i>Annals of Oncology</i> , 2020, 31, 1594-1596.	0.6	1
1628	Developing themes in targeted therapies for hormone receptor-positive breast cancer. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2020, 15, 15-23.	0.6	0
1629	Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. <i>Translational Oncology</i> , 2020, 13, 100847.	1.7	20
1630	How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?. <i>Cancers</i> , 2020, 12, 2638.	1.7	4
1632	Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer. <i>Cancer Medicine</i> , 2020, 9, 8821-8831.	1.3	4
1633	Fasting-mimicking diet and hormone therapy induce breast cancer regression. <i>Nature</i> , 2020, 583, 620-624.	13.7	198
1634	The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis. <i>Medicina (Lithuania)</i> , 2020, 56, 348.	0.8	3
1635	Early Changes of the Standardized Uptake Values (SUV _{max}) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 3314.	1.7	5
1636	Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors. , 2020, , 403-420.		0
1637	Regional Nodal Recurrence after Treatment for Breast Cancer. <i>Current Breast Cancer Reports</i> , 2020, 12, 336-343.	0.5	1
1638	Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane. <i>Medicine (United States)</i> , 2020, 99, e21211.	0.4	1

#	ARTICLE	IF	CITATIONS
1640	Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094093.	1.4	55
1642	CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 161-170.	2.0	7
1643	Clinical implications of breast cancer tumor genomic testing. <i>Breast Journal</i> , 2020, 26, 1565-1571.	0.4	3
1644	From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 1423.	2.2	5
1645	The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 ⁻) metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 729-739.	1.1	2
1646	The role of PI3K/Akt/mTOR signaling in dose-dependent biphasic effects of glycine on vascular development. <i>Biochemical and Biophysical Research Communications</i> , 2020, 529, 596-602.	1.0	18
1647	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). <i>Cancer</i> , 2020, 126, 3867-3882.	2.0	15
1648	Neuroendocrine breast carcinoma: a rare but challenging entity. <i>Medical Oncology</i> , 2020, 37, 70.	1.2	27
1649	Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. <i>Breast Care</i> , 2020, 15, 347-354.	0.8	46
1650	Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 421-431.	1.1	9
1651	PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. <i>Nature Communications</i> , 2020, 11, 4053.	5.8	77
1652	Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer. <i>Chinese Medical Journal</i> , 2020, 133, 2338-2345.	0.9	8
1653	Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?. <i>Cancers</i> , 2020, 12, 3077.	1.7	4
1654	The efficacy of gefitinib supplementation for breast cancer. <i>Medicine (United States)</i> , 2020, 99, e22613.	0.4	5
1655	PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 1258-1267.	1.3	47
1656	The Future of ER+/HER2 ⁻ Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors. <i>Anticancer Research</i> , 2020, 40, 4829-4841.	0.5	21
1657	Management of ER positive metastatic breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 270-277.	0.8	25
1658	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor ⁺ positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6141-6148.	3.2	6

#	ARTICLE	IF	CITATIONS
1659	Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors” proceedings from breast cancer expert group meeting. Chinese Clinical Oncology, 2020, 9, 61-61.	0.4	4
1660	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. ESMO Open, 2020, 5, e000842.	2.0	16
1661	Emerging roles of the MAGE protein family in stress response pathways. Journal of Biological Chemistry, 2020, 295, 16121-16155.	1.6	42
1662	Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer. Cancers, 2020, 12, 2586.	1.7	9
1663	Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342094486.	0.6	20
1664	Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs, 2020, 80, 1685-1697.	4.9	72
1665	Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. International Journal of Molecular Sciences, 2020, 21, 6479.	1.8	71
1666	Upregulation of CIP2A in estrogen depletion-resistant breast cancer cells treated with low-dose everolimus. FEBS Open Bio, 2020, 10, 2072-2080.	1.0	3
1667	POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone-receptor-positive advanced breast cancer. Future Oncology, 2020, 16, 2475-2485.	1.1	9
1668	Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096725.	1.4	0
1669	<p>Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer</p>. Cancer Management and Research, 2020, Volume 12, 12905-12913.	0.9	10
1670	Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review. Epigenomes, 2020, 4, 27.	0.8	6
1671	Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. New England Journal of Medicine, 2020, 383, 2557-2570.	13.9	146
1672	<p>Alpelisib in the Treatment of Breast Cancer: A Short Review on the Emerging Clinical Data</p>. Breast Cancer: Targets and Therapy, 2020, Volume 12, 251-258.	1.0	10
1673	Still Living Better through Chemistry: An Update on Caloric Restriction and Caloric Restriction Mimetics as Tools to Promote Health and Lifespan. International Journal of Molecular Sciences, 2020, 21, 9220.	1.8	13
1674	Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis. Targeted Oncology, 2020, 15, 723-732.	1.7	6
1675	Cyclin-dependent kinase 4/6 inhibitors in combination with fulvestrant for previously treated metastatic hormone receptor-positive breast cancer patients: A systematic review and meta-analysis of randomized clinical trials. Cancer Treatment and Research Communications, 2020, 23, 100175.	0.7	7
1676	Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. Tumori, 2020, 106, 257-266.	0.6	2

#	ARTICLE	IF	CITATIONS
1677	Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?. <i>Current Oncology Reports</i> , 2020, 22, 57.	1.8	26
1678	Therapy after cyclinâ€dependent kinase inhibition in metastatic hormone receptorâ€positive breast cancer: Resistance mechanisms and novel treatment strategies. <i>Cancer</i> , 2020, 126, 3400-3416.	2.0	19
1679	Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3528.	1.8	30
1680	Sorafenib and everolimus in patients with advanced solid tumors and KRASâ€mutated NSCLC: A phase I trial with early pharmacodynamic FDGâ€PET assessment. <i>Cancer Medicine</i> , 2020, 9, 4991-5007.	1.3	14
1681	Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Chinese Medical Journal</i> , 2020, 133, 1099-1108.	0.9	17
1682	The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. <i>Breast Cancer</i> , 2020, 27, 973-981.	1.3	4
1683	Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. <i>Cancer Medicine</i> , 2020, 9, 5035-5050.	1.3	8
1684	UHPLCâ€MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study. <i>Bioanalysis</i> , 2020, 12, 367-378.	0.6	1
1685	Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Aisertib) in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4633-4642.	3.2	7
1686	A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. <i>Nature Communications</i> , 2020, 11, 2935.	5.8	57
1687	<p>Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3477-3487.	0.9	40
1688	Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. <i>Cancers</i> , 2020, 12, 1404.	1.7	78
1689	A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors. <i>Cancers</i> , 2020, 12, 1425.	1.7	3
1690	Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs. <i>EClinicalMedicine</i> , 2020, 21, 100332.	3.2	80
1691	<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptorâ€Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. <i>Clinical Cancer Research</i> , 2020, 26, 5172-5177.	3.2	82
1692	Pharmacological management of male breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1493-1504.	0.9	3
1693	Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. <i>Clinical and Translational Oncology</i> , 2020, 22, 1698-1709.	1.2	9
1694	Study protocol for efficacy and safety of steroid-containing mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study. <i>BMJ Open</i> , 2020, 10, e033446.	0.8	3

#	ARTICLE	IF	CITATIONS
1695	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. <i>Cancer Research</i> , 2020, 80, 2190-2203.	0.4	4
1696	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. <i>Cancers</i> , 2020, 12, 617.	1.7	4
1697	Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. <i>Clinical and Translational Oncology</i> , 2020, 22, 1857-1866.	1.2	2
1698	Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. <i>Lancet, The</i> , 2020, 395, 817-827.	6.3	260
1699	2. Therapie des metastasierten Mammakarzinoms. , 2020, , 71-120.		0
1700	4. Supportivtherapie. , 2020, , 127-216.		0
1701	<p>Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 607-615.	0.9	3
1702	<p><p><p>Double Agent: SPDEF Gene with Both Oncogenic and Tumor-Suppressor Functions in Breast Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3891-3902.	0.9	15
1703	A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. <i>Journal of Controlled Release</i> , 2020, 326, 628-647.	4.8	149
1704	Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 5534-5538.	3.2	15
1705	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4777-4784.	3.2	31
1706	Bioactivation of α,β -Unsaturated Carboxylic Acids Through Acyl Glucuronidation. <i>Drug Metabolism and Disposition</i> , 2020, 48, 819-829.	1.7	5
1707	Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature” “Are We There Yet?” <i>Cancers</i> , 2020, 12, 308.	1.7	23
1708	Management of brain metastases in breast cancer: a review of current practices and emerging treatments. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 279-300.	1.1	52
1709	Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 7-22.	0.4	5
1710	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 187-204.	1.0	5
1711	Prognostic study for isolated local recurrence operated with salvage excision in hormone-receptor-positive patients with invasive breast cancer after primary breast surgery. <i>Biomedical Journal</i> , 2020, 43, 83-93.	1.4	4
1712	High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-7.	0.6	2

#	ARTICLE	IF	CITATIONS
1713	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2 ⁺ advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. <i>Breast</i> , 2020, 50, 64-70.	0.9	12
1714	Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 581-587.	3.2	60
1715	Flawed trials for cancer. <i>Annals of Oncology</i> , 2020, 31, 331-333.	0.6	5
1716	A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy. <i>Journal of Molecular Medicine</i> , 2020, 98, 375-382.	1.7	7
1717	RICTOR/mTORC2 affects tumorigenesis and therapeutic efficacy of mTOR inhibitors in esophageal squamous cell carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1004-1019.	5.7	19
1718	Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 1364-1377.	1.2	1
1719	<p>Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 675-686.	0.9	27
1720	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 345-357.	5.1	138
1721	Capivasertib inhibits a key pathway in metastatic breast cancer. <i>Lancet Oncology</i> , The, 2020, 21, 318-319.	5.1	2
1722	Pharmacological cancer treatment and venous thromboembolism risk. <i>European Heart Journal Supplements</i> , 2020, 22, C2-C14.	0.0	11
1723	<i>Pneumocystis</i> Pneumonia and Acute Kidney Injury Induced by Everolimus Treatment in a Patient with Metastatic Breast Cancer. <i>Case Reports in Oncology</i> , 2020, 13, 170-175.	0.3	3
1724	Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor ⁺ positive, HER2 ⁻ negative advanced breast cancer molecularly stratified for <i>PIK3CA</i> mutations and loss of PTEN expression. <i>Cancer Medicine</i> , 2020, 9, 4527-4539.	1.3	7
1725	Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 233-248.	1.1	19
1726	The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients [®] Part II: Metastatic Disease. <i>Drugs and Aging</i> , 2020, 37, 349-358.	1.3	3
1727	Overcoming Endocrine Resistance in Breast Cancer. <i>Cancer Cell</i> , 2020, 37, 496-513.	7.7	411
1728	Informative censoring [®] a neglected cause of bias in oncology trials. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 327-328.	12.5	43
1729	Biologic therapy for advanced breast cancer: recent advances and future directions. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1009-1024.	1.4	23
1730	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with<i>AKT1</i>E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	3.2	54

#	ARTICLE	IF	CITATIONS
1731	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2825.	1.8	11
1732	Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 245-255.	1.8	19
1733	Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. <i>Breast</i> , 2020, 52, 17-22.	0.9	12
1734	Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1 α pathway suppression. <i>Nature Communications</i> , 2020, 11, 1869.	5.8	129
1735	Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. <i>Scientific Reports</i> , 2020, 10, 6367.	1.6	45
1736	Lucitanib for the Treatment of HR+/HER2 α Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	3.2	40
1737	Molecular subtypes and precision treatment of triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 499-499.	0.7	64
1738	Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 847-857.	1.9	91
1739	Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. <i>BMC Cancer</i> , 2020, 20, 286.	1.1	3
1740	Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. <i>Breast Cancer Research</i> , 2020, 22, 33.	2.2	26
1741	Breast Cancer: 45 Years of Research and Progress. <i>Journal of Clinical Oncology</i> , 2020, 38, 2454-2462.	0.8	15
1742	Chemoprevention in familial adenomatous polyposis: past, present and future. <i>Familial Cancer</i> , 2021, 20, 23-33.	0.9	27
1743	Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 235-237.	0.5	2
1744	Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 81-92.	1.1	6
1745	The complex balance of PI3K inhibition. <i>Annals of Oncology</i> , 2021, 32, 127-128.	0.6	4
1746	RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 191-206.	2.9	16
1747	Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. <i>Oncologist</i> , 2021, 26, 101-106.	1.9	28
1748	Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes. <i>Cancer Letters</i> , 2021, 500, 64-74.	3.2	5

#	ARTICLE	IF	CITATIONS
1749	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103191.	2.0	9
1750	Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+/HER2 ⁻) advanced breast cancer: a meta-analysis and systemic review of randomized clinical trials. <i>Frontiers of Medicine</i> , 2021, 15, 208-220.	1.5	8
1751	Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. <i>Advances in Therapy</i> , 2021, 38, 109-136.	1.3	23
1752	A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 337-347.	1.1	5
1753	Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e150-e153.	1.1	7
1754	Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome. <i>Oncologist</i> , 2021, 26, e580-e587.	1.9	7
1755	SOLAR1s: alpelisib returns to earth?. <i>Annals of Oncology</i> , 2021, 32, 129-132.	0.6	2
1756	Alpelisib in the treatment of metastatic HR+ breast cancer with <i>PIK3CA</i> mutations. <i>Future Oncology</i> , 2021, 17, 13-36.	1.1	9
1757	Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier. <i>Clinical Breast Cancer</i> , 2021, 21, 120-127.	1.1	2
1758	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor ⁺ positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1247-1255.	3.2	5
1759	Cutaneous Adnexal Carcinoma with Apocrine Differentiation: A Challenging Diagnosis and Personalized Treatment with mTOR Inhibitor in a Very Rare Disease. <i>Case Reports in Oncology</i> , 2021, 13, 1091-1096.	0.3	2
1760	Landscape of clinically actionable mutations in breast cancer – A cohort study [™] . <i>Translational Oncology</i> , 2021, 14, 100877.	1.7	4
1761	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. <i>Cancer Discovery</i> , 2021, 11, 92-107.	7.7	36
1762	Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 418-428.	3.2	16
1763	Drug repurposing for breast cancer therapy: Old weapon for new battle. <i>Seminars in Cancer Biology</i> , 2021, 68, 8-20.	4.3	74
1764	Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC. <i>BMC Cancer</i> , 2021, 21, 34.	1.1	3
1765	Systemic Therapy for the Treatment of Breast Cancer. , 2021, , 81-87.		0
1766	Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. , 2021, 4, 573-595.		17

#	ARTICLE	IF	CITATIONS
1767	Oral adverse effects of CDK4/6 inhibitors among breast cancer patients: a systematic review and meta-analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 6556-6563.	0.5	5
1768	Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study. <i>JMIR Cancer</i> , 2021, 7, e27073.	0.9	3
1769	Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(âˆ-) breast cancer receiving salvage treatment with everolimus/exemestane. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 277-287.	1.1	5
1771	Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. <i>Breast Care</i> , 2021, 16, 115-128.	0.8	10
1772	Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression. <i>Cancer Prevention Research</i> , 2021, 14, 551-562.	0.7	6
1773	Raptor and rictor expression in patients with human papillomavirus-related oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 87.	1.1	11
1774	The advance of adjuvant treatment for triple-negative breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	11
1775	Pharmacodynamic Drugâ€“Drug Interaction on Human Peripheral Blood Mononuclear Cells Between Everolimus and Tacrolimus at the Therapeutic Concentration Range in Renal Transplantation. <i>Annals of Transplantation</i> , 2021, 26, e928817.	0.5	0
1776	Targeted Neoadjuvant Therapies in HR+/HER2âˆ- Breast Cancers: Challenges for Improving pCR. <i>Cancers</i> , 2021, 13, 458.	1.7	6
1777	Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. <i>Cancers</i> , 2021, 13, 369.	1.7	35
1778	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	2.2	15
1779	Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1631.	1.8	23
1780	Clinical Perspectives in Addressing Unsolved Issues in (Neo)Adjuvant Therapy for Primary Breast Cancer. <i>Cancers</i> , 2021, 13, 926.	1.7	5
1781	Solitary Pancreatic Head Metastasis from Ductal Carcinoma of Breast: A Case Report. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 193-196.	0.3	1
1782	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. <i>Genes</i> , 2021, 12, 285.	1.0	18
1784	Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. <i>European Journal of Cancer</i> , 2021, 144, 341-350.	1.3	5
1785	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <i>Breast Cancer Research</i> , 2021, 23, 21.	2.2	22
1786	Alpelisib for the treatment of <i>PIK3CA</i>-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 667-675.	0.9	7

#	ARTICLE	IF	CITATIONS
1787	Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGF β ² /CTGF Axis. <i>Cells</i> , 2021, 10, 430.	1.8	14
1788	Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 638895.	1.1	6
1789	Clinical application of circulating tumor DNA in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1431-1442.	1.2	5
1790	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	1.7	17
1791	Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer. <i>Scientific Reports</i> , 2021, 11, 5566.	1.6	5
1792	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 644737.	1.3	70
1793	Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. <i>Cancers</i> , 2021, 13, 1538.	1.7	37
1794	Risk and prognostic factors of breast cancer with liver metastases. <i>BMC Cancer</i> , 2021, 21, 238.	1.1	31
1795	Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer. <i>Cureus</i> , 2021, 13, e14088.	0.2	0
1796	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. <i>Npj Precision Oncology</i> , 2021, 5, 28.	2.3	19
1797	Genomic Alterations in <i>PIK3CA</i> -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3K Inhibitors. <i>Cancer Research</i> , 2021, 81, 2470-2480.	0.4	20
1798	Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 433-468.	0.9	7
1799	Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 77-89.	1.1	7
1800	Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	8
1801	First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. <i>Breast Cancer Research</i> , 2021, 23, 29.	2.2	31
1802	Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. <i>Clinical Cancer Research</i> , 2021, 27, 3845-3853.	3.2	25
1803	Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 640314.	1.3	10
1804	Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer. <i>Future Science OA</i> , 2021, 7, FSO672.	0.9	1

#	ARTICLE	IF	CITATIONS
1805	Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study. <i>Clinical Imaging</i> , 2021, 71, 29-33.	0.8	4
1806	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1052.	1.7	5
1807	The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients. <i>BMC Cancer</i> , 2021, 21, 333.	1.1	6
1808	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021, 39, 1366-1374.	1.2	17
1809	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	3.2	4
1810	Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 628690.	1.6	165
1811	Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITY-1). <i>Clinical Cancer Research</i> , 2021, 27, 4177-4185.	3.2	47
1813	Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 44.	2.3	11
1814	Next-Generation Endocrine Therapies for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1383-1388.	0.8	19
1815	Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?. <i>Cancers</i> , 2021, 13, 1701.	1.7	19
1816	Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. <i>Cancer Research and Treatment</i> , 2021, 53, 291-300.	1.3	8
1817	Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review. <i>Frontiers in Endocrinology</i> , 2021, 12, 639967.	1.5	3
1818	Advances in epigenetic therapeutics with focus on solid tumors. <i>Clinical Epigenetics</i> , 2021, 13, 83.	1.8	53
1819	N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer. <i>Medical Science Monitor</i> , 2021, 27, e929615.	0.5	3
1820	ESMO pays tribute to Professor JosÃ© Baselga. <i>Immuno-Oncology Technology</i> , 2021, , 100027.	0.2	0
1821	Genomic landscape of extraordinary responses in metastatic breast cancer. <i>Communications Biology</i> , 2021, 4, 449.	2.0	3
1822	A Role for TGFÎ² Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4463.	1.8	6
1823	AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?. <i>Frontiers in Pharmacology</i> , 2021, 12, 662232.	1.6	109

#	ARTICLE	IF	CITATIONS
1824	SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2. <i>Npj Breast Cancer</i> , 2021, 7, 40.	2.3	9
1825	An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient. <i>Annals of Coloproctology</i> , 2021, 37, 120-124.	0.5	2
1827	Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study. <i>Annals of Oncology</i> , 2021, 32, 427-430.	0.6	1
1828	Final results of the randomized phase 2 <i>LEO</i> trial and bone protective effects of everolimus for premenopausal hormone receptor- <i>positive</i> , <i>HER2</i> - <i>negative</i> metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 917-924.	2.3	5
1829	Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer. <i>Immunotherapy</i> , 2021, 13, 587-603.	1.0	13
1830	Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor- <i>positive</i> <i>HER2</i> - <i>negative</i> metastatic breast cancer in China: a real-world study. <i>Annals of Translational Medicine</i> , 2021, 9, 831-831.	0.7	5
1831	The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 48.	2.3	3
1832	ESMO pays tribute to Professor Jos ^Å Baselga. <i>ESMO Open</i> , 2021, , 100130.	2.0	0
1833	Optimal integration of CDK4/6 inhibitors for treatment of hormone receptor- <i>positive</i> metastatic breast cancer. <i>Practical Oncology</i> , 2021, 4, 11-18.	0.1	0
1834	Treatment Strategy for Patients with HR- <i>Positive</i> <i>HER2</i> - <i>Negative</i> Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors. <i>Breast Care</i> , 2022, 17, 1-8.	0.8	2
1835	Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization. <i>Cell Death and Disease</i> , 2021, 12, 509.	2.7	33
1836	Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. <i>Investigational New Drugs</i> , 2021, 39, 1707-1715.	1.2	4
1837	The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in <i>HER2</i> - <i>Positive</i> Breast Cancer Models. <i>Cancers</i> , 2021, 13, 2778.	1.7	3
1838	Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor- <i>Positive</i> , <i>HER2</i> - <i>Negative</i> Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 469-477.	1.3	5
1839	First- and second-line treatment strategies for hormone-receptor (HR)- <i>positive</i> <i>HER2</i> - <i>negative</i> metastatic breast cancer: A real-world study. <i>Breast</i> , 2021, 57, 104-112.	0.9	14
1840	PI3K inhibitors are finally coming of age. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 741-769.	21.5	222
1841	Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e000082.	1.6	55
1842	Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy. <i>Cancers</i> , 2021, 13, 3276.	1.7	6

#	ARTICLE	IF	CITATIONS
1843	Dormant mechanisms reveal the clinical significance of tumor dormancy: a narrative review. <i>Annals of Blood</i> , 0, 6, 15-15.	0.4	0
1844	Secondary histiocytic sarcoma with <i>BRAF</i> ^{V600E} mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29166.	0.8	1
1845	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , 2021, 6, 100117.	2.0	37
1846	Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer. <i>PLoS ONE</i> , 2021, 16, e0252822.	1.1	10
1847	Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer. <i>Cancers</i> , 2021, 13, 3254.	1.7	10
1848	Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer. <i>Cancer Cell International</i> , 2021, 21, 306.	1.8	4
1849	A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia. <i>Current Problems in Cancer</i> , 2022, 46, 100776.	1.0	7
1850	ESMO pays tribute to Professor JosÃ© Baselga. <i>Annals of Oncology</i> , 2021, 32, 823-824.	0.6	0
1851	Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. <i>Nature Cancer</i> , 2021, 2, 680-692.	5.7	56
1852	The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3211-3224.	1.2	10
1853	Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5012-5019.	3.2	10
1854	Bone metastasis: mechanisms, therapies, and biomarkers. <i>Physiological Reviews</i> , 2021, 101, 797-855.	13.1	153
1855	Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions. <i>Cancers</i> , 2021, 13, 3739.	1.7	27
1856	Mechanisms of endocrine therapy resistance in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2021, 532, 111322.	1.6	40
1857	Alpelisib in combination with everolimus and exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. <i>European Journal of Cancer</i> , 2021, 151, 49-62.	1.3	19
1858	Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer. <i>Cancers</i> , 2021, 13, 3612.	1.7	4
1859	Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 760-774.	0.9	1
1860	Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3463-3473.	2.0	2

#	ARTICLE	IF	CITATIONS
1861	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. <i>Nature Communications</i> , 2021, 12, 5112.	5.8	38
1862	Breast Cancer Treatments: Updates and New Challenges. <i>Journal of Personalized Medicine</i> , 2021, 11, 808.	1.1	108
1863	Everolimus plus anastrozole for female adnexal tumor of probable Wolffian origin (FATWO) with STK11 mutation. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100838.	0.3	3
1864	Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting. <i>BMC Proceedings</i> , 2021, 15, 15.	1.8	5
1865	Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study. <i>Annals of Translational Medicine</i> , 2021, 9, 1334-1334.	0.7	3
1866	Metastatic Breast Cancer, Organotropism and Therapeutics: A Review. <i>Current Cancer Drug Targets</i> , 2021, 21, 813-828.	0.8	6
1867	Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial. <i>Frontiers in Immunology</i> , 2021, 12, 669965.	2.2	16
1868	Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer. <i>Cancers</i> , 2021, 13, 4375.	1.7	14
1869	Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators. <i>JAMA Oncology</i> , 2021, 7, e213428.	3.4	18
1870	Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 127.	6.9	12
1871	Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. <i>European Journal of Cancer</i> , 2021, 154, 21-29.	1.3	8
1872	Effects of PI3K inhibition in AI-resistant breast cancer cell lines: autophagy, apoptosis, and cell cycle progression. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 227-240.	1.1	2
1873	A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. <i>Breast Cancer Management</i> , 2021, 10, BMT59.	0.2	2
1874	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6115-6123.	3.2	9
1875	ER β is an RNA-binding protein sustaining tumor cell survival and drug resistance. <i>Cell</i> , 2021, 184, 5215-5229.e17.	13.5	76
1876	From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data. <i>Journal of Chemotherapy</i> , 2021, , 1-6.	0.7	0
1877	FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 125.	2.3	9
1878	Management of hormone receptor-positive, human epidermal growth factor-2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 189-201.	1.1	10

#	ARTICLE	IF	CITATIONS
1879	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6354-6365.	3.2	31
1880	Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study. <i>Clinical Transplantation</i> , 2021, 35, e14415.	0.8	3
1881	Combined endocrine and targeted therapy in luminal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1237-1251.	1.1	12
1882	Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. <i>Breast</i> , 2021, 59, 294-300.	0.9	12
1883	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3171-3181.	0.8	54
1884	Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14603-14619.	2.9	6
1885	Inappropriate censoring in Kaplan-Meier analyses. <i>Lancet Oncology</i> , The, 2021, 22, 1358-1360.	5.1	8
1886	FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188595.	3.3	13
1887	Energy metabolism in bone tumors. , 2022, , 337-355.		0
1888	Drug Screening of Potential Multiple Target Inhibitors for Estrogen Receptor-±-positive Breast Cancer. <i>In Vivo</i> , 2021, 35, 761-777.	0.6	3
1889	Hormone Resistance. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 391-401.	0.8	1
1890	Computational analysis of Cyclin D1 gene SNPs and association with breast cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	10
1891	The Breast Cancer Stem Cells Traits and Drug Resistance. <i>Frontiers in Pharmacology</i> , 2020, 11, 599965.	1.6	40
1892	Mutant SF3B1 promotes AKT- and NF-±-driven mammary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	22
1893	Treatment of NETs from Rare Origin. , 2021, , 211-229.		0
1895	Molecular docking studies of biflavonoids from <i>Selaginella doederleinii</i> hieron as anticancer agents to inhibit mTOR. , 2021, , .		0
1896	A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110± in cell lines and tumor tissues. <i>Analyst</i> , The, 2021, 146, 6566-6575.	1.7	1
1898	Molecular Pathology of Breast Cancer. , 2013, , 95-128.		3

#	ARTICLE	IF	CITATIONS
1899	Critical Boundary Refinement in a Group Sequential Trial When the Primary Endpoint Data Accumulate Faster Than the Secondary Endpoint. <i>ICSA Book Series in Statistics</i> , 2019, , 205-224.	0.0	2
1900	Symptoms: Fatigue and Cognitive Dysfunction. <i>Advances in Experimental Medicine and Biology</i> , 2015, 862, 53-75.	0.8	31
1901	Resistance to PI3K Pathway Inhibition. <i>Cancer Drug Discovery and Development</i> , 2016, , 125-147.	0.2	2
1902	Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma. <i>Current Cancer Research</i> , 2017, , 313-345.	0.2	1
1903	PI3K/Akt/mTOR/PTEN and ERK/MAPK Pathways. <i>Molecular Pathology Library</i> , 2018, , 367-379.	0.1	2
1905	Emerging Therapeutic Approaches to Overcome Breast Cancer Endocrine Resistance. <i>Cancer Drug Discovery and Development</i> , 2019, , 379-403.	0.2	1
1906	Endocrine Therapy in Clinical Practice. <i>Cancer Drug Discovery and Development</i> , 2019, , 215-240.	0.2	1
1907	Pyrans and Benzo Derivatives: Applications. , 2022, , 491-511.		4
1908	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
1910	Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100606.	1.0	11
1911	Efficacy of buparlisib in treating breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 2007-2016.	0.9	8
1912	Innovations in targeted therapies for triple negative breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 34-47.	0.9	4
1913	CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Openâ€”Cancer Horizons pro and con discussion. <i>ESMO Open</i> , 2019, 4, e000565.	2.0	8
1914	Hormone-Targeted Therapy and Resistance. <i>Annual Review of Cancer Biology</i> , 2018, 2, 291-312.	2.3	11
1915	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2â” Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428.	3.2	11
1916	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 2551-2563.	3.9	108
1917	ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. <i>Journal of Clinical Investigation</i> , 2013, 123, 4329-4343.	3.9	49
1918	Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. <i>Journal of Clinical Investigation</i> , 2016, 126, 3526-3540.	3.9	82

#	ARTICLE	IF	CITATIONS
1919	Article Commentary: Everolimus in Advanced Solid Tumors: When to Start, Early or Late?. <i>Tumori</i> , 2014, 100, e2-e3.	0.6	7
1920	Synthesis and validation of [18F]mBPET-1, a fluorine-18 labelled mTOR inhibitor derivative based on a benzofuran backbone. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 3.	1.8	2
1921	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e395-e401.	1.8	67
1922	Long-term complete remission of metastatic breast cancer induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor. <i>American Journal of Case Reports</i> , 2014, 15, 85-89.	0.3	9
1923	Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019. <i>F1000Research</i> , 2019, 8, 849.	0.8	50
1924	Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer. <i>F1000Research</i> , 2019, 8, 591.	0.8	15
1925	Advances in managing breast cancer: a clinical update. <i>F1000prime Reports</i> , 2014, 6, 66.	5.9	11
1926	Risk of Hormone Escape in a Human Prostate Cancer Model Depends on Therapy Modalities and Can Be Reduced by Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2012, 7, e42252.	1.1	12
1927	PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e53292.	1.1	80
1928	Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma. <i>PLoS ONE</i> , 2013, 8, e55096.	1.1	131
1929	Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen through Activation of Akt/mTOR Signaling. <i>PLoS ONE</i> , 2013, 8, e72053.	1.1	36
1930	The Synergistic Effect of Everolimus and Chloroquine on Endothelial Cell Number Reduction Is Paralleled by Increased Apoptosis and Reduced Autophagy Occurrence. <i>PLoS ONE</i> , 2013, 8, e79658.	1.1	24
1931	Development and Validation of a Gene Expression Score That Predicts Response to Fulvestrant in Breast Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e87415.	1.1	25
1932	Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0141589.	1.1	38
1933	Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance. <i>PLoS ONE</i> , 2016, 11, e0155840.	1.1	20
1934	P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2017, 12, e0170302.	1.1	5
1935	Factors Associated with Metastatic Breast Cancer in Patients Who Show Long-Term Stable Disease Status. <i>Journal of Breast Disease</i> , 2017, 5, 1-7.	0.2	3
1936	A Dickens Tale of the Treatment of Advanced Breast Cancer: The Past, the Present, and the Future. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 28-38.	1.8	4

#	ARTICLE	IF	CITATIONS
1937	Treatment Algorithms for Hormone Receptor-Positive Advanced Breast Cancer: Applying the Results from Recent Clinical Trials into Daily Practice—Insights, Limitations, and Moving Forward. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e20-e27.	1.8	11
1938	Treatment Algorithms for Hormone Receptor-Positive Advanced Breast Cancer: Going Forward in Endocrine Therapy—Overcoming Resistance and Introducing New Agents. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e28-e36.	1.8	5
1939	Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e395-e401.	1.8	51
1940	Visceral Crisis Means Short Survival Among Patients With Luminal A Metastatic Breast Cancer: A Retrospective Cohort Study. World Journal of Oncology, 2017, 8, 105-109.	0.6	13
1941	Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocrine-Related Cancer, 2019, 26, R15-R30.	1.6	96
1942	The NF- κ B pathway and endocrine therapy resistance in breast cancer. Endocrine-Related Cancer, 2019, 26, R369-R380.	1.6	85
1943	Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. Oncologist, 2020, 25, e130-e137.	1.9	19
1944	Influence of the results of international studies on the choice of treatment tactics for unresectable forms of squamous cell carcinoma of the head and neck. Opuholi Golovy I Sei, 2020, 10, 10-21.	0.1	4
1945	Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma. Oncology & Hematology Review, 2013, 09, 41.	0.2	4
1946	Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer. Aging, 2016, 8, 958-977.	1.4	8
1947	Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience, 2015, 2, 576-580.	0.9	42
1948	Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. Oncotarget, 2016, 7, 48206-48219.	0.8	32
1949	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	0.8	44
1950	Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. Oncotarget, 2016, 7, 80543-80553.	0.8	26
1951	Kinetics, prognostic and predictive values of <i>ESR1</i> circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget, 2016, 7, 74448-74459.	0.8	80
1952	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget, 2016, 7, 76362-76373.	0.8	22
1953	Potential of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells. Oncotarget, 2017, 8, 2936-2948.	0.8	20
1954	Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.8	64

#	ARTICLE	IF	CITATIONS
1955	Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes. <i>Oncotarget</i> , 2017, 8, 27997-28007.	0.8	23
1956	Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study. <i>Oncotarget</i> , 2017, 8, 55582-55592.	0.8	9
1957	Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study. <i>Oncotarget</i> , 2017, 8, 59810-59822.	0.8	11
1958	Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. <i>Oncotarget</i> , 2017, 8, 41227-41241.	0.8	16
1959	Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors. <i>Oncotarget</i> , 2017, 8, 40558-40567.	0.8	28
1960	Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. <i>Oncotarget</i> , 2014, 5, 3029-3038.	0.8	40
1961	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. <i>Oncotarget</i> , 2014, 5, 2349-2354.	0.8	54
1962	A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 84224-84236.	0.8	47
1963	Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN. <i>Oncotarget</i> , 2017, 8, 84426-84433.	0.8	4
1964	Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. <i>Oncotarget</i> , 2017, 8, 113874-113884.	0.8	22
1965	Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition. <i>Oncotarget</i> , 2018, 9, 29587-29600.	0.8	18
1966	Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. <i>Oncotarget</i> , 2018, 9, 31606-31619.	0.8	11
1967	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. <i>Oncotarget</i> , 2018, 9, 31877-31887.	0.8	4
1968	A systematic review and meta-analysis of selected toxicity endpoints of alpelisib. <i>Oncotarget</i> , 2020, 11, 3793-3799.	0.8	9
1969	DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1. <i>Oncotarget</i> , 2015, 6, 427-440.	0.8	51
1970	Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. <i>Oncotarget</i> , 2015, 6, 2407-2420.	0.8	50
1971	Oncogenic mutations of thyroid hormone receptor β^2 . <i>Oncotarget</i> , 2015, 6, 8115-8131.	0.8	27
1972	Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment. <i>Oncotarget</i> , 2015, 6, 11264-11280.	0.8	64

#	ARTICLE	IF	CITATIONS
1973	Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. <i>Oncotarget</i> , 2015, 6, 32027-32038.	0.8	36
1974	Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells. <i>Oncotarget</i> , 2015, 6, 21892-21905.	0.8	41
1975	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <i>Oncotarget</i> , 2015, 6, 39538-39549.	0.8	27
1976	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. <i>Oncotarget</i> , 2016, 7, 3548-3558.	0.8	114
1977	The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 9718-9731.	0.8	19
1978	Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. <i>Oncotarget</i> , 2016, 7, 64431-64446.	0.8	161
1979	mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials. <i>Oncotarget</i> , 2016, 7, 27055-27066.	0.8	14
1980	Comparative genomic analysis of primary tumors and metastases in breast cancer. <i>Oncotarget</i> , 2016, 7, 27208-27219.	0.8	69
1981	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. <i>Oncotarget</i> , 2016, 7, 40073-40084.	0.8	15
1982	Targeting BET bromodomain proteins in solid tumors. <i>Oncotarget</i> , 2016, 7, 53997-54009.	0.8	86
1983	<i>ESR1</i> alterations and metastasis in estrogen receptor positive breast cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	62
1984	Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics. , 2019, 2, 1069-1085.		11
1985	Triple negative breast cancer: special histological types and emerging therapeutic methods. <i>Cancer Biology and Medicine</i> , 2020, 17, 293-306.	1.4	50
1986	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1603-1603.	0.7	8
1987	Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years. <i>Annals of Translational Medicine</i> , 2017, 5, 481-481.	0.7	11
1988	Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers. <i>Annals of Translational Medicine</i> , 2018, 6, 284-284.	0.7	7
1989	The role of radiation therapy and systemic therapies in elderly with breast cancer. <i>Translational Cancer Research</i> , 2020, 9, S97-S109.	0.4	2
1990	Ribociclib for the treatment of hormone-positive HER2-negative breast cancer. <i>Meditinskiy Sovet</i> , 2019, , 72-80.	0.1	3

#	ARTICLE	IF	CITATIONS
1991	Therapeutic Targeting of Cancers with Loss of PTEN Function. <i>Current Drug Targets</i> , 2014, 15, 65-79.	1.0	194
1992	New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 19, 2156-2176.	0.9	4
1993	Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. <i>Journal of Medical Internet Research</i> , 2017, 19, e322.	2.1	48
1994	Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors. <i>International Journal of Cancer and Clinical Research</i> , 2015, 2, .	0.1	22
1995	Medication-Related Osteonecrosis of the Jaw with the mTOR Inhibitor Everolimus in a Patient with Estrogen-Receptor Positive Breast Cancer: A Case Report. <i>International Journal of Oral and Dental Health</i> , 2016, 2, .	0.2	5
1996	STUDY OF ACUTE VIRAL MENINGOENCEPHALITIS IN CHILDREN IN SUB-HIMALAYAN TARAI REGION: CLINICO-EPIDEMIOLOGICAL, ETIOLOGICAL, AND IMAGING PROFILE. <i>Indian Journal of Child Health</i> , 2015, 02, 177-181.	0.2	6
1997	PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 173.	1.8	293
1998	Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer. <i>International Journal of Oncology</i> , 2020, 56, 932-944.	1.4	14
1999	Hormone Therapy for Metastatic Breast Cancer. <i>Korean Journal of Medicine</i> , 2017, 92, 251-258.	0.1	1
2000	National consensus in China on diagnosis and treatment of patients with advanced breast cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 242.	0.7	14
2001	Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: Review of the present evidence and future direction. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 229-237.	0.1	16
2002	Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2016, 37, 116-118.	0.1	3
2003	Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1112-1116.	0.3	3
2004	mTORC1 signaling in primary central nervous system lymphoma. , 2016, 7, 475.		6
2005	Metastatic breast cancer: Endocrine therapy landscape reshaped. <i>Avicenna Journal of Medicine</i> , 2017, 07, 144-152.	0.3	7
2006	Letrozole and Palbociclib in Advanced Breast Cancer: Outcome from Cancer Institute, Chennai. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 182-186.	0.1	2
2007	Everolimus-associated acute kidney injury in patients with metastatic breast cancer. <i>Indian Journal of Nephrology</i> , 2017, 27, 406.	0.2	7
2008	The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus. <i>Translational Oncogenomics</i> , 2016, Suppl. 1, 1-7.	1.7	2

#	ARTICLE	IF	CITATIONS
2009	Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Cancer Research and Treatment</i> , 2017, 49, 1153-1163.	1.3	9
2010	Molecular Targeting Therapy and Biomarker for Advanced Gastric Cancer. , 2012, 02, .		4
2011	Cohort Study of Secondary Endocrine Therapy in Metastatic Breast Cancer with a Poor Response to Initial Endocrine Therapy. <i>Journal of Clinical Trials</i> , 2016, 06, .	0.1	2
2012	The Role of Everolimus in the Treatment of Breast Cancer. <i>Journal of Cancer Therapy</i> , 2013, 04, 1167-1176.	0.1	1
2013	Targeted treatments for metastatic esophageal squamous cell cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2013, 5, 88.	0.8	8
2014	Frontier of therapeutic antibody discovery: The challenges and how to face them. <i>World Journal of Biological Chemistry</i> , 2012, 3, 187.	1.7	31
2015	Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 248.	0.9	48
2016	Antineoplastic effects of mammalian target of rapamycin inhibitors. <i>World Journal of Transplantation</i> , 2012, 2, 74.	0.6	12
2017	Problems of diagnostic assessment in advanced pancreatic neuroendocrine neoplasm and treatment implications: a case report and literature review. <i>Nuclear Medicine Review</i> , 2016, 19, 54-57.	0.3	1
2018	Impact of genetic alterations on mTOR-targeted cancer therapy. <i>Chinese Journal of Cancer</i> , 2013, 32, 270-274.	4.9	8
2019	Molecular targeted agents--where we are and where we are going. <i>Chinese Journal of Cancer</i> , 2013, 32, 225-232.	4.9	4
2020	Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014, 5, 246-60.	0.2	11
2021	Metastatic Breast Cancer, Version 1.2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 821-829.	2.3	94
2022	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 452-478.	2.3	848
2023	Luteolin Inhibits Proliferation Induced by IGF-1 Pathway Dependent ER ⁺ in Human Breast Cancer MCF-7 Cells. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1431-1437.	0.5	63
2024	Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 117-122.	0.5	10
2025	PI3K/Akt/mTOR inhibitors in breast cancer. <i>Cancer Biology and Medicine</i> , 2015, 12, 342-54.	1.4	183
2026	Bone Health in Cancer Patients. <i>UNIPA Springer Series</i> , 2021, , 365-380.	0.1	0

#	ARTICLE	IF	CITATIONS
2027	Updates in endocrine therapy for metastatic breast cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	6
2028	Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. <i>Clinics</i> , 2021, 76, e3146.	0.6	2
2029	Subclinical Rejection and Immunosuppression in Pediatric Kidney Transplant Recipients : Single Centre Study. <i>Biomedical and Pharmacology Journal</i> , 2021, 14, 1149-1159.	0.2	0
2030	CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 329-330.	1.4	3
2031	Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors. <i>Clinical Breast Cancer</i> , 2022, 22, 143-148.	1.1	12
2032	The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. <i>Clinical Breast Cancer</i> , 2022, 22, 223-234.	1.1	2
2033	Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. <i>Journal of Molecular Medicine</i> , 2021, 99, 1691-1710.	1.7	40
2034	Cardiometabolic consequences of targeted anticancer therapies. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	0.8	3
2035	Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 319-327.	1.4	40
2036	Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma. <i>European Endocrinology</i> , 2010, 9, 18.	0.8	1
2039	Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. <i>Yearbook of Oncology</i> , 2012, 2012, 74-75.	0.1	0
2040	Acquis et limites de l'œœhormonothœœrapie adjuvante. , 2013, , 113-118.		0
2042	The Legacy of Tamoxifen. <i>Milestones in Drug Therapy</i> , 2013, , 165-178.	0.1	0
2044	Breast cancer and molecular targeted drugs. <i>Okayama Igakkai Zasshi</i> , 2013, 125, 243-250.	0.0	0
2045	Breast Cancer Stem Cells: From Theory to Therapy. , 2013, , 477-489.		1
2046	ADJUVANT ANTIHORMONE THERAPY. , 2013, , 229-254.		0
2047	ANTIHORMONE DRUG RESISTANCE. , 2013, , 295-323.		0
2048	Pathophysiology of Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , 3-17.	0.1	1

#	ARTICLE	IF	CITATIONS
2050	Targeted therapieÃ«n. , 2014, , 55-66.		1
2051	Mammacarcinoom. , 2014, , 89-97.		0
2053	Intracellular Signaling. , 2014, , 22-39.e8.		1
2054	The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer. Current Clinical Urology, 2014, , 77-94.	0.0	0
2055	Management of Metastatic Breast Cancer. , 2015, , 473-497.		0
2056	Treatment Considerations for the Management of Patients With Hormone Receptorâ€“Positive Metastatic Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2014, 5, .	0.2	5
2057	Hormonal Therapy in Nonmetastatic Breast Cancer. , 2015, , 339-344.		0
2058	Clinical Use of Aromatase Inhibitors in Breast Cancer: History and Present. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 1-11.	0.1	0
2059	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
2060	CDK inhibitors in hormone receptor positive advanced breast cancer. Marmara Medical Journal, 2015, 28, 35.	0.2	1
2061	Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptorâ€“Positive, HER2-Negative Breast Cancer. Journal of the Advanced Practitioner in Oncology, 2015, 6, .	0.2	0
2062	Treatment of Metastatic Breast Cancer: Endocrine Therapy. , 2016, , 489-522.		0
2063	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2016, , 1-25.		0
2064	Clinical Management of Transplant Recipients. , 2016, , 171-184.		0
2065	Aromatase Inhibitors for Breast Cancer Prevention. , 2016, , 103-111.		1
2066	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
2067	Metastatic Breast Cancer. , 2016, , 451-474.		0
2068	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. Endocrinology, 2016, , 1-21.	0.1	0

#	ARTICLE	IF	CITATIONS
2069	Systemic Therapy. , 2016, , 335-390.		0
2070	Endocrine Therapy. , 2016, , 323-334.		0
2071	Combination Therapies Targeting the PI3K/AKT/mTOR Pathways. Cancer Drug Discovery and Development, 2016, , 151-180.	0.2	0
2072	Breast Cancer in the Older Adult. , 2016, , 519-528.		0
2073	LKB1, A New Biomarker in Breast Cancer. Journal of Cancer Therapy, 2016, 07, 690-699.	0.1	2
2074	Systemic Therapies to Reduce the Risk of Recurrence in Early Breast Cancer: New Strategies. , 2016, , 83-91.		0
2075	Traitements du futur dans la prise en charge du cancer: vers un traitement individualisé du cancer du sein. , 2016, , 183-187.		0
2076	Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario. Journal of the Advanced Practitioner in Oncology, 2016, 7, 550-561.	0.2	1
2077	New Neurological Disorders in a New Patient. Long Term VEGFR Inhibitors Effects. , 2016, 2, .		0
2078	Mammatumoren. , 2017, , 419-444.		0
2079	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2017, , 613-637.		0
2080	Basisprincipes van "targeted therapy", inclusief hormonale therapie. , 2017, , 161-179.		0
2081	The Heat Shock Protein Story"From Taking mTORC1,2 and Heat Shock Protein Inhibitors as Therapeutic Measures for Treating Cancers to Development of Cancer Vaccines. Journal of Cancer Therapy, 2017, 08, 962-1029.	0.1	4
2082	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-34.	0.1	0
2083	Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing. Anticancer Research, 2017, 37, 705-712.	0.5	3
2084	Invasive Carcinomas. , 2018, , 191-232.		1
2085	DLI Induced by Molecular Target Antineoplastic Drug: What Are the Characteristics of DLI in Molecular Target Antineoplastic Drugs?. Respiratory Disease Series, 2018, , 139-164.	0.1	0
2089	Novel Options in Metastatic and Non-surgically Curable Bladder Cancer. European Oncology and Haematology, 2018, 14, 87.	0.0	0

#	ARTICLE	IF	CITATIONS
2090	Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, .	0.2	3
2091	Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 1579-1584.	0.5	4
2092	Palbociclib to reverse endocrine resistance in breast cancer: a TREN in the right direction?. <i>Oncotarget</i> , 2018, 9, 34031-34032.	0.8	0
2093	Endocrine Therapy of Metastatic Breast Cancer. , 2019, , 533-555.		0
2094	Molecular Targeting Agents for Breast Cancer. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2018, 14, 180-182.	0.0	0
2096	Treatment of Metastatic Breast Cancer: Endocrine Therapy. , 2019, , 419-447.		0
2097	Efficacy and tolerability of eribulin mesylate in the treatment of anthracycline and taxan resistance to metastatic breast cancer. Single central experience. <i>Ortado Tıp Dergisi</i> , 2019, 11, 10-14.	0.1	0
2099	13C TM CE ² ç TM ,ã«ãšãšã,ç, â†âœ™çš,,è—ãf»æš—ã½“âCE»è—ã® ç¾4çš¶ã±æœ». <i>Journal of Otolaryngology of Japan</i> , 2010, 122, 835-839.		0
2100	Endometrial Cancer Genetic Classification and Its Clinical Application. , 2020, , 23-47.		0
2101	Toward precision medicine in inflammatory breast cancer. <i>Translational Cancer Research</i> , 2019, 8, S469-S478.	0.4	4
2102	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
2103	Genomic Characterization of Brain Metastases: Implications for Precision Medicine. , 2020, , 43-58.		0
2104	Protocole homœopathique d'accompagnement des inhibiteurs oraux des kinases dépendantes des cyclines 4 et 6 (CDK 4/6), dans le cancer du sein post-ménopausique métastatique hormonodépendant. <i>Revue D'Homeopathie</i> , 2019, 10, 193-198.	0.1	0
2105	Role of Precision Medicine in Patients with CNS Metastasis. , 2020, , 69-82.		0
2107	The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	8
2108	Efficacy and toxicity of everolimus plus exemestane in third and later lines treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Journal of Surgery and Medicine</i> , 0, , .	0.0	1
2110	Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. <i>Oncotarget</i> , 2020, 11, 2172-2181.	0.8	5
2111	Clinical aspects of the use of ribociclib. <i>Meditinskiy Sovet</i> , 2020, , 44-56.	0.1	0

#	ARTICLE	IF	CITATIONS
2112	Surgical therapy for breast cancer liver metastases. <i>Translational Cancer Research</i> , 2020, 9, 5053-5062.	0.4	2
2113	Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3890-3896.	0.8	0
2114	Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases. <i>Drug Delivery and Translational Research</i> , 2021, 11, 2344-2370.	3.0	8
2115	Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2- Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. <i>Cancers</i> , 2021, 13, 5397.	1.7	7
2116	Adverse events of targeted therapies approved for women's cancers. <i>International Journal of Women's Dermatology</i> , 2021, 7, 552-559.	1.1	0
2117	Role of plant derived bioactive compounds against cancer. <i>South African Journal of Botany</i> , 2022, 149, 1017-1028.	1.2	17
2118	Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2022, 28, 821-830.	3.2	26
2119	Amphiregulin retains ER \pm expression in acquired aromatase inhibitor resistant breast cancer cells. <i>Endocrine-Related Cancer</i> , 2020, 27, 671-683.	1.6	5
2120	Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene. <i>Meditinskiy Sovet</i> , 2020, , 40-46.	0.1	1
2121	Microgravity: New aspect for breast cancer treatment, a review. <i>Acta Astronautica</i> , 2022, 190, 62-73.	1.7	5
2122	Development of Molecularly Targeted Agents in Early Phase Clinical Trials. , 2020, , 199-220.		0
2123	PEComas: An Uncommon Family of Sarcomas Sensitive to Targeted Therapy. , 2020, , 41-68.		0
2124	Basisprincipes van -targeted therapy™, inclusief hormonale therapie. , 2020, , 173-190.		0
2125	Why CDK 4/6 Inhibitors are Practice Changing in Advanced Breast Cancer. <i>Oncology & Hematology Review</i> , 2020, 16, 23.	0.2	0
2126	Management of Advanced Breast Cancer in Young Women: What's New in Systemic Treatment. , 2020, , 127-142.		0
2127	Single nucleotide polymorphisms Rs1045642 C>T genetic alteration in ATP Binding Cassette Subfamily B Member 1 role in increasing everolimus toxicity in metastatic breast cancer. <i>AIMS Molecular Science</i> , 2020, 7, 1-11.	0.3	0
2128	Bone as a New Milieu for Disseminated Tumor Cells: An Overview of Bone Metastasis. , 2020, , 78-95.		0
2130	Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis. <i>Journal of Breast Cancer</i> , 2020, 23, 460.	0.8	1

#	ARTICLE	IF	CITATIONS
2131	Effect of genetic polymorphisms in CYP3A4, CYP3A5, and m-TOR on everolimus blood exposure and clinical outcomes in cancer patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 647-654.	0.9	1
2133	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2021, 32, 1475-1495.	0.6	454
2134	Abemaciclib as an original inhibitor of cyclin-dependent kinase for the treatment of luminal HER2-negative disseminated breast cancer. <i>Meditinskiy Sovet</i> , 2020, , 27-42.	0.1	0
2135	Single nucleotide polymorphisms Rs1045642 C>T genetic alteration in ATP Binding Cassette Subfamily B Member 1 role in increasing everolimus toxicity in metastatic breast cancer. <i>AIMS Molecular Science</i> , 2020, 7, 1-11.	0.3	0
2138	Role of mTOR inhibition in preventing resistance and restoring sensitivity to hormone-targeted and HER2-targeted therapies in breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 217-24.	0.3	18
2140	Plasma tumor DNA: on your markers, get set, go!. <i>Annals of Translational Medicine</i> , 2014, 2, 2.	0.7	8
2141	Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 3333-43.	1.3	8
2143	MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. <i>American Journal of Cancer Research</i> , 2015, 5, 1-19.	1.4	29
2145	Treatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014, 5, 321-30.	0.2	10
2147	First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer. <i>P and T</i> , 2015, 40, 511-20.	1.0	16
2150	Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2015, 6, 577-81.	0.2	3
2151	mTOR function and therapeutic targeting in breast cancer. <i>American Journal of Cancer Research</i> , 2017, 7, 383-404.	1.4	53
2153	Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 43-54.	0.2	5
2154	A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. <i>American Journal of Cancer Research</i> , 2018, 8, 2359-2376.	1.4	24
2155	ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. <i>American Journal of Cancer Research</i> , 2019, 9, 2821-2831.	1.4	24
2156	Renalase overexpression in ER-positive breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 1297-1307.	0.5	4
2157	A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy. <i>American Journal of Cancer Research</i> , 2021, 11, 2867-2892.	1.4	1
2158	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-“positive Breast Cancer, SWOG S1222. <i>Clinical Cancer Research</i> , 2022, 28, 611-617.	3.2	4

#	ARTICLE	IF	CITATIONS
2159	Next-Generation Sequencing Whole-Genome Analysis for Targeted Treatment Approach of Metastatic Bartholin Gland Adenocarcinoma: An Emblematic Case Report and Review of the Literature. <i>Diagnostics</i> , 2021, 11, 2085.	1.3	3
2160	A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. <i>Targeted Oncology</i> , 2022, 17, 15-24.	1.7	7
2161	Development of novel agents for the treatment of early estrogen receptor positive breast cancer. <i>Breast</i> , 2022, 62, S34-S42.	0.9	8
2162	Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. <i>Clinical Cancer Research</i> , 2022, 28, 1107-1116.	3.2	7
2163	Efficacy of Everolimus in Treating Breast Cancer. <i>International Journal of Pharmaceutical Sciences Review and Research</i> , 2020, 65, 52-55.	0.1	0
2164	Endocrine Treatment of Breast Cancer. , 2022, , 1783-1789.		0
2165	Breast Cancer Treatment: The Case of Gold(I)-Based Compounds as a Promising Class of Bioactive Molecules. <i>Biomolecules</i> , 2022, 12, 80.	1.8	9
2166	Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence. <i>Advances in Therapy</i> , 2022, 39, 862.	1.3	5
2167	Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology. <i>Genes</i> , 2022, 13, 234.	1.0	6
2168	A case of sternal osteomyelitis during treatment with everolimus for recurrent breast cancer. <i>Surgical Case Reports</i> , 2022, 8, 23.	0.2	0
2169	Prioritising systemic cancer therapies applying ESMO™s tools and other resources to assist in improving cancer care globally: the Kazakh experience. <i>ESMO Open</i> , 2022, 7, 100362.	2.0	8
2171	Biomarkers of everolimus efficacy in breast cancer therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522110736.	0.5	2
2172	The initial hormone receptor/HER2 subtype is the main determinant of subtype discordance in advanced breast cancer: a study of the SONABRE registry. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 331.	1.1	3
2173	Usefulness of new shear wave elastography in early predicting the efficacy of neoadjuvant chemotherapy for patients with breast cancer: where and when to measure is optimal?. <i>Breast Cancer</i> , 2022, 29, 478-486.	1.3	6
2175	Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 1033-1046.	1.2	5
2176	Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. <i>Oncologist</i> , 2022, 27, 97-103.	1.9	6
2177	Palbociclib plus endocrine therapy significantly enhances overall survival of HR ⁺ /HER2 ⁻ metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. <i>International Journal of Cancer</i> , 2022, 150, 2025-2037.	2.3	16
2178	ZDHC22-mediated mTOR palmitoylation restrains breast cancer growth and endocrine therapy resistance. <i>International Journal of Biological Sciences</i> , 2022, 18, 2833-2850.	2.6	11

#	ARTICLE	IF	CITATIONS
2179	Breast cancer management in 2021: A primer for the obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 82, 30-45.	1.4	18
2180	Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review. <i>Cancers</i> , 2022, 14, 920.	1.7	10
2181	Metformin and Breast Cancer: Where Are We Now?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2705.	1.8	26
2182	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. <i>Scientific Reports</i> , 2022, 12, 2742.	1.6	13
2184	Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead. <i>JAMA Oncology</i> , 2022, 8, 679.	3.4	25
2185	<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100370.	1.5	17
2186	Factors influencing the anticancer effects of metformin on breast cancer outcomes: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 415-436.	1.1	4
2187	Insulin and cancer: a tangled web. <i>Biochemical Journal</i> , 2022, 479, 583-607.	1.7	22
2188	Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 253-264.	1.1	38
2189	Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies. <i>Drugs and Aging</i> , 2022, 39, 257.	1.3	0
2190	How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. <i>Life</i> , 2022, 12, 378.	1.1	8
2191	Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. <i>Molecular Biomedicine</i> , 2022, 3, 8.	1.7	38
2192	Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer. <i>Targeted Oncology</i> , 2022, 17, 111-124.	1.7	7
2193	Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2248-2256.	3.2	3
2194	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. <i>ESMO Open</i> , 2022, 7, 100409.	2.0	25
2195	Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2237-2247.	3.2	16
2196	Consumption of “Diabetes Risk Reduction Diet” and Odds of Breast Cancer Among Women in a Middle Eastern Country. <i>Frontiers in Nutrition</i> , 2022, 9, 744500.	1.6	8
2197	Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Quantum Leap in the Treatment of Advanced Breast Cancers. <i>Cureus</i> , 2022, 14, e23901.	0.2	1

#	ARTICLE	IF	CITATIONS
2198	Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112824.	2.5	6
2199	Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13512.	1.8	6
2200	Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. <i>Cancers</i> , 2022, 14, 196.	1.7	4
2201	Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. <i>Cancer Investigation</i> , 2022, 40, 199-209.	0.6	1
2202	Clinical case of the treatment of metastatic luminal breast cancer. <i>Meditinskiy Sovet</i> , 2021, , 160-166.	0.1	0
2203	Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2~ Breast Cancer at a Single Cancer Center. <i>Oncologist</i> , 2022, 27, 646-654.	1.9	7
2204	Translational Strategies to Target Metastatic Bone Disease. <i>Cells</i> , 2022, 11, 1309.	1.8	4
2205	Drug Repurposing in Cancer Therapy: Influence of Patient's Genetic Background in Breast Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4280.	1.8	30
2211	Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210903.	0.8	5
2212	Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics. <i>Chinese Clinical Oncology</i> , 2013, 2, 22.	0.4	2
2213	From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer. <i>Chinese Clinical Oncology</i> , 2014, 3, 16.	0.4	3
2215	Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09). <i>Cancer Research and Treatment</i> , 2022, , .	1.3	0
2218	Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 172-199.	0.5	6
2219	Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor~Positive Recurrent or Metastatic Endometrial Cancer. <i>JAMA Oncology</i> , 2022, 8, 1001.	3.4	24
2221	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
2222	Elicestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor~Positive, Human Epidermal Growth Factor Receptor 2~Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 3246-3256.	0.8	190
2223	Brain metastases in breast cancer. , 2022, , 63-85.		0
2224	Everolimus and exemestane in hormone receptor positive advanced breast cancer: A comprehensive cancer center's experience. <i>Bulletin Du Cancer</i> , 2022, 109, 723-723.	0.6	1

#	ARTICLE	IF	CITATIONS
2225	Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3699-3708.	0.8	11
2226	Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. <i>Annals of Oncology</i> , 2022, 33, 769-785.	0.6	37
2227	Role of anti-angiogenic factors in the pathogenesis of breast cancer: A review of therapeutic potential. <i>Pathology Research and Practice</i> , 2022, 236, 153956.	1.0	7
2228	Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2229	Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2230	Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	14
2231	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 851-864.	5.1	50
2232	Oncologic emergencies and urgencies: A comprehensive review. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 570-593.	157.7	18
2233	Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 498-510.	0.9	1
2234	Exploring new pathways in endocrine-resistant breast cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 337-361.	0.5	2
2236	ENDORSE: a prognostic model for endocrine therapy in estrogen-receptor-positive breast cancers. <i>Molecular Systems Biology</i> , 2022, 18, .	3.2	5
2237	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103749.	2.0	37
2239	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 461-481.	0.6	6
2240	A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. <i>Cancer Research Communications</i> , 2022, 2, 570-576.	0.7	1
2242	Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2243	Drug Repurposing by Tumor Tissue Editing. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
2244	Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients. <i>Therapie</i> , 2022, , .	0.6	0
2245	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	12

#	ARTICLE	IF	CITATIONS
2246	ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer. <i>Siberian Journal of Oncology</i> , 2022, 21, 135-142.	0.1	0
2247	Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7079.	1.8	4
2248	A Computational Framework to Characterize the Cancer Drug Induced Effect on Aging Using Transcriptomic Data. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
2249	Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
2250	Breast cancer brain metastasis: Current evidence and future directions. <i>Cancer Medicine</i> , 2023, 12, 1007-1024.	1.3	18
2251	Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	3
2252	The role of phosphoinositide 3-kinases in immune-inflammatory responses: potential therapeutic targets for abdominal aortic aneurysm. <i>Cell Cycle</i> , 2022, 21, 2339-2364.	1.3	1
2254	Leptomeningeal Metastases: New Opportunities in the Modern Era. <i>Neurotherapeutics</i> , 2022, 19, 1782-1798.	2.1	9
2255	Current State of Cell Therapies for Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 301-309.	1.0	5
2256	Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors. <i>Anticancer Research</i> , 2022, 42, 3913-3919.	0.5	4
2257	Marker assessments in ER-positive breast cancers: old markers, new applications?. <i>Histopathology</i> , 2023, 82, 218-231.	1.6	3
2258	Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
2259	Overview of Research into mTOR Inhibitors. <i>Molecules</i> , 2022, 27, 5295.	1.7	32
2260	Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer. <i>Cancer Prevention Research</i> , 2022, 15, 791-802.	0.7	3
2261	CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2262	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. <i>Archives of Pharmacal Research</i> , 2022, 45, 597-617.	2.7	6
2263	Targeted therapy for breast cancer: An overview of drug classes and outcomes. <i>Biochemical Pharmacology</i> , 2022, 204, 115209.	2.0	38
2264	Deubiquitinase OTUD5 modulates mTORC1 signaling to promote bladder cancer progression. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	10

#	ARTICLE	IF	CITATIONS
2265	Quatramer α_4 mediated co-delivery of PI3-K β /HDAC6 dual inhibitor augments the anti-cancer efficacy of Epirubicin in breast cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 179, 184-193.	2.0	2
2266	Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 76, 128991.	1.0	4
2267	Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 343-352.	0.7	2
2268	Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211136.	1.4	34
2269	Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 171-194.	0.8	2
2270	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2022, , 715-741.		0
2271	Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 229-237.	1.1	3
2272	Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. <i>ELife</i> , 0, 11, .	2.8	10
2273	Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2 α Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b ComPLEEment-1 Study. <i>Targeted Oncology</i> , 0, , .	1.7	1
2274	Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies. <i>Cancers</i> , 2022, 14, 4665.	1.7	3
2275	<sc>NANOG</sc> regulates epithelial \rightarrow mesenchymal transition via <sc>AMPK</sc>/<sc>mTOR</sc> signalling pathway in ovarian cancer <sc>SKOV</sc> β and <sc>A2780</sc> cells. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 5277-5291.	1.6	3
2276	Targeting senescence as an anticancer therapy. <i>Molecular Oncology</i> , 2022, 16, 3855-3880.	2.1	19
2277	Palbociclib Rechallenge for Hormone Receptor α Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. <i>Clinical Cancer Research</i> , 2023, 29, 67-80.	3.2	11
2278	Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 4279.	1.7	2
2279	Somatic Mutations of <i>TP53</i> Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study. <i>Journal of Breast Cancer</i> , 2022, 25, 379.	0.8	5
2280	Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone. <i>Npj Genomic Medicine</i> , 2022, 7, .	1.7	2
2282	Myokines derived from contracting skeletal muscle suppress anabolism in MCF7 breast cancer cells by inhibiting mTOR. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	3
2283	Statin use in patients with hormone receptor α positive metastatic breast cancer treated with everolimus and exemestane. <i>Cancer Medicine</i> , 2023, 12, 5461-5470.	1.3	1

#	ARTICLE	IF	CITATIONS
2284	Modern breast cancer therapy: from tamoxifen to T-cell engineering. <i>Siberian Journal of Oncology</i> , 2022, 21, 109-122.	0.1	1
2286	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
2287	A patient with stage IIIB advanced breast cancer who is still alive 24 years after surgery: a case report and remarks on the treatment strategies. <i>Translational Cancer Research</i> , 2022, 11, 3903-3911.	0.4	1
2289	Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. <i>Cancers</i> , 2022, 14, 5206.	1.7	14
2290	Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier. <i>Cancers</i> , 2022, 14, 5132.	1.7	2
2291	Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development. <i>Cancer Gene Therapy</i> , 2023, 30, 324-334.	2.2	1
2292	Predicting clinical response to everolimus in ER+ breast cancers using machine-learning. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
2294	The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 975-990.	2.7	23
2297	Co-encapsulation of PI3-KÎ/HDAC6 dual inhibitor and Navitoclax in Quatramerâ,,¢ nanoparticles for synergistic effect in ER+Âbreast cancer. <i>International Journal of Pharmaceutics</i> , 2022, 628, 122343.	2.6	2
2298	Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study. <i>Japanese Journal of Clinical Oncology</i> , 2023, 53, 105-114.	0.6	2
2299	A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE). <i>ESMO Open</i> , 2022, 7, 100601.	2.0	3
2300	Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. <i>Cancer Treatment Reviews</i> , 2023, 112, 102496.	3.4	18
2301	Newly identified lncRNA-45 promotes breast cancer metastasis through activating the mTOR signaling pathway. <i>Biochemical and Biophysical Research Communications</i> , 2023, 640, 40-49.	1.0	2
2302	Effect of Soybean Isoflavones on Proliferation and Related Gene Expression of Sow Mammary Gland Cells In Vitro. <i>Animals</i> , 2022, 12, 3241.	1.0	0
2303	An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer. <i>Investigational New Drugs</i> , 2023, 41, 70-75.	1.2	4
2304	Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
2307	Emerging Therapies for Breast Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2023, 13, a041333.	2.9	2
2308	Mechanism and Role of Endoplasmic Reticulum Stress in Osteosarcoma. <i>Biomolecules</i> , 2022, 12, 1882.	1.8	4

#	ARTICLE	IF	CITATIONS
2309	Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases. <i>CNS Drugs</i> , 0, , .	2.7	4
2310	¹⁸ F-FDG and ¹⁸ F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR Therapies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 0, , .	0.7	1
2311	Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
2313	Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , 2023, 80, .	1.3	27
2314	Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. <i>Biomedicines</i> , 2023, 11, 109.	1.4	18
2315	Application of Dual-Drug Loaded Metal Organic Framework Nanomaterials Targeting PI3K Signaling Pathway in Triple Negative Breast Cancer Cells. <i>Journal of Biomedical Nanotechnology</i> , 2022, 18, 2340-2349.	0.5	2
2317	The Importance of mTORC1-Autophagy Axis for Skeletal Muscle Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 297.	1.8	10
2318	Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression. <i>Biomedicines</i> , 2023, 11, 99.	1.4	3
2319	Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
2320	Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	5
2321	Exploration of chemotherapy-free regimen after multi-line chemotherapy-induced renal impairment in recurrent ovarian cancer: Case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2322	A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 217-229.	1.1	1
2323	Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 91, 361-373.	1.1	2
2324	CDK4/6 Inhibitors-Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 1763.	1.7	4
2325	Nanoscale metal-organic framework delivers rapamycin to induce tissue immunogenic cell death and potentiates cancer immunotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2023, 50, 102678.	1.7	2
2326	Multiple ulcers and perforation of small intestine with everolimus use in a patient with rectal neuroendocrine tumor: A case report. <i>International Journal of Surgery Case Reports</i> , 2023, 106, 108094.	0.2	1
2327	A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6834.	1.8	23
2328	Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. <i>ESMO Open</i> , 2023, 8, 101214.	2.0	4

#	ARTICLE	IF	CITATIONS
2329	KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 186, 103987.	2.0	3
2330	Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer. <i>Plastic and Reconstructive Surgery</i> , 0, Publish Ahead of Print, .	0.7	0
2331	Metastatic Breast Cancer to the Spine: Incidence of Somatic Gene Alterations and Association of Targeted Therapies With Overall Survival. <i>Neurosurgery</i> , 2023, 92, 1183-1191.	0.6	0
2332	Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
2333	Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective. <i>Biomedicines</i> , 2023, 11, 510.	1.4	0
2334	Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. <i>BMC Cancer</i> , 2023, 23, .	1.1	9
2335	How I treat endocrine-dependent metastatic breast cancer. <i>ESMO Open</i> , 2023, 8, 100882.	2.0	6
2336	Can We Use Artificial Intelligence Cluster Analysis to Identify Patients with Metastatic Breast Cancer to the Spine at Highest Risk of Postoperative Adverse Events?. <i>World Neurosurgery</i> , 2023, 174, e26-e34.	0.7	0
2337	Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
2338	Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4522.	1.8	16
2339	Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 1906.	1.0	0
2340	Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. <i>Biomedicines</i> , 2023, 11, 735.	1.4	0
2341	Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	1
2342	Systematic review of the management of brain metastases from hormone receptor positive breast cancer. <i>Journal of Neuro-Oncology</i> , 2023, 162, 45-57.	1.4	6
2343	Chemotherapy-Induced Oral Complications and Prophylaxis Strategies. <i>Cancer Investigation</i> , 2023, 41, 432-455.	0.6	0
2344	Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. <i>Cancers</i> , 2023, 15, 1766.	1.7	6
2345	What Is Known about Breast Cancer in Young Women?. <i>Cancers</i> , 2023, 15, 1917.	1.7	18
2346	The emerging role of PI3K inhibitors for solid tumour treatment and beyond. <i>British Journal of Cancer</i> , 2023, 128, 2150-2162.	2.9	18

#	ARTICLE	IF	CITATIONS
2347	Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 2015.	1.7	3
2348	Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. <i>Current Oncology Reports</i> , 2023, 25, 689-698.	1.8	2
2350	Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. <i>Cancers</i> , 2023, 15, 2204.	1.7	10
2351	Cancer prevention with rapamycin. <i>Oncotarget</i> , 2023, 14, 342-350.	0.8	12
2352	Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	1
2365	Targeted Therapy and Personalized Medicine. <i>Cancer Treatment and Research</i> , 2023, , 177-205.	0.2	2
2393	Therapeutic resistance to anti-oestrogen therapy in breast cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 673-685.	12.8	10
2396	Targeted breast cancer treatment: progress and challenges. , 2023, , 145-172.		0
2405	Targeting sex steroid biosynthesis for breast and prostate cancer therapy. <i>Nature Reviews Cancer</i> , 2023, 23, 686-709.	12.8	1
2441	Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy. , 2024, 41, .		1
2446	Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. <i>Cancer Treatment and Research</i> , 2023, , 219-235.	0.2	1
2450	Macrolides for Cancer. , 2024, , 223-254.		0